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ABSTRACT 
 
Breann Louise Wolfe 
Clathrin-dependent Internalization of Protease-activated Receptor-1:  
Regulation by Ubiquitination and Epsin 
(Under the direction of Dr. JoAnn Trejo) 
 
Thrombin, the main effector protease of the coagulation cascade elicits its cellular 
effects via activation of a family of G-protein coupled receptors (GPCRs) called protease-
activated receptors (PARs).  PAR1, the prototype of this family, is expressed in cells in and 
around blood vessels and mediates thrombin elicited cellular responses that are essential for 
hemostasis and thrombosis, embryonic development, and cancer progression.  Thrombin 
binds to and cleaves the amino-terminal exodomain of PAR1, thus exposing a newly formed 
amino-terminus that binds intramolecularly to the body of the receptor and causes 
transmembrane signaling.  Due to the irreversible, proteolytic mechanism of PAR1 
activation, processes that contribute to signal termination, including desensitization, 
internalization and downregulation, are critically important for thrombin-elicited cellular 
responses.  PAR1 displays two modes of receptor trafficking.  Constitutive PAR1 
internalization is mediated by the adaptor protein complex-2 (AP2), but is independent of 
arrestins, and is important for resensitization of thrombin signaling.  Activated PAR1 
internalizes by a clathrin- and dynamin-dependent pathway that is independent of arrestins 
and AP2 and is then sorted directly to lysosomes for degradation, a process that is important 
for signal termination.     
iii
 Studies of mammalian and yeast GPCRs have demonstrated a role for ubiquitination 
in trafficking of GPCRs.  A major focus of this dissertation was to understand the role of 
ubiquitination in PAR1 trafficking.  We found that PAR1 is basally ubiquitinated and 
undergoes agonist-induced deubiquitination.  Ubiquitination of PAR1 negatively regulates 
constitutive internalization and specifies a distinct clathrin adaptor requirement for activated 
receptor internalization.  PAR1 ubiquitination appears to inhibit binding of AP2 to PAR1 and 
therefore helps to retain PAR1 at the cell surface.  The clathrin adaptor protein epsin binds to 
activated and ubiquitinated PAR1 to mediate receptor internalization.  A deubiquitinated 
form of the receptor is sorted to lysosomes by a ubiquitin-independent mechanism that 
requires sorting nexin-1.  These studies reveal a novel function for ubiquitination in 
regulation of GPCR trafficking.   
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 CHAPTER 1 
INTRODUCTION
1.1.   Thrombin and protease-activated receptors  
1.1.1.   Thrombin generation 
Thrombin, the main effector of the coagulation cascade, has a critical function in 
hemostasis and thrombosis.  The generation of thrombin occurs by the extrinsic and intrinsic 
pathways and is mediated by a series of zymogen conversions resulting in the formation of 
active thrombin from its precursor prothrombin (Figure 1.1).  The extrinsic pathway, or tissue 
factor (TF) pathway, is initiated when TF expressed on cells outside of the vasculature is 
exposed to plasma following vascular damage.  TF binds to Factor VII and mediates its 
activation to Factor VIIa.  Factor VIIa bound to TF catalyzes the conversion of Factor X to 
Factor Xa.  Prothrombin is converted to thrombin by Factor Xa bound to the TF/Factor VIIa 
complex.  The intrinsic pathway, or contact activation pathway, is activated upon blood 
vessel damage when blood contacts matrix fibers in the subendothelium.  The intrinsic 
pathway results in activation of Factors XII, XI, IX, and X, in a manner that is dependent on 
calcium and a negatively charge surface.  Factors XIIa, XIa, IXa and Xa form a complex on 
the surface of platelets which promotes conversion of prothrombin to thrombin (Figure 1.1) 
[1, 2]. 
 
1.1.2.   Protease-activated receptors 
 Thrombin elicits a variety of cellular responses in multiple cell types in and around 
the blood vessels following vascular injury.  The mechanism by which thrombin promotes 
cellular responses involves the activation of a family of cell surface receptors called protease-
activated receptors (PARs).  The family of PARs includes four members, which are activated 
by extracellular proteases.  The proteases bind to and cleave the amino-terminal exodomain 
of the receptor, thus exposing a new amino terminus that acts as a tethered ligand and binds 
intramolecularly to the body of the receptor to trigger signaling.  The irreversible, proteolytic 
activation of PARs is unlike most G-protein coupled receptors (GPCRs) which are reversibly 
activated.  Most proteases capable of PAR cleavage and activation are serine proteases, 
which have a serine residue in the active site and cleave peptide sequences with a basic 
residue immediately amino-terminal to the cleavage site.  Other proteases, such as cysteine 
and metalloproteases, have been shown to cleave and activate PAR family members, 
although the mechanism remains unclear [3].   
 
1.1.2.1.   PAR1 
In 1991, Coughlin and colleagues identified a receptor for thrombin dubbed the 
“thrombin receptor”, or PAR1, responsible for mediating the cellular effects elicited by 
thrombin [4].  Dami cells, a megakaryocyte-like cell line, were used to generate cDNA 
reverse-transcribed from size-fractionated pools of mRNA which was injected into Xenopus 
oocytes following conversion to cRNA.  Thrombin responses were then assessed by 
measuring release of 45Ca2+ and activation of Ca2+-dependent chloride currents.  Using a 
dilution strategy, a single cDNA was isolated consisting of an open reading frame encoding a 
425 amino acid protein that yielded a 100-fold higher calcium release induced by thrombin 
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 compared to control nonspecific cDNA [4].  Thrombin is an extremely potent activator of 
PAR1 with an EC50 of 50 pM, while trypsin which also activates the receptor displays much 
lower potency.  Hirudin, a leech peptide and natural inhibitor of thrombin, binds to 
thrombin’s fibrinogen binding exosite and was shown to block thrombin mediated activation 
of the receptor [4], further suggesting that thrombin functions as an endogenous activator of 
PAR1.  Hydropathy plots of the cloned thrombin receptor revealed seven transmembrane 
spanning regions typical of GPCR family members.  The thrombin receptor, or PAR1, is 
most closely related to the substance P/ neurokinin-1 receptor (SPR), a peptide receptor, and 
the glycoprotein hormone receptor subfamilies [4].  To date, PAR1 has been cloned from 
human, hamster, bovine, rat, mouse, Xenopus laevis, and baboon [5-9]. 
A protease cleavage site was identified within the amino terminus of the cloned 
thrombin receptor (LDPR41 ↓ S42FLLRN) based on similarity with the sequence in the 
zymogen Protein C which was known to be cleaved by thrombin (Figure 2.1) [4, 10].  
Cleavage of PAR1 by thrombin at the R41 ↓ S42 site results in the exposure of the tethered 
ligand sequence, SFLLRN, which binds intramolecularly to the receptor to initiate 
transmembrane signaling.  Mutation of the LDPR41 ↓ S42 sequence in PAR1 (R41A) renders 
the receptor unresponsive to thrombin activation, confirming the importance of this site in 
receptor activation.  Furthermore, a mutant receptor in which the LDPR41 ↓ S42 site is 
replaced with an enterokinase site (DDDDK41 ↓ S42), which is cleaved by the protease 
enterokinase, is unresponsive to thrombin, but is responsive to enterokinase, although at a 
much lower potency [11].  These data suggest that cleavage of PAR1 is sufficient for 
activation, but that additional binding sites may facilitate the ability of thrombin to bind to 
the receptor.  The acidic sequence DFEEIPEE in hirudin was shown to bind to the anion 
3
 exosite on α-thrombin.  A similar sequence (E53PFWEDEEKENES64) was identified in the 
amino terminus of PAR1 carboxyl to the thrombin cleavage site and was termed the hirudin-
like domain (Figure 1.2).  α-thrombin initially binds to the hirudin-like domain in the amino-
terminus of PAR1 leading to recognition of the R41 ↓ S42 peptide bond by thrombin thus 
facilitating cleavage of the receptor [12].  γ-thrombin, which is unable to recognize the 
hirudin-like binding domain, activates PAR1 with a much lower potency [13, 14].  Synthetic 
peptides corresponding to the newly exposed amino terminus of PAR1 activate the wild type 
receptor and a cleavage inactive R41A mutant receptor, although with a much lower potency 
than α-thrombin [15].  Receptor chimeras of human PAR1 in which the extracellular loops 
were exchanged with cognate sequences of Xenopus laevis PAR1 or human PAR2 indicated 
that the second extracellular loop of PAR1 is important for intramolecular activation by the 
tethered ligand [16, 17]. 
In addition to thrombin, several other proteases cleave and activate PAR1, including 
trypsin, Factor Xa, Factor VIIa, activated Protein C (APC), plasmin and Granzyme A [4, 18-
21].  In the case of Factor VIIa, TF is required as a cofactor to localize Factor VIIa to the 
plasma membrane and presents Factor VIIa to PAR1 in a conformation that allows it to 
cleave and activate the receptor [19].  APC also binds to the membrane spanning cofactor 
endothelial Protein C receptor (EPCR), which is important for recognition and cleavage of 
PAR1 by APC [22].  Other proteases such as cathepsin G, elastase and proteinase 3 also 
cleave PAR1, but in a non-productive manner by cleaving downstream of the R41 ↓ S42 
activation site [23-26], resulting in truncation of the tethered ligand domain.  The 
significance of the permanent inactivation of PAR1 by these proteases remains unknown, but 
may antagonize thrombin responses in certain physiological settings.   
4
 PAR1 is expressed in platelets, endothelial cells, fibroblasts, smooth muscle cells, 
neutrophils, leukocytes, neurons, glial cells and other cell types.  Most of the cellular 
responses elicited by thrombin activation of PAR1 contribute to repair of vascular damage, 
including platelet aggregation, regulation of vessel diameter and control of endothelial barrier 
permeability [3].  PAR1 also plays an important role in embryonic development by mediating 
vascular repair upon spontaneous rupture of blood vessels in the embryo [27, 28].  More 
detail about the physiological roles of PAR1 in the vasculature is given in the second section 
of this introduction.   
 
1.1.2.2.   PAR2 
In 1994, a second protease-activated receptor was identified in a mouse genomic 
library screen using primers corresponding to the substance K receptor as a probe.  The 
identified open reading frame was shown to encode seven transmembrane spanning regions 
based on hydropathy analysis and appeared to be most closely related to PAR1 with 30% and 
28% identity with the human and mouse isoforms, respectively.  The gene was cloned and 
named protease-activated receptor-2 (PAR2) [29].  Although thrombin weakly activates 
PAR2 in a Xenopus oocyte system that uses calcium release as an indicator of receptor 
activation, trypsin activates PAR2 with an EC50 of approximately 1 nM [29] and is not 
considered a thrombin receptor.  A trypsin cleavage site at R34 ↓ S35 is present in PAR2 and 
synthetic peptides corresponding to the newly exposed amino terminus activate PAR2 with 
an EC50 of 5 µM.  PAR2 is also activated by mast cell tryptase [30], Factors VIIa and Xa 
[19], and several other serine proteases.  PAR2 mRNA is highly abundant in the kidney, 
pancreas, stomach, small intestine, colon and eye based on Northern blot analysis [29, 31]. 
5
 PAR2 mediates various physiological effects in the cardiovascular system, the 
gastrointestinal system and the skin.  In the vasculature, PAR2 regulates vascular tone by 
mediating relaxation of the endothelium [32] and vasoconstriction of smooth muscle cells 
[33-35].  PAR2 also plays an important role in wound healing and vessel repair by 
stimulating the activation of T-cells and neutrophils and promoting leukocyte rolling and 
adhesion [36].  In the gastrointestinal tract, PAR2 stimulates a short circuit current resulting 
in the transport of chloride ions in enterocytes [37] and mediates secretion of amylase in the 
pancreas and general secretion by the salivary, parotid and sublingual glands [38, 39].  In the 
skin, the level of PAR2 expression is higher in differentiated keratinocytes than in cells 
present in the proliferating basal layer [40, 41], suggesting a role for PAR2 in keratinocyte 
differentiation.   
 
1.1.2.3.   PAR3  
The search for a second thrombin receptor was prompted by the observation that the 
tail bleeding times, an in vivo measure of hemostasis, of PAR1 knockout mice (Par1-/-) were 
indistinguishable from their wildtype littermates.  Additionally, platelets from Par1-/- mice 
were able to aggregate and elicit an increase in intracellular calcium in response to thrombin 
similar to platelets isolated from wildtype littermates, suggesting the presence of a second 
receptor for thrombin [27].  PAR3, was cloned using degenerate PCR and rat platelet mRNA 
[42] and has 27% identity to PAR1 and 28% identity to PAR2.  PAR3 contains a serine 
protease cleavage site, LPIKT39 ↓ F40, in the amino-terminus [43] and a hirudin-like binding 
domain C-terminal the cleavage site, similar to PAR1 [42].  Human PAR3 confers an 
increase in phosphatidylinositol (PI) hydrolysis in response to thrombin in COS7 cells and 
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 Xenopus oocytes, while cleavage inactivatable (T39P or F40A) receptors are unable to respond 
to thrombin.  Other serine protease, such as Factor Xa or VIIa, trypsin, tissue plasminogen 
activator or plasmin are not able to activate human PAR3, suggesting specificity for 
proteases which cleave and activate PAR3 that is at least as stringent as that observed with 
PAR1.  Unlike PAR1, peptides corresponding to the newly formed amino terminus of human 
PAR3 are not able to promote of PI hydrolysis in COS7 cells where the receptor is 
heterologously expressed [42]; however, signaling to other downstream effectors was not 
been examined.  Signaling induced directly by the murine PAR3 in response to thrombin and 
agonist peptides have not been detected, suggesting species differences in PAR3 function 
[44].   
Interestingly in mice, PAR3 plays an important role in platelet aggregation.   Platelets 
from PAR3 knockout mice respond to high, but not low, concentrations of thrombin, 
suggesting that although murine PAR3 cannot signal on its own, it may facilitate thrombin 
activation of another platelet receptor [45].  PAR3 does not function in human platelet 
aggregation as human platelets express PAR1 and PAR4, but not PAR3.  The function of 
PAR3 in other cell types has not been explored due to lack of PAR3 specific agonist peptides 
and inability to discriminate between thrombin signaling mediated by the different PARs.  
However, PAR3 is expressed in a number of organs and cell types, including the heart, small 
intestines, bone marrow, airway smooth muscle cells, vascular endothelium and astrocytes 
[42, 46, 47].  The expression of PAR3 in these cell types suggests an important role for 
PAR3 in physiological settings.  
 
1.1.2.4.   PAR4 
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 Since Par3-/- platelets retained responses to high concentrations of thrombin, a search 
for a third thrombin receptor was initiated.  PAR4 was identified by searches of expressed 
sequence tag (EST) databases for PAR-like sequences [45, 48].  The receptor was 
subsequently cloned from a lymphoma Daudi cell line cDNA library and mouse embryo and 
mouse brain endothelial cell line cDNAs, followed by cloning of the human receptor.  PAR4 
shares approximately 33% sequence identity with other PAR family members and contains a 
serine protease cleavage site at PAPR47 ↓ G48, but no hirudin-like binding sequence.   PAR4 
is cleaved and activated by thrombin, trypsin and cathepsin G by a proteolytic mechanism as 
a cleavage defective receptor cannot signal in response to these proteases but does signal in 
response to synthetic peptides corresponding the new amino terminus [48, 49].  Both α- and 
γ-thrombin activate PAR4 with equal efficacy, which is probably due to the lack of a hirudin-
like binding site [48].   
Thrombin signaling is delayed and less efficacious in platelets from Par3-/- mice [45], 
whereas thrombin signaling is completely ablated in platelets from Par4-/- mice [50].  
Additionally, mouse PAR3 does not stimulate PI hydrolysis and PAR4 only stimulates PI 
hydrolysis at concentrations of thrombin below those that activate platelets from wildtype 
mice [44, 48, 49], suggesting a cooperative, functional response between PAR3 and PAR4.  
Despite its inability to initiate a signaling response alone, PAR3 mediates thrombin signaling 
by functioning to localize thrombin near PAR4 on the plasma membrane.  Thrombin binds to 
the hirudin-like binding site on PAR3 which localizes the protease on the cell surface to 
facilitate cleavage and activation of PAR4.  Co-expression of PAR3 and PAR4 in a COS7 
system where the receptors are heterologously expressed promotes PI hydrolysis at lower 
concentrations of thrombin than when either of the receptors are expressed alone [44].  Thus, 
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 PAR4 is considered a low affinity receptor for thrombin and PAR3 is thought to function as a 
coreceptor.   
PAR4 is expressed in platelets, lung, pancreas, thyroid, testes and small intestine, 
suggesting unique roles for PAR4 in human physiology based on its varied expression 
compared to other PARs [48].  In addition, proteases other than thrombin are potent 
activators of PAR4, suggesting that the activating protease for PAR4 may not be thrombin in 
all physiological settings.  In addition, the coexpression of either PAR1 or PAR3 in some cell 
types modulates thrombin activation of PAR4.  Given the varied expression and the different 
requirements for activation of PAR4 compared to PAR1, the role of PAR4 in many human 
physiological responses remains to be determined.  
 
1.1.3.   Physiological roles of PAR1 
1.1.3.1.   Embryonic development 
A role for the thrombin receptor, PAR1, in embryonic development is evident by the 
observation that half of Par1-/- embryos die at midgestation resulting from defective blood 
vessel formation and subsequent bleeding that occurs independent of platelets [27, 28].  This 
hemorrhage is independent of the role of PAR1 in platelet activation and fibrin formation as 
platelets are not present at this stage of development, murine platelets do not express PAR1, 
and fibrinogen is not necessary for development in wild type or Par1-/- mice.  Rather, Par1-/- 
bleeding and lethality are likely due to defective PAR1 signaling in endothelial cells, since 
PAR1 is highly expressed in the endocardium and endothelium at midgestation and Par1-/- 
embryos are rescued by an endothelial cell-specific PAR1 transgene [28].  This finding 
suggests that proper signaling by PAR1 in endothelial cells during development plays a 
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 critical role in sensing occasional ruptures in the vasculature and in mounting a non-
traditional hemostatic response, an essential process for developing blood vessels.  
Interestingly, ischemia increases the permeability of endothelial cells and induces TF 
expression in adults [28], suggesting that the coagulation cascade and its effects on PARs 
may mediate a mechanism whereby vessels sense and respond to inadequate tissue perfusion.  
Recent work examining Gα13 knockout mice (Gα13-/-) suggests that PAR1 may exert its 
effects on the vasculature during development via activation of Gα13 and downstream 
effectors.  Gα13-/- mice display defects in vascular development similar to phenotypes in 
Par1-/- mice, which are rescued by endothelial specific expression of Gα13 [51].   
 
1.1.3.2.   Platelet activation 
PARs display species specific differences in expression in platelets.  PAR1 and PAR4 
are expressed in human platelets and PAR3 and PAR4 are expressed in mouse platelets.  In 
human platelets, PAR1 mediates platelet secretion and activation at low concentrations of 
thrombin, while PAR4 mediates platelet activation at high concentrations of thrombin and 
displays sustained signaling compared to PAR1 [52-54].  In mouse platelets, PAR3 does not 
appear to signal, but instead acts as a cofactor for PAR4 activation by facilitating thrombin 
recognition of PAR4 [44]. 
 Thrombin is the most potent activator of platelet aggregation in vivo and in vitro [55].  
In human platelets, thrombin induces platelet shape change and causes release of ADP and 
thromboxane A2, which act in an autocrine or paracrine fashion to further promote platelet 
activation [56].  In addition, the integrin αIIb/β3 is activated and exteriorized on the platelet 
surface and mediates binding to fibrinogen and von Willebrand factor in order to facilitate 
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 platelet linkages [57, 58].  P-selectin and CD40 ligand are also activated and translocated to 
the plasma membrane to facilitate binding of platelets to endothelial cells [59, 60].   
Selective inhibition of PAR1 activation by thrombin in human platelets using 
blocking antibodies and antagonists blocks platelet activation at low concentrations of 
thrombin [54, 61-63]; however, inhibition of PAR4 using blocking antibodies has no effect 
on thrombin-stimulated activation of platelets.  Dual inhibition of PAR1 and PAR4 is 
sufficient to completely block thrombin stimulated activation of human platelets [54].  Taken 
together, these data suggest that PAR1 is the major physiological mediator of thrombin 
activation of platelets.  PAR4 function in platelet activation is not clear, but PAR4 may 
contribute by sustaining thrombin signaling, by providing redundancy in an extremely 
important physiological process or by mediating responses to other proteases such as 
Cathepsin G which activates PAR4 but not PAR1.   
 In mouse platelets, which express PAR3 and PAR4, a dual receptor exists where 
PAR3 serves as a cofactor for PAR4 activation at low concentrations of thrombin [64].  
Thrombin is capable of stimulating activation of platelets from PAR3 knockout mice only at 
high concentrations (due to the presence of PAR4) [45], while platelets from PAR4 knockout 
mice are unresponsive to all concentrations of thrombin [50].   
Platelets from PAR4 knockout mice (Par4-/-) provide an excellent model to determine 
the role of thrombin activation of platelets in hemostasis.  Par4-/- mice display prolonged 
bleeding times, but develop normally with no anemia or spontaneous bleeding [50].  
Interestingly, the phenotypes observed in these mice are not as severe as those observed in 
mice deficient in other major hemostatic effectors, such as fibrinogen and prothrombin [65-
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 67].  Thus, studies utilizing mouse models suggest that PAR receptors may be excellent 
targets for drug targets for anti-thrombotic treatments.   
 
1.1.3.3.   Cardiovascular system 
 Activation of PAR1 on endothelial cells and smooth muscle cells in the vasculature 
controls resistance and blood flow and endothelial barrier permeability.  The effect of PAR1 
activation on resistance and blood flow depends on the vessel being studied and also whether 
PAR1 activation is occurring in the endothelium or smooth muscle cells.  In aortic and 
coronary arteries from several species, PAR1 activation causes relaxation of precontracted 
blood vessels, possibly due to endothelium-mediated relaxation of vascular smooth muscle 
cells [68-71], which is believed to occur due to the release of prostaglandin I2 and nitric 
oxide [72, 73].  Alternatively, PAR1 activation of vascular smooth muscle cells independent 
of the endothelium also mediates a contractile response [72, 73].  Furthermore, a PAR1-
mediated contractile response of human umbilical vein and placental arteries was observed 
despite the presence of the endothelium [74].  
 Thrombin also activates endothelial cells and causes translocation of P-selectin to the 
plasma membrane [75], secretion of von Willebrand factor [75], growth factors [76], and 
cytokines [77], and change in shape and permeability of the endothelial barrier [78].  Low 
concentrations of thrombin appear to have a protective affect, while high concentrations of 
thrombin appear to increase barrier permeability.  The effects of thrombin on endothelial 
barrier permeability are due to direct activation of PAR1, but the level of receptor activation 
can induce opposing effects.  For instance, APC binds to its cell surface receptor, EPCR, to 
cleave and activate PAR1, although less efficiently than thrombin [79, 80].  Activation of 
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 PAR1 by APC leads to barrier protective effects in endothelial cell culture model systems 
[79].  Therefore, in the context of vascular damage, PAR1 appears to mediate the endothelial 
cellular responses elicited by thrombin in hemostasis.   
 
1.1.4.   Pathology of PAR1 and therapeutics 
1.1.4.1.   Hemostasis and thrombosis 
 Hemostasis is responsible for bleeding cessation and occurs by activation of platelets, 
formation of a matrix plug by fibrin, and vasoconstriction of vascular walls.  Thrombin 
activation of PAR1 in platelets and endothelial cells play an important function in regulating 
hemostasis and therefore, much focus has been on developing therapies aimed at inhibiting 
thrombin function.  However, the finding that a significant portion of prothrombin deficient 
mice die at midgestation due to cardiovascular collapse and the surviving mice die from 
uncontrollable bleeding, suggests that thrombin is not a viable therapeutic target [66, 67].   
Indeed, clinical studies indicate that inhibition of thrombin in humans increases bleeding 
risks and provides very narrow therapeutic windows for drug dosing.  Work in platelets from 
Par4-/- mice, which are not activated by thrombin, suggests that PARs are viable therapeutic 
targets [50].  However, due to species differences in PAR expression in platelets, antagonism 
of PARs in humans as anti-coagulant therapies is more complicated than in mice.  In humans, 
both PAR1 and PAR4 mediate platelet activation upon thrombin stimulation, raising the 
possibility that antagonism of both PAR1 and PAR4 may be necessary for therapeutics aimed 
at inhibiting thrombin activation of platelets.  Primates, such as cynomolgus monkeys, 
express PAR1 and PAR4 on their platelets similar to humans; thus, providing a model 
organism to examine the effects of anti-PAR therapeutics [81].   
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  Several occlusive vascular disorders, including stroke, angina, and myocardial 
infarction, are caused by the formation of atherosclerotic plaques within the vasculature that 
result from thrombus formation of inappropriately aggregated platelets.  Par3-/- and Par4-/- 
mice, which are defective in thrombin induced platelet activation, are protected against 
thrombosis [50, 82].  Recent studies in Par4-/- mice suggest that thrombin activation of 
platelets is not required for the initial thrombus formation, but is required for propagation and 
growth of the platelet thrombus [83].  Together, these studies suggest that PARs activated by 
thrombin in human platelets may be an excellent target for anti-thrombotic therapies.   
 
1.1.4.2.   Cancer 
Hyperactivation of the coagulation cascade is implicated in the progression of several 
types of malignant cancer.  Coagulant proteases and PARs are present in the tumor 
microenvironment and PARs are expressed in cancer cells themselves.  Indeed, PAR1 is 
overexpressed in aggressive melanoma [84], colon [85], prostate cancer [86], and invasive 
breast cancer [87].  In addition, stromal fibroblasts within the tumor microenvironment also 
have increased PAR1 expression [88].   
In the tumor microenvironment, proteases are abundantly present and active and 
several are capable of activating PAR1.  For instance, tumor cells upregulate urokinase-
plasminogen activator (uPA), which binds to its cell surface receptor uPAR and cleaves and 
activates plasminogen, thus generating plasmin [89].  Plasmin cleaves and activates PAR1 
[20].  Plasmin also cleaves and activates several matrix-metalloproteases (MMPs) including 
MMP-1 which has been shown to activate PAR1 [90].   
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 Activation of PAR1 in tumor cells leads to persistent signaling which has been 
implicated in cancer progression.  PAR1 stimulates cell proliferation through the activation 
of extracellular regulated kinase 1/2 (ERK1/2) [91].  ERK1/2 not only promotes cell cycle 
progression, but also contributes to cellular transformation, migration and survival.  In 
invasive breast carcinoma cell lines, proteolytic activation of PAR1 leads to prolonged 
signaling to ERK1/2 [92] and promotes breast carcinoma cell invasion [85, 86].  Activation 
of PAR1 also inhibits apoptosis in some cell types [93, 94], suggesting another possible 
mechanism by which PAR1 promotes tumor growth.   Additionally, a role for PAR1 in 
promoting tumor cell migration and metastasis exists.  Overexpression of PAR1 in non-
invasive MCF-7 breast carcinoma cells is sufficient to promote migration and invasion in a 
xenograft nude mouse model [90].  Alternatively, knockdown of PAR1 expression by siRNA 
in invasive breast carcinoma cells is able to suppress migration and invasion in vitro and in 
vivo [87, 92, 95].  PAR1 also plays a role in promoting angiogenesis in the tumor 
microenvironment as PAR1 expression in prostate and melanoma cancer cells causes release 
of vascular endothelial growth factor, enhanced angiogenesis, and tumor growth [96].  
 
1.2.   Regulation of PAR1 signaling 
1.2.1.   PAR1 signaling  
 GPCRs elicit cellular responses by coupling to heterotrimeric G-proteins composed of 
Gα, Gβ, and Gγ subunits.  Under basal conditions, the Gα subunit binds GDP and Gα⋅GDP 
binds to the Gβγ dimer.  Upon activation, GPCRs act as guanine nucleotide exchange factors 
(GEFs) and catalyze the exchange of GDP for GTP on the Gα subunit and the release of the 
Gβγ dimer.  Both the GTP bound form of Gα and the Gβγ dimer signal to downstream 
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 effectors.  The Gα subunit is returned to its inactive state upon hydrolysis of GTP to GDP 
which is achieved by the intrinsic guanosine triphosphatase (GTPase) activity of the Gα 
subunit.  The GTPase activity of Gα subunits is enhanced by proteins containing an RGS 
(regulators of G-protein signaling) domain which act as GTPase accelerating proteins 
(GAPs) for the Gα subunit.  The GDP bound form of Gα then reassociates with the Gβγ 
dimer to terminate signaling to downstream effectors, followed by reassociation with 
resensitized receptors [97].   
Similar to other GPCRs, PAR1 couples to multiple heterotrimeric G-protein subtypes 
to mediate diverse cellular responses.  PAR1 couples to Gαq/11, Gαi and Gα12/13, often within 
the same cell (Figure 1.3).  The extent of coupling to each of these pathways is mediated in 
part by the level of expression of the G-proteins and downstream effectors in various cell 
types.  In addition, compartmentalization of the receptor and G-proteins within subdomains 
of the plasma membrane or the conformational state of the receptor may play a role in PAR1 
coupling to distinct G-protein subtypes.   
Activated PAR1 couples to Gαq/11 and results in activation of phospholipase C (PLC) 
isozymes, including PLCβ, which catalyzes the hydrolysis of PIP2 (phosphatidylinositol 
(4,5)-bisphosphate) resulting in the formation of diacylglycerol (DAG) and inositol (1,4,5) 
trisphosphate (IP3).  DAG facilitates the activation of protein kinase C (PKC) and IP3 
activates the ryanodine receptor on the endoplasmic reticulum resulting in the release of 
intracellular calcium (Figure 1.3) [61, 98].  PAR1 stimulation of PLCβ in Rat1 fibroblasts 
accounts for the early increase in PI hydrolysis, but not for sustained PI hydrolysis, 
suggesting that other PLC isozymes are activated by PAR1 [99].  Coupling of PAR1 to 
Gαq/11 also results in activation of the mitogen-actived protein (MAP) kinase pathways [100].  
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 Interestingly, Gαq-deficient mice display increased bleeding times probably due to 
diminished thrombin-induced platelet activation and degranulation as a result of insufficient 
PLC activation by PAR4 [101].   
PAR1 also couples directly to the Gαi family of proteins, which inhibits adenylyl 
cyclase and decreases the formation of cAMP in a pertussis toxin (Ptx)-sensitive manner.  
Ptx catalyzes ADP-ribosylation of the Gα subunit of GαiGβγ, thus preventing disassociation 
of Gαi the Gβγ subunits.  Thrombin mediated effects on cellular proliferation are partially 
Ptx-sensitive implicating Gαi family members in mitogenic responses [100].  The release of 
the Gβγ dimer by Gαi upon thrombin stimulation results in activation of phosphatidylinositol 
3-kinase (PI3K) and some isoforms of PLC.  Signaling by Gβγ dimers upon thrombin 
stimulation mediates changes in the actin cytoskeletal structure, cell motility, survival and 
mitogenesis [102]. 
Activated PAR1 also couples to Gα12 family members.  A [α-32P] GTP-azidoanilide 
analog is incorporated into Gα12 and Gα13 following stimulation with thrombin in platelets 
and astrocytoma cells [103, 104].  Gα12/13 interacts with and activates GEFs for the small G-
protein, Rho, leading the activation of Rho kinase.  Activation of Gα12/13 and Rho 
downstream of PAR1 also leads to activation of PLCε [105], which is responsible for the 
sustained PI hydrolysis stimulated by thrombin observed in Rat1 fibroblasts [99].  Inhibition 
of Gα12/13 in platelets leads to a decrease in the ability of platelets to undergo shape change 
following thrombin stimulation [106], while fibroblasts from Gα13 knockout mice exhibit 
decreased migratory responses upon thrombin stimulation [107].  A role for Rho activation in 
mediating cell rounding and endothelial barrier function downstream of thrombin activation 
of PAR1 has been demonstrated in human umbilical vein endothelial cells (HUVECs) [108].  
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 In addition to its function in cell migration and cell shape, Gα12 also plays a role in thrombin 
stimulated cellular proliferation as injection of Gα12 antibodies into human astrocytoma cells 
blocked thrombin stimulated gene transcription and DNA synthesis [104].  However, the role 
of Gα12/13 in other thrombin elicited cellular responses remains to be defined. 
 
1.2.2.   PAR1 desensitization 
Proteolytic activation of PAR1 results in the formation of a tethered ligand that does 
not diffuse away.  Despite the irreversible proteolytic mechanism of activation, signaling by 
PAR1 is rapidly terminated.  Indeed, the cumulative amount of inositol phosphates formed 
upon thrombin stimulation correlates with the amount of cleaved receptor at any given time 
[109], suggesting that each activated receptor generates a defined amount of second 
messenger and then shuts-off.  Thus, the mechanisms that contribute to PAR1 signal 
termination are critical for controlling the magnitude and duration of thrombin-elicited 
cellular responses.   
Most activated GPCRs, such as the β2-adrenergic receptor (β2AR), are rapidly 
desensitized by rapid phosphorylation mediated by G-protein receptor kinases (GRKs) [110].  
Phosphorylation of the activated receptor enhances the binding affinity of arrestins which 
prevent the receptor from interacting with G-proteins.  PAR1 desensitization is also initiated 
by rapid phosphorylation mediated by GRK3 and GRK5, as overexpression of these kinases 
markedly inhibits thrombin-induced PI hydrolysis accumulation [111, 112].  A mutant of 
PAR1 in which all of the serines and threonines the C-tail were converted to alanines is not 
phosphorylated, displays enhanced signaling at least to Gαq, and is insensitive to GRK-
mediated desensitization [111, 113].   
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 Despite a clear role for GRKs in mediating PAR1 C-tail phosphorylation and 
desensitization, a PAR1 C-tail serine and threonine mutant displays a typical dose response 
to thrombin in some cell systems [111, 113], suggesting that other mechanisms may function 
in PAR1 desensitization.  The ubiquitously expressed β-arrestin1 and β-arrestin2 (also 
known as arrestin2 and arrestin3) play a role in desensitization of most activated GPCRs 
[114].  In mouse embryonic fibroblasts (MEFs) generated from β-arrestin1 and β-arrestin2 
knockout mice, PAR1 mediated PI hydrolysis is enhanced compared to MEFs derived from 
wildtype littermates, despite similar levels of cell surface receptor expression in both cell 
types [115].  Moreover, desensitization of PAR1 by arrestins occurs by a phosphorylation-
independent mechanism [116].  Interestingly, the β-arrestin1 isoform appears to be the 
critical isoform for PAR1 desensitization.  The effects of phosphorylation and arrestin 
binding on PAR1 uncoupling from Gαi and Gα12/13 has not been determined.  Although, 
arrestins clearly function in PAR1 desensitization, they are not essential for PAR1 
internalization.  
 
1.3.   GPCR internalization 
In addition to desensitization, PAR1 trafficking is critically important for regulating 
signaling response to thrombin.  Here, we will discuss what is currently known about 
mechanisms of receptor endocytosis, the mechanisms that control GPCR endocytosis and the 
molecular mechanisms of PAR1 endocytosis. 
 
1.3.1.   Clathrin-mediated endocytosis 
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 The majority of cell surface receptors and integral membrane proteins are internalized 
by clathrin-mediated endocytosis.  Clathrin-coated pits are composed of clathrin heavy and 
light chain molecules that form a polymeric lattice as well as dozens of regulatory proteins. 
Release of the clathrin-coated pit from the plasma membrane is mediated by the large 
GTPase dynamin.  Clathrin, adaptor proteins and numerous accessory proteins are recruited 
to plasma membrane regions enriched in PIP2 and together support coated pit assembly and 
invagination [117].  The function of clathrin adaptors is to enrich select cargo within a 
forming vesicle.  The adaptor protein complex-2 (AP2) is the most abundant adaptor protein 
found in clathrin-coated pits at the plasma membrane and recognizes short linear tyrosine- 
and dileucine-based cytoplasmic sequences of cargo proteins (Table 1.1) [118].  However, 
endocytic clathrin-coated pits also accommodate cargo proteins that do not harbor these 
motifs, suggesting that AP2 alone is unlikely to have a universal function in cargo 
recruitment. 
 Increasing evidence suggests that monomeric clathrin adaptors that bind clathrin and 
PIP2 cooperate with AP2 to recruit cargo and promote clathrin-dependent endocytosis 
(Figure 1.4).  Recent work has also identified an α-helical motif in several monomeric 
adaptor proteins including arrestins, autosomal recessive hypercholesterolemia (ARH) and 
epsins that bind the β2-appendage of AP2 with high affinity [119].  Clathrin adaptors interact 
with short linear sequences, in addition to recognizing phosphorylated
and ubiquitinated cargo (Table 1.1).  Clathrin adaptors themselves are also modified by 
phosphorylation and ubiquitination, suggesting that clathrin adaptor activity is tightly 
regulated (Figure 1.5).  The first monomeric adaptor proteins shown to function in clathrin-
mediated endocytosis were the non-visual arrestins.  Non-visual arrestins interact with 
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 clathrin and AP2 and facilitate internalization of activated and phosphorylated GPCRs.  A 
second group of monomeric clathrin adaptor proteins include epsins, clathrin assembly 
lymphoid myeloid leukemia protein (CALM)/AP180 (AP180 is a neuronal orthologue of 
CALM) and huntington-interacting protein-1 (HIP1) and HIP1R (HIP1 related).  These 
proteins contain an N-terminal PIP2 binding domain (termed ENTH/ANTH domain) and 
interact with clathrin and AP2.  In addition, epsin (eps15-interacting protein) harbors three 
ubiquitin-binding domains (UBDs), binds eps15 (EGFR pathway substrate 15) and eps15R 
(eps15 related), which also contain UBDs, and recruits ubiquitinated cargo to clathrin-coated 
pits.  Both CALM/AP180 and HIP/HIP1R lack UBDs and how they function in cargo 
recruitment is unclear.  HIP1 and HIP1R dimerize via their coiled-coil regions and HIP1R 
binds directly to F-actin linking the actin cytoskeleton to the endocytic machinery (Figure 
1.4).  A third group of monomeric clathrin adaptors includes disabled-2 (Dab2), ARH and 
numb (Figure 1.4).  Members of this group bind AP2, some interact with clathrin, and all 
contain a phosphotyrosine-binding (PTB) domain that recognizes FXNPXY motifs, although 
tyrosine phosphorylation is not a prerequisite for binding.  Besides arrestins, the function of 
other clathrin adaptors in mammalian GPCR endocytosis is relatively unexplored and has 
been described for only a few GPCRs as discussed below.  Distinct clathrin adaptors might 
function to ensure noncompetitive endocytosis of diverse GPCRs through the same clathrin-
coated pit.  Moreover, distinct clathrin adaptors might function to control critical aspects of 
GPCR signaling, similar to arrestins. 
 
1.3.2.   Clathrin-independent endocytosis 
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 Although the majority of cell surface receptors are internalized by a clathrin-
dependent mechanism, clathrin-independent mechanisms of endocytosis also exist.  One 
clathrin-independent pathway utilized in cells involves caveolin.  A unique pit coated by 
caveolin was identified by electron microscopy in the 1950s by Palade and Yamada [120, 
121].  There are three caveolin isoforms that consist of a thirty-three amino acid central 
hydrophobic domain that inserts into the plasma membrane in a hairpin loop and N- and C-
terminal cytoplasmic domains [122].  Caveolin-1 and caveolin-2 are expressed in endothelial 
cells, adipocytes and other cell types, while caveolin-3 is restricted to skeletal and cardiac 
muscle cells.  Some cells, such as lymphocytes and many neuronal cells, lack expression of 
all caveolins [123].  The plasma membranes of endothelial cells appear to be composed of 
30% caveolae [120], which are microdomains or lipid rafts that are composed of caveolins, 
cholesterol and glycosphingolipids [124, 125].  Interestingly, caveolin-1 knockout mice 
contain no caveolae except in certain cells where caveolin-3 is expressed and caveolin-2 
knockout mice have normal caveolae densities. Several cargo, such as GPI-anchored 
membrane components, extracellular ligands, non-enveloped viruses and toxins appear to 
internalize via caveolae [122].   
 Caveolae are also thought to serve as “hot spots” for receptor signaling at the plasma 
membrane.  Many components of G-protein signaling cascades are modified by fatty acid 
side chains, such as myristyl, palmitoyl, farnesyl, and geranylgeranyl groups, suggesting that 
caveolae may be especially important for signaling by GPCRs [126].  Interestingly, Kobilka 
and colleagues found that the β2AR resides in caveolae in a basal state and this 
compartmentalization is essential for signaling [127].  Caveolae-mediated internalization 
may also be regulated by intracellular signaling.  Upon engagement with caveolae, cargo 
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 activate the non-receptor tyrosine kinase Src leading to actin rearrangement and recruitment, 
followed by dynamin recruitment and activation that helps to detach the caveolae from the 
plasma membrane [123].  However, the exact role of caveolae in receptor trafficking and 
signaling remains controversial and will require better methods for a thorough investigation.   
Another mode of clathrin-independent endocytosis involves macropinocytosis.  The 
non-specific uptake of solutes and membrane that results from formation and scission of 
large circular or curved ruffles of the plasma membrane.  Bulk uptake of viruses, bacteria, 
apoptotic cell fragments, and small latex beads have been described to utilize a 
macropinocytic pathway [128-131].  Macropinocytosis is distinguished from other 
internalization mechanisms in that it is clathrin- and dynamin-independent [132] and usually 
occurs in response to growth factor or mitogenic agent stimulation.  The actin cytoskeleton is 
integral to scission of the forming vesicle and formation of the macropinosome [133, 134], 
while the GTPase ARF6 plays a role in recycling of macropinosomes to the plasma 
membrane [135].  The lack of specific cargo molecules that utilize a macropinocytic pathway 
has contributed to the difficulty in studying the intracellular fate of macropinosomes.  
 
1.3.3.   G protein-coupled receptor endocytosis 
The original reports of GPCR internalization (also termed sequestration) were from 
studies of the endogenous β2AR in frog erythrocytes and human astrocytoma cells.  Chuang 
and Costa observed that incubation of frog erythrocytes with isoproterenol caused an increase 
in the number of "soluble" β2ARs detected in a cytosolic fraction by radioligand binding 
[136].  Using human astrocytoma cells, Harden et al. showed that agonist induced the 
redistribution of a β2AR population from a heavy vesicle fraction (plasma membrane) to a 
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 light vesicle fraction that exhibited properties of a "desensitized" receptor, that is loss of high 
affinity ligand binding and insensitivity to guanine nucleotides [137].  Subsequent studies 
confirmed the movement of activated β2AR to clathrin-coated pits and internalization from 
the plasma membrane in intact cells [110]. 
 Several reports indicate that GPCRs of distinct conformations internalize through 
clathrin-coated pits by different mechanisms.  GPCRs isomerize between distinct 
conformational states, including the active and inactive states stabilized by agonists and 
antagonists, respectively.  In many cases, most notably the β2AR, activated GPCR 
phosphorylation mediated by GRKs and arrestin binding is required for endocytosis.  In 
contrast, some unactivated GPCRs constitutively internalize through clathrin-coated pits 
independent of phosphorylation and arrestin binding.  This has been well documented for 
PAR1 and the thromboxane-A2β receptor (TPβ) [115, 138].  However, phosphorylation is 
required for agonist-induced internalization of PAR1 and TPβ, suggesting that constitutive 
and agonist-induced internalization are specified by distinct endocytic machinery.  In 
addition, antagonist binding to the 5-hydroxytryptamine 2A (5-HT2A) serotonin receptor 
promotes internalization through an arrestin-independent but dynamin-dependent pathway 
without affecting receptor activity [139], indicating that for some GPCRs stabilization of an 
inactive conformation is sufficient to trigger endocytosis.  PKC-mediated phosphorylation of 
unactivated chemokine receptor 4 (CXCR4) also induces receptor endocytosis through a 
dynamin-dependent mechanism that appears distinct from ligand-induced internalization 
[140, 141].  Internalization of several other unactivated GPCRs by direct activation of PKC 
has also been reported [142].  Thus, multiple distinct GPCR conformations appear to require 
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 different endocytic machinery for internalization, suggesting that diverse mechanisms control 
clathrin-dependent endocytosis of GPCRs in mammalian cells. 
  The internalization of cargo through clathrin-coated pits is a highly regulated and 
dynamic process occurring within the 20-90 second lifetime of a clathrin bud.  Endocytosis 
of different types of cargo can be saturated but is non-competitive, indicating that diverse 
cargo can proceed efficiently through the same clathrin-coated pit, perhaps by using different 
endocytic machinery [143, 144].  A substantial literature supports the notion that clathrin-
coated pits are high capacity carriers that efficiently internalize diverse cargo probably 
through the use of distinct clathrin adaptors [145].  Classic electron microscopy studies as 
well as live cell imaging of fluorescently tagged clathrin adaptors also strongly suggest that 
clathrin-coated pits are uniform and homogenous in nature [146].  Recent studies from von 
Zastrow and co-workers suggest that internalization of certain GPCRs occurs through 
subpopulations of clathrin-coated pits [147].  These findings raise the possibility that distinct 
endocytic machinery is segregated in subsets of clathrin-coated pits.  Moreover, these subsets 
of clathrin coated-pits appear to have the capacity to regulate GPCRs containing PDZ 
(Postsynaptic density of the Drosophilia septate junction Discs-large and the epithelial tight 
junctions protein ZO-1) ligands through an actin-dependent mechanism.  This results in a 
difference in the surface residence times, but not in the early recruitment of diverse GPCRs 
to clathrin-coated pits, and suggests a new role for actin in directly regulating mammalian 
GPCR endocytosis.  Interestingly, Mundell et al. recently observed that the P2Y1 and P2Y12 
purinergic GPCRs, which both contain type-I PDZ ligands in their cytoplasmic tails, 
segregate from each other and internalize through distinct populations of clathrin-coated pits 
[148].  Clearly, this newly proposed regulated form of GPCR endocytosis deserves further 
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 research.  Although clathrin-coated-pits appear to form at preferential sites on the plasma 
membrane perhaps through interactions with the actin cytoskeleton and are unlikely to be 
induced by overexpressed cargo proteins [144, 149], it will be important to determine 
whether endogenous GPCRs, like ectopically expressed GPCRs, are sequestered and/or 
retained in subsets of clathrin coated-pits in native systems.   
 
1.3.4.   Arrestins 
The ubiquitously expressed arrestins are best known to function in regulation of 
GPCR desensitization and internalization.  Arrestins bind activated and phosphorylated 
GPCRs, which promotes receptor uncoupling from G-proteins and, in some cases, 
internalization through clathrin-coated pits.  Structural studies of arrestin have revealed 
distinct N- and C-domains composed of antiparallel β-sheets that are linked by an unusual 
twelve residue polar core [150].  The basal conformation of arrestin is maintained by a 
network of intramolecular interactions between charged residues buried within the polar core 
[151].  The N-domain of arrestin binds to diverse GPCR intracytosolic sequences, whereas 
the positively charged polar core engages receptor-associated phosphates.  Upon binding to 
activated and phosphorylated GPCRs, arrestins undergo a conformational change induced by 
engagement of receptor-associated phosphates with the polar core.  This confers high affinity 
binding of arrestin to cytoplasmic sequences of some, but not all GPCRs.  Binding is 
followed by exposure of the arrestin C-terminal domain, which interacts with components of 
the endocytic machinery including the clathrin heavy chain and the β2-adaptin subunit of 
AP2, and thereby facilitates GPCR internalization.  In Drosophila, visual arrestins have 
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 recently been shown to function in endocytosis of rhodopsin, a light-activated GPCR, 
although these arrestin variants lack a clathrin binding domain [152, 153]. 
 The mechanism by which arrestins promote GPCR endocytosis is best characterized 
for the β2AR and has been recently reviewed [154].  Activation of β2AR causes translocation 
of arrestins to the plasma membrane where the receptor preferentially binds arrestin3 rather 
than arrestin2.  The activated β2AR-arrestin complex redistributes to clathrin-coated pits and 
arrestin dissociates upon receptor internalization.  Arrestin interaction with clathrin and AP2 
is essential for agonist-induced β2AR internalization.  The endocytic activity of arrestin is 
controlled by both phosphorylation and ubiquitination (Figure 1.5).  Arrestins are basally 
phosphorylated and dephosphorylated upon recruitment to the plasma membrane.  
Dephosphorylation of arrestins is required for agonist-promoted β2AR internalization.  In 
addition to phosphorylation, the ubiquitination status of arrestin is important for its endocytic 
activity.  Arrestins interact with the E3 ubiquitin ligase mouse double minute-2, Mdm2, 
which specifically ubiquitinates arrestins bound to activated β2AR [155].  Ubiquitination of 
arrestin is essential for β2AR internalization (Figure 1.6).  Other regulators of clathrin-
dependent β2AR endocytosis include ARF6 and its GEF ARNO that bind arrestins, and the 
GTPase activating protein GIT1, PI3K and ezrin, all of which interact with GRK2.  The 
β2AR illustrates the complexity by which clathrin-dependent GPCR endocytosis is controlled 
and suggests that endocytosis of other GPCRs is equally complex.  In addition to GPCRs, 
arrestins regulate endocytosis of other cell surface receptors and integral membrane proteins 
including the insulin-like growth factor-1 (IGF-1) receptor, type III transforming growth 
factor-β (TGF-β) receptor, low-density lipoprotein (LDL) receptor, the Na+/H+ exchanger 5 
(NHE5) transporter and most recently VE-cadherin (Table 1.1) [156].  In some cases, 
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 arrestins facilitate endocytosis by binding to phosphorylated serine/threonine residues in the 
cytoplasmic regions of these cargo proteins.  Thus, arrestins are capable of regulating 
endocytosis of diverse cargo like other clathrin adaptors. 
 
1.3.5.   Adaptor protein complex-2 
The finding that several GPCRs internalize independent of arrestins suggests that 
other clathrin adaptors function as critical regulators of mammalian GPCR endocytosis.  The 
first reports of arrestin independent GPCR internalization employed dominant-negative 
arrestin and dynamin mutants.  Using these mutants, the m1, m2, m3 and m4 muscarinic 
acetylcholine receptors [157, 158], prostacyclin receptor [159], and 5-HT2A serotonin 
receptor [139] were shown to internalize through an arrestin-independent, but dynamin-
dependent pathway.  More definitive evidence for an arrestin independent mechanism for 
GPCR endocytosis came from the use of MEFs derived from arrestin2,3 double knockout 
mice [160].  Both constitutive and agonist-induced internalization of PAR1 were shown to 
proceed through an arrestin independent but clathrin- and dynamin-dependent pathway in 
MEFs lacking endogenous arrestins [115].  Subsequent studies used arrestin null MEFs to 
demonstrate arrestin-independent internalization of the N-formyl peptide receptor [161], the 
human viral chemokine receptor US28 [162], and the urotensin receptor [163].  These studies 
provide strong evidence that alternate clathrin adaptors function in GPCR endocytosis. 
 One clathrin adaptor shown to function directly in mammalian GPCR endocytosis is 
AP2.  The heterotetrameric AP2 complex is composed of α, β2, µ2, and σ2 subunits and 
recognizes short linear sequences that reside in the intracytosolic regions of transmembrane 
proteins [164].  The α subunit of AP2 binds to PIP2, localizing AP2 on the plasma 
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 membrane, whereas the β2 subunit binds to the clathrin heavy chain.  AP2 is able to recruit 
cargo through µ2 subunit interactions with intracytosolic tyrosine-based motifs (YXXφ).  
Additionally, α/σ2 subunits, and possibly β2 subunit, recognize acidic dileucine motifs 
([DE]XXXL[LI]) in the cytosolic regions of cargo proteins (Table 1.1).  The endocytic 
activity of AP2 is regulated by µ2 subunit phosphorylation mediated by the AP2-associated 
kinase-1, AAK1, which enhances µ2 affinity for YXXφ motifs (Figure 1.5) [165].  AP2 is 
known to mediate endocytosis of a variety of cell surface receptors and integral membrane 
proteins and a recent study indicates that AP2 functions directly in GPCR endocytosis.  We 
previously found that rather than arrestins, AP2 is required for PAR1 constitutive 
internalization through a clathrin- and dynamin-dependent pathway (Figure 1.3) [166].  
PAR1 constitutive endocytosis generates an intracellular protected pool of naïve receptor that 
replenishes the cell surface after thrombin exposure and is required for rapid cellular 
resensitization independent of de novo receptor synthesis.  The µ2 subunit of AP2 was shown 
to directly bind to a tyrosine-based motif (YXXL) in the cytoplasmic tail of PAR1 using 
surface plasmon resonance.  Moreover, the expression of a PAR1 tyrosine mutant or 
depletion of AP2 by siRNA led to significant inhibition of PAR1 constitutive internalization, 
loss of intracellular uncleaved PAR1, and failure of endothelial cells and other cell types to 
resensitize to thrombin signaling.  However, internalization of activated PAR1 is neither 
dependent on AP2 nor arrestins, suggesting that constitutive and agonist-induced 
internalization operate with distinct endocytic machinery.  The mechanisms responsible for 
activated PAR1 endocytosis are the focus of the work described in Chapters 2 and 4 of this 
dissertation.   
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  Several other GPCRs also contain tyrosine and dileucine-based motifs conforming to 
canonical and non-canonical AP2 recognition motifs in their cytoplasmic tails [166], 
suggesting that AP2 might function in trafficking of other GPCRs.  A related YXXXφ motif 
exists in the TPβ receptor cytoplasmic tail and functions in arrestin-independent constitutive 
internalization, but the role of AP2 has not been tested [138].  Interestingly, YXXGφ motifs 
bind µ2 at the same site as canonical YXXφ motifs, where the Y and φ residues are 
accommodated in the same hydrophobic pockets [167], further suggesting that AP2 might 
function in TPβ constitutive endocytosis.  The chemokine CXCR2 receptor has two 
cytoplasmic tail dileucine motifs and a dileucine mutant receptor bound arrestin but failed to 
interact with AP2 and to undergo agonist-induced internalization [168].  The β2AR and 
CXCR4 also contain a cytoplasmic tail dileucine motif that appears to function in receptor 
endocytosis.  Mutation of the β2AR cytoplasmic tail dileucine motif impairs agonist-induced 
endocytosis [169], but the affects on arrestin and AP2 binding are not known.  Interestingly, 
agonist-induced CXCR4 internalization is dependent on serine residues and an adjacent 
dileucine motif in certain cell types [140], whereas in other cell types the serine and dileucine 
endocytic signals are required for PKC-mediated internalization but not for agonist-induced 
internalization [141, 170].  Other GPCRs harbor non-canonical sequences that bind AP2 and 
function in endocytosis.  The µ2 subunit of AP2 was shown to interact with an unusual 
stretch of eight arginine residues in the cytoplasmic tail of the α1b-adrenergic receptor, and a 
receptor mutant, in which the arginine stretch was deleted, failed to bind µ2 and displayed 
defects in agonist-induced endocytosis [171].  The constitutively active human viral 
chemokine receptor US28 has also been reported to internalize through a clathrin-dependent 
pathway involving AP2, and not arrestins, but the AP2 recognition motif has not been 
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 identified [162].  Although the clathrin adaptor AP2 can directly regulate GPCR endocytosis 
independent of arrestins as shown for PAR1, in some cases, such as the β2AR, AP2 is likely 
to cooperate with arrestins to promote endocytosis.  
 
1.3.6.   CALM/AP180 
 CALM is a homologue of the clathrin assembly synaptic protein AP180.  AP180 is 
expressed mostly in the brain, while CALM is the more ubiquitously expressed homologue.  
Like AP180, CALM is found in clathrin coated pits at the cell surface and is able to bind 
clathrin heavy chain via a clathrin binding motif in its C-terminus which promotes the 
assembly of clathrin cages in vitro [172].  CALM also binds PIP2 in the plasma membrane 
via its N-terminal ANTH domain [173].  Overexpression or depletion of CALM attenuates 
internalization of epidermal growth factor receptor (EGFR) [172, 174]; however, the 
mechanism by which CALM mediates EGFR internalization remains unknown.   
 
1.3.7.   Dab2, ARH, Numb 
Numb, Dab2 and ARH are clathrin adaptors that contain a PTB domain that 
specifically recognizes FXNPXY motifs in the cytosolic sequences of cargo proteins (Figure 
1.4).  ARH and Dab2 have well-established functions in low-density lipoprotein (LDL) 
receptor internalization, whereas numb has been shown to regulate endocytosis of a variety 
of integral membrane proteins including EGFR and Notch (Table 1.1).  A study recently 
demonstrated that numb is phosphorylated and redistributed to the plasma membrane 
following activation of the G-protein coupled SPR which stimulates PLCβ activity and 
activates PKC [175]; but numb is not essential for GPCR endocytosis. Although a critical 
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 role for numb, Dab2 and ARH function in GPCR endocytosis has not been demonstrated, a 
highly conserved N/DPX(n)Y motif is found at the end of the seventh transmembrane of 
most GPCRs. However, unlike FXNPXY motifs, the N/DPX(n)Y motif seems to be 
important for maintaining the structural integrity of the receptor protein and is unlikely to 
directly regulate GPCR trafficking [169], but whether FXNPXY motifs exist elsewhere in the 
receptor protein remains to be determined. 
 
1.3.8.   Actin  
An essential role for a dynamic actin cytoskeleton in yeast S. cerevisiae endocytosis 
has been clearly established, whereas its precise function in mammalian endocytosis is less 
clear.  Yeast and mammalian endocytosis not only differ in their requirement for actin, but 
also for dynamin.  Although dynamin is essential for release of clathrin-coated pits in 
mammalian cells, it does not appear to have a direct role in yeast endocytosis.  Recent studies 
from Drubin and others have pioneered the use of total internal reflection fluorescence 
(TIRF) microscopy in living cells to define the dynamics of actin, clathrin and cargo 
recruitment to endocytic sites in yeast [176].  These studies used a combination of 
fluorescently tagged Ste2 or α-factor, pharmacological inhibitors, and mutant yeast strains 
lacking critical actin components to clearly establish an essential role for the actin 
cytoskeleton in Ste2 endocytosis.  In budding yeast, actin appears to function mainly in 
plasma membrane invagination, constriction and scission.  
 In contrast to yeast Ste2 receptor, the role of actin in mammalian GPCR endocytosis 
is less clear.  In mammalian cells, actin appears at the plasma membrane in transient bursts 
just prior to clathrin-coated pit scission in living cells, but its precise function in endocytosis 
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 is not well understood [146].  One issue contributing to the controversial role of actin in 
mammalian endocytosis is the apparent differences observed upon perturbation of the actin 
cytoskeleton with pharmacological inhibitors in different cell types and on different surfaces 
of polarized cells.  Endocytosis in fibroblasts shows sensitivity to pharmacological inhibitors 
of actin compared to neuronal cells, which do not.  Actin depolymerizing agents inhibit 
clathrin-mediated endocytosis on the apical membrane of polarized epithelial cells, but not at 
the basolateral surface.  Given that many GPCRs interact directly or indirectly with a variety 
of actin binding proteins such as EBP50, spinophilin, filamin A/ABP-280, cofilin, and 
spectrin, endocytosis of at least certain GPCRs will likely be regulated in an actin-dependent 
manner.  Indeed, recent work showed that linking GPCRs to cortical actin by fusion of the 
actin binding domain of ezrin slows endocytosis [147].  Moreover, the cystic fibrosis 
transmembrane conductance regulator (CFTR) also transiently associates with the actin 
cytoskeleton through its C-terminal PDZ-ligand binding domain [177], but whether this 
affects the rate of endocytosis has not been determined.  More research is clearly needed to 
define the function of actin in mammalian GPCR endocytosis.  
 
1.3.9.   Ubiquitin and GPCR Trafficking 
 Ubiquitination has been shown to function as a signal for internalization and 
endocytic sorting of GPCRs.  Here we discuss ubiquitin, the mechanisms of ubiquitin 
conjugation and deubiquitination, and its role in GPCR trafficking. 
 
1.3.9.1.   Ubiquitin 
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 Ubiquitin is a 76 amino acid polypeptide that is highly conserved among higher order 
eukaryotes, but is not expressed in bacteria or archaea.  Yeast and human ubiquitin only 
differ by three amino acids.  Ubiquitin is a post-translational modification that is attached to 
substrate proteins via an isopeptide linkage between the carboxyl-terminal glycine residue of 
ubiquitin and the ε-amino group of lysine residues in substrate proteins (Figure 1.7).  
Substrate proteins can be monoubiquitinated where a single ubiquitin molecule is attached to 
a single lysine residue, which normally functions in endocytosis, histone modification and 
the budding of viruses from the plasma membrane [178].  Multi-monoubiquitination occurs 
when a single ubiquitin molecule is attached to several lysine residues within the same 
substrate protein and appears to function in endocytosis.  The most common form of 
ubiquitination is polyubiquitination which is defined by a chain of four or more ubiquitin 
molecules formed on a substrate protein where one of the seven lysine residues within 
ubiquitin is modified with other ubiquitin molecules.  The site on ubiquitin where 
polyubiquitination occurs can have different cellular consequences.  Polyubiquitination of 
K48 in ubiquitin is the most common form and mediates recognition and degradation of 
substrate proteins in the proteasome, while ubiquitination of K63 mediates DNA repair, 
activation of transcription factors and endocytosis [179, 180].  K48-linked ubiquitin chains 
form a kinked, closed structure, while K63-linked ubiquitin chains form an open, linear 
structure [181], which may explain how the different linkages are able to mediate different 
cellular processes. 
 
1.3.9.2.    Ubiquitin conjugation and deubiquitination 
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 Ubiquitin conjugation to substrate proteins occurs via the action of three ubiquitin 
conjugating enzymes: E1, E2 and E3 ubiquitin ligases (Figure 1.7).  The E1 ligase or 
activating enzyme adenylates ubiquitin on its C-terminus in an ATP-dependent reaction.  The 
anhydride bond formed between ubiquitin and ATP is conjugated onto the sulfhydryl group 
of a cysteine residue in the active site of the E1 enzyme via a high energy thioester bond.   
The ubiquitin molecule is then transferred to a sulfhydryl group on an active site cysteine 
residue in the E2, or ubiquitin conjugating enzyme.  Ubiquitin is then conjugated onto lysine 
residues in substrate proteins by a large family of E3 ubiquitin ligases composed of several 
hundred members of which there are two main types, RING and HECT domain ligases.  
RING domain containing ligases assist in the transfer of the ubiquitin molecule from the E2 
enzyme onto the substrate lysine residue, where ubiquitin is never directly attached to the E3 
ligase, although the ligase provides the specificity for substrate recognition.  In the case of 
HECT domain containing ligases, the ubiquitin molecule is transferred from the E2 enzymes 
onto a catalytic cysteine residue in the E3 ligase.  The E3 then transfers the ubiquitin 
molecule onto the lysine residue in the substrate protein (Figure 1.7) [182].  The specificity 
of substrate recognition is mainly mediated by the E3 ligase, although E2 conjugation 
enzymes may play a role in some instances [183].   
There are approximately 100 deubiquitinating enzymes (DUBs) encoded in the 
human genome [184], thus emphasizing the importance of ubiquitin recycling following 
conjugation on substrate proteins.  Most DUBs are cysteine proteases, although some are 
metalloproteases [185].  DUBs are defined by the thiol group of a cysteine residue in the 
active site that in conjunction with adjacent histidine and aspartic acid residues cleaves the 
carbonyl group of the isopeptide bond between the lysine residue on the substrate protein and 
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 the C-terminal glycine residue on the ubiquitin molecule (Figure 1.7) [186].  There are two 
main classes of DUBs, ubiquitin C-terminal hydrolases (UCHs) and ubiquitin-specific 
processing proteases (USPs).  UCHs generally process ubiquitin on smaller substrate 
proteins, while USPs generally process ubiquitin on larger substrate proteins and 
polyubiquitin chains [183]. 
 
1.3.9.3.   Ubiquitin-dependent GPCR trafficking in yeast 
The yeast S. cerevisiae express three GPCRs, Ste2, Ste3 and Gpr1 which mediate 
important cellular responses such as mating and glucose sensing.  Upon ligand binding, Ste2 
and Ste3 are internalized thrombin mechanisms involving ubiquitin and independent of 
arrestins, as yeast do not express any known homologues of arrestin [187, 188].  Ste2 is 
basally ubiquitinated and is further ubiquitinated upon activation by its ligand α-factor.  
Ubiquitination of Ste2 occurs on a single lysine residue within the S331INNDAKSS339 motif 
in the C-tail of the receptor and a receptor mutant in which K337 was mutated to arginine is 
defective in α-factor internalization [187].  Additionally, disruption of receptor 
ubiquitination by deletion of the E2 ubiquitin conjugating enzymes, Ubc1, Ubc4, and Ubc5, 
attenuates internalization of α-factor [187].   Further work identified Rsp5, a member of the 
NEDD4 family of E3 ligases, as the E3 ligase responsible for ubiquitinating Ste2 [189].  
Interestingly, a receptor mutant of Ste2 in which several key serine and threonine residues 
within the S331INNDAKSS339 motif were mutated to alanine is defective in phosphorylation 
and ubiquitination and is therefore unable to undergo agonist-induced internalization [190].  
Alternatively, a receptor mutant of Ste2 which has the C-tail replaced with a single ubiquitin 
molecule is still able to undergo agonist-induced endocytosis [188, 191].  These data suggest 
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 that Ste2 is ubiquitinated following receptor phosphorylation and that ubiquitination is both 
necessary and sufficient for Ste2 endocytosis.  The ubiquitin attached to the C-tail of Ste2 
serves as a sorting signal for Ste2 internalization which is recognized by the adaptor proteins, 
Ent1,2 and Ede1.  Ent1,2 and Ede1, the yeast homologues of the mammalian epsin and 
eps15/eps15R, recognize a hydrophobic surface on the ubiquitin that is attached to Ste2 
(Figure 1.3) [192].  Additionally, the a-factor receptor, Ste3, also undergoes agonist-induced 
ubiquitination which is increased in endocytosis defective yeast strains, suggesting that 
ubiquitination of Ste3 is linked to receptor internalization although the molecular 
mechanisms have not been investigated [193]. 
 
1.3.9.4.   Ubiquitin and clathrin adaptors 
Epsin 
Epsin functions as an adaptor protein which binds to ubiquitinated cargo proteins, 
clathrin, and phosphoinositides [194, 195].  An ENTH (epsin amino-terminal homology) 
domain is located at the extreme N-terminus of epsin and is composed of several α-helices 
that are stabilized by an additional α-helix that is ordered upon PIP2 binding as determined 
by X-ray crystallography [173, 196].  The ENTH domain of epsin is sufficient to drive 
curvature of lipids in vitro via utilization of the additional α-helix which inserts into the lipid 
bilayer suggesting that epsin alone may be sufficient to facilitate curvature of clathrin-coated 
pits [173].  Additionally, expression of a fluorescently tagged ENTH domain of epsin is 
targeted to the plasma membrane suggesting that PIP2 binding by the ENTH domain is 
sufficient for membrane targeting of epsin [197].  The ENTH domain of epsin also interacts 
with GAPs for small G-proteins, including Cdc42 and Rac [198, 199], suggesting that epsin 
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 may have additional functions outside of its traditional role as a clathrin adaptor protein.  The 
interaction of the ENTH domain of epsin with GAPs for Cdc42 is required for proper cell 
viability and polarity and actin organization in yeast [199]. 
C-terminal to the ENTH domain in epsin is three tandem UBDs which are capable of 
binding to ubiquitin [200].  The UBDs of epsin are necessary for mono-ubiquitination of 
epsin, although the ubiquitination occurs outside of the UBDs themselves [201, 202].  Recent 
work has suggested that the UBDs of other clathrin adaptor proteins such as eps15 and Hrs 
bind intramolecularly to the ubiquitin moiety that is attached to the adaptor protein to inhibit 
its endocytic function [203].  Furthermore, epsin is basally ubiquitinated and undergoes de-
ubiquitination by the DUB, FAM/USP9X, following an increase in intracellular calcium 
levels (Figure 1.2) [204], thus suggesting that intracellular signaling events may mediate the 
ability of epsin to recognize ubiquitinated cargo.  The UBDs of epsin interact with 
ubiquitinated EGFR, mediate internalization of the yeast Ste2 receptor and are necessary for 
functional responses of the epithelial sodium channel (ENaC) [192, 205, 206].  Epsin appears 
to function in coordination with other adaptor proteins to mediated EGFR and Ste2 
internalization and alone to mediate ENaC internalization.   
Further evidence for the importance of the UBD domains of epsin in receptor 
internalization was found in Drosophila melangoster.  The development and patterning of 
photoreceptor cells in the Drosophila compound eye are controlled through signaling by 
Delta/Notch [207, 208].  Genetic screens searching for proteins involved in eye patterning 
revealed a role for fat facets (faf) [209] and liquid facets (lqf), the Drosophila homologues of 
FAM/USP9X and epsin, respectively [210].   Subsequent studies showed that lqf recognizes 
ubiquitinated Delta and mediates its internalization and signaling [211, 212].  These data 
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 confirm that epsin mediates internalization of cargo via the UBDs which recognize ubiquitin 
molecules attached to the cargo.   
The C-terminus of epsin contains several short peptide motifs that mediate interaction 
with AP2, clathrin, and EH domain containing proteins. The DPW motifs that are found C-
terminal to the UBDs in epsin mediate interaction with the α-adaptin subunit of AP2 [194].  
Overexpression of the DPW (aspartic acid/proline/tryptophan) motifs of epsin attenuates 
internalization of transferrin and EGF presumably by perturbing the network of protein-
protein interactions that facilitates general clathrin-mediated endocytosis [194].  A clathrin 
binding motif which is C-terminal to the DPW motifs, binds to clathrin and exhibits clathrin 
assembly activity similar to AP2 [213].  By using membrane tethered fluorescently tagged 
ubiquitin molecules, De Camilli and colleagues suggested that epsin binding to clathrin and 
ubiquitinated cargo may be mutually exclusive processes [214]; however, whether this 
phenomenon occurs with bona fide cargo is unclear.  Several NPF (Asn-Pro-Phe) motifs 
which bind to EH domain proteins are found C-terminal to the clathrin binding motif in 
epsin.  Indeed, epsin was first identified by its ability to bind to eps15, which contains EH 
domains [194]. 
 
Eps15/Eps15R 
EGFR pathway substrate 15 (Eps15) was originally identified as a substrate of 
tyrosine phosphorylation upon EGFR activation [215].  Eps15R is a highly related protein 
that contains additional amino acids inserted between the second and third EH domains.  
Eps15 and eps15R are encoded by distinct genes, but seems have similar functions [216].  
Eps15 and eps15R are composed of three domains.  Domain I contains three tandem copies 
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 of an EH domain.  EH domains are approximately 100 amino acids in length, are composed 
of two EF-hand domains connected by a short β-sheet, and bind to NPF motifs in other 
endocytic adaptor proteins such as epsin [217].  X-ray crystallography of the EH domain of 
eps15 suggest the EH domain interaction with NPF motifs occurs within a hydrophobic 
pocket located between two alpha helixes [218].  Domain II contains a coiled-coiled domain 
that mediates homo- and hetero-dimerization of eps15 and eps15R [219].  Domain III 
contains DPF motifs that mediate its interaction with the α-adaptin subunit of AP2 [220], 
UBDs which bind ubiquitinated cargo, and a proline-rich motif which binds to SH3 domains 
[221].  Similar to epsin, the UBDs of eps15 are necessary for ubiquitination of the adaptor 
protein which occurs outside of the UBD domains [201].  Interestingly, eps15 and eps15R do 
not bind clathrin directly, although, the majority of eps15 and eps15R are associated with 
AP2 and other components of clathrin coated pits in cells [222-224], suggesting a major role 
in clathrin-mediated endocytosis.  Indeed, overexpression of the EH domains of eps15 blocks 
clathrin-mediated endocytosis and disrupts the distribution of AP2 and clathrin [225, 226].  
Based on these observations, overexpression of Domain I of eps15 is often used to examine 
the role of clathrin-mediated mechanisms in endocytosis of cargo.  Further work is needed to 
determine if eps15 or eps15R directly interact with cargo proteins to mediate internalization.  
  
1.3.10.   PAR1 Internalization 
PAR1 displays two modes of receptor trafficking.  Constitutive internalization is 
important for cellular resentization of thrombin signaling and agonist-induced internalization 
is critical termination of thrombin signaling.  Constitutive internalization of PAR1 occurs by 
tonic internalization of uncleaved receptors from the plasma membrane to an endosomal 
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 recycling compartment.  The constitutive internalization of PAR1 results in approximately 
10-20% of receptors residing in an internal endosomal compartment that is protected from 
receptor cleavage and activation in most cell types, including fibroblasts and endothelial cells 
[109, 166, 227, 228].  Following an initial exposure to thrombin, the receptors residing in the 
intracellular pool recycle to the plasma membrane where they mediate rapid recovery of 
receptor signaling that is independent of de novo synthesis [166, 227].  The constitutive 
internalization of PAR1 is not due to activation by the presence of low levels of thrombin as 
a receptor mutant that is defective in thrombin cleavage (R41A) is still able to undergo 
constitutive internalization [227].  PAR1 constitutive internalization occurs via a clathrin- 
and dynamin-dependent pathway [229], but independent of phosphorylation [230] and 
arrestins [115].  PAR1 interacts with the clathrin adaptor protein AP2 via a tyrosine-based 
motif (Y420KKL) in the extreme C-tail of the receptor and mutation of this motif abolishes 
constitutive internalization of PAR1 (Figure 1.2) [166].  Knockdown of the µ2 subunit of 
AP2, which depletes cells of the entire complex, also inhibits constitutive internalization of 
PAR1 in a HeLa cells system with ectopic expression of the receptor and in HUVECs with 
endogenously expressed receptor.  Furthermore, AP2 was shown to be essential for restoring 
thrombin responsiveness in endothelial cells [166].   
Activated PAR1 internalizes into endosomes and is then rapidly sorted to a lysosomal 
degradation pathway [62, 91, 231].  Agonist-induced internalization occurs via a dynamin- 
and clathrin-dependent pathway that is also phosphorylation-dependent as a receptor mutant 
with the serines and threonines in the C-tail mutated to alanine fails to undergo agonist-
induced internalization [230].  PAR1 is able to undergo agonist-induced internalization in 
MEFs lacking both isoforms of arrestins, suggesting that PAR1 agonist-induced 
41
 internalization is independent of arrestins [115].  Unlike most other GPCRs which internalize 
and recycle to the plasma membrane, activated PAR1 internalizes and sorts directly to a 
lysosomal degradation pathway [62, 227].  Although we have identified the mechanism 
mediating PAR1 constitutive internalization and its role in regulating thrombin 
resensitization, the mechanisms mediating clathrin-dependent internalization of activated 
PAR1 are not known and are the focus of Chapters 2 and 4 of this dissertation.   
 
1.4.   GPCR Downregulation 
1.4.1.   ESCRT mediated receptor downregulation 
 Transport of cargo proteins to the lysosome or the vacuole, the yeast equivalent of the 
lysosome, generally occurs through ubiquitin-dependent sorting to multivesicular bodies 
(MVBs).  Downregulation of cargo is mediated by the fusion of endosomes with the limiting 
membrane of MVBs followed by invagination and budding of the vesicles into intralumenal 
vesicles (ILVs) found within MVBs.  The MVB then fuses with the lysosome or vacuole and 
the ILVs are degraded by the hydrolases within the lysosome or vacuole.  The involution of 
the ILVs from the limiting membrane of the MVB is not a passive process.  A genetic screen 
in yeast for proteins whose deletion resulted in an enlarged multilamellar endocytic 
compartment identified many proteins involved in the formation of the MVB.  The identified 
proteins were later shown to function in one of three ESCRT (endosomal sorting complexes 
required for transport) complexes which mediate receptor downregulation.  In addition, 
several accessory proteins were also shown to function in the ESCRT pathway [232-234].   
  Sorting of many membrane proteins to MVBs by the ESCRT complexes is mediated 
by receptor ubiquitination.  Hepatocyte growth factor regulated substrate (Hrs) and its yeast 
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 homologue vacuolar protein sorting 27 (Vps27) function upstream of the ESCRT complexes 
by binding to clathrin and ubiquitinated cargo in an early endosomal compartment.  Indeed, 
the UBDs of Hrs and Vps27 are required for sorting ubiquitinated cargo, such as a transferrin 
receptor-ubiquitin fusion protein and Ste2, to the lysosome or vacuole for degradation [192, 
235].  Hrs has been shown to bind to a component of the ESCRT complex, tumor suppressor 
gene 101 (Tsg101) in mammalian cells or Vps23 in yeast.  Hrs has also been shown to 
interact with sorting nexin-1 (SNX1), a component of thre retromer.  Hrs, Tsg101 and SNX1 
play an important role in EGFR downregulation, suggesting that Hrs, Tsg101 and SNX1 may 
function together to mediate receptor downregulation [236-239].  Tsg101 appears to mediate 
receptor downregulation via recognition of ubiquitinated cargo by its UBD.  The exact role 
SNX1 plays in receptor downregulation is not known; furthermore, whether SNX1 truly 
functions independent of the retromer complex to mediate downregulation of cargo is 
unknown.    The role of Hrs, Tsg101, and SNX1 in downregulation of PAR1 are the focus of 
Chapter 3 of this dissertation.   
 
1.4.2.    Downregulation of mammalian GPCRs 
In 2001, the β2AR and CXCR4, were both shown to undergo agonist-induced 
ubiquitination [155, 240].  Ubiquitination of the β2AR is not essential for receptor 
endocytosis, but is important for agonist-induced downregulation.  Although arrestins are 
required for β2AR ubiquitination and bind to the E3 ligase, Mdm2, Mdm2 does not appear to 
be required for ubiquitination of the receptor [155]. The mechanism by which ubiquitination 
of β2AR mediates lysosomal sorting of the receptor, along with the E3 ligase for the receptor, 
remain to be determined.  
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 Similarly, CXCR4 also undergoes agonist promoted ubiquitination that occurs on 
three lysine residues within a motif (S324SLKILSKGK333) located in the C-tail of the 
receptor.  Mutation of the three lysine residues within this motif to arginine abolishes 
receptor ubiquitination and also inhibits receptor downregulation [240].   The E3 ligase AIP4 
ubiquitinates CXCR4 and is required for receptor downregulation.  AIP4 also ubiquitinates 
Hrs, which is essential for agonist-promoted downregulation of CXCR4 [241].  Hrs contains 
a UBD domain that is believed to recognize the ubiquitin that is attached to the receptor and 
mediate sorting of the receptor by the ESCRT complexes to MVBs and the lysosome for 
degradation.  The role of other proteins within the ESCRT complexes, such as Tsg101, in 
CXCR4 has not been investigated.  However, the AAA ATPase, Vps4, which promotes 
disassembly of the ESCRT complexes  and ubiquitin recycling prior to formation of ILVs, is 
required for CXCR4 downregulation [241], further confirming the role of ubiquitination in 
CXCR4 downregulation. 
In addition to the β2AR and CXCR4, ubiquitination of several other mammalian 
GPCRs has been demonstrated.  The vasopressin-2 receptor, PAR2, and SPR undergo 
agonist-promoted ubiquitination that is required for receptor downregulation [242-244].  
Interestingly, ubiquitination of the delta opioid receptor (DOR) is not required for receptor 
internalization or downregulation, as a receptor mutant with all intracellular lysine residues 
mutated to arginine was still able to undergo agonist-induced internalization and 
downregulation [245].  However, Hrs is required for proper sorting of activated DOR to 
lysosomes for degradation, but the mechanism by which this occurs is unclear [246].  The 
platelet activating factor receptor (PAFR) is basally ubiquitinated and agonist-stimulation has 
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 no effect on its ubiquitination status, although the role of ubiquitination in PAFR trafficking 
was not examined [43].  
 
1.4.3.   Agonist-induced downregulation of PAR1 
Following internalization of activated PAR1, the receptor is sorted directly to 
lysosomes for degradation [62, 231], a process that is critical for termination of receptor 
signaling.  A PAR1 chimera in which the C-tail was exchanged with that of SPR fails to 
degrade and instead recycles to the plasma membrane where it continues to signal to G-
proteins [91, 231].  SNX1 contains a coiled-coiled domain and phox domain (PX domain), 
which is believed to bind to phosphatidylinositol-3-phosphate (PI3P) and was originally 
identified as having a role in EGFR degradation [247].  Overexpression of the C-terminal 
domain of SNX1 inhibits downregulation of PAR1, but has no effect on internalization [248].  
Although a C-terminal deletion mutant of SNX1 markedly inhibits down-regulation of EGFR 
[249, 250], depletion of SNX1 by siRNA has no effect on EGFR down-regulation [250].  
These data suggest that overexpression studies utilizing wildtype and deletion mutants of 
SNX1 may not have elucidated the true role of SNX1 in trafficking of cell surface receptors, 
such as PAR1.  The mechanism(s) mediating trafficking of activated PAR1 to lysosomes, 
including the role of endogenous SNX1, remains unknown. Given the diverse roles of 
ubiquitination in both yeast and mammalian GPCR trafficking, we sought to determine the 
role of ubiquitination in PAR1 downregulation which will be discussed in Chapter 3 of this 
dissertation.   
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Figure 1.1.  Simplification of the coagulation cascade.  Thrombin, the main effector of the 
coagulation cascade is generated by activation of the coagulation cascade.  Most of the 
enzymes involved are serine proteases and are activated upon their cleavage by the upstream 
protease.  The extrinsic pathway is activated upon exposure of tissue factor due to damage to 
blood vessels, while the intrinsic pathway is activated upon exposure of fibrous matrix 
proteins, such as collagen, in the subendothelium.  Blot clotting is achieved by cleavage of 
fibrinogen into fibrin by thrombin resulting in formation of a fibrous matrix plug.   
46
  
 
Figure 1.2.  Snakelike diagram of PAR1.  PAR1 protein sequence is depicted based on 
hydropathy plot predictions.  Thrombin initially binds to PAR1 via recognition of the 
hirudin-like domain which is colored in blue. The arrow indicates the site of thrombin 
cleavage site.  Upon thrombin cleavage the newly formed amino terminus serves as a 
tethered ligand, which is colored yellow.  The tyrosine-based motif in the C-tail of PAR1 that 
binds AP2 is colored red.  
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Figure 1.3.   PAR1 coupling to heterotrimeric G-proteins.  PAR1 activates multiple G-
protein subtypes, thus resulting in the activation of several downstream effector pathways, 
leading to several physiological outcomes.    
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Figure 1.4.  A graphical representation of the endocytic clathrin adaptor protein-
protein interaction network.  Monomeric clathrin adaptors interact with AP2 and clathrin, 
and function to recruit diverse cargo to the plasma membrane.  Clathrin adaptors bind to the 
plasma membrane PIP2, and clathrin binds to adaptor proteins but not PIP2.  The dotted line 
indicates that HIP1 and HIP1R can dimerize and link the endocytic machinery to the actin 
cytoskeleton.  Epsin and eps15 (and eps15R) also interact and function cooperatively to 
recruit ubiquitinated cargo to endocytic clathrin-coated pits.  Stonin2 interacts with AP2 and 
eps15 to promote endocytosis of cargo proteins.  Note that not all proteins involved in 
clathrin-mediated endocytosis are shown.  Adapted from L. M. Traub [251].  
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Figure 1.5.  Clathrin adaptor endocytic activity is regulated by phosphorylation and 
ubiquitination.  Arrestins are basally phosphorylated and dephosphorylated upon 
recruitment to activated and phosphorylated GPCRs.  Arrestins are also ubiquitinated by the 
E3 ligase Mdm2 which is critical for its endocytic function.  The µ2 subunit of AP2 is 
phosphorylated by the serine/threonine protein kinase AAK1, which enhances its affinity for 
tyrosine-based motifs.  In contrast, epsin dephosphorylation by the phosphatase calcineurin 
and deubiquitination by the deubiquitinating enzyme, DUB, FAM/USP9X is important for 
increasing its endocytic activity. 
50
  
 
Figure 1.6.  GPCRs are regulated by distinct clathrin adaptors.  The best characterized 
pathway for mammalian GPCR endocytosis is exemplified by the β2AR which involves 
arrestin recruitment to activated and phosphorylated GPCRs.  PAR1, a GPCR for thrombin, 
contains a tyrosine-based motif within its cytoplasmic tail that directly binds the µ2 subunit 
of AP2.  Both AP2 and the tyrosine-based motif are essential for PAR1 constitutive 
internalization.  The mechanisms that regulate activated PAR1 internalization have yet to be 
defined.  Ste2, a yeast GPCR, is phosphorylated and ubiquitinated and internalization is 
facilitated by ent1,2, epsin homologues, and ede1, an eps15 homologue.  
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Figure 1.7.  Schematic of conjugation and removal of ubiquitin from substrate proteins.  
The addition of ubiquitin onto a substrate protein requires the action of three enzymes.  (1) 
An E1 activating enzyme uses ATP to conjugate the C-terminal glycine (Gly) residue onto an 
active site cysteine (Cys) residue in the enzyme. (2) The ubiquitin molecule is then 
transferred onto an active site Cys residue in the E2 conjugating enzyme.  (3) The E3 ligase 
either assists in the transfer of the ubiquitin molecule from the E2 enzyme to the lysine (Lys) 
residue in the substrate as in the case of RING domain ligases or the ubiquitin molecule is 
transferred to an active site cysteine residue of E3 ligases containing HECT domains and 
then subsequently transferred to the Lys residue in the substrate (S) protein.  (4) The 
ubiquitin molecule is then removed from substrate proteins by DUBs that help to recycle 
activated, conjugatable ubiquitin in the cell.  Adapted from [182]. 
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 Table 1.1.  Clathrin adaptors and cargo selection 
 
Adaptor              Signal type                   Recognition                      Cargo examples 
                                                                   domain  
AP2                     YXXφ                        µ2 subunit                         Transferrin receptor        
                                                                                                         aLAMP-1, bCI-MPR 
                                                                                                         PAR1 (GPCR) 
                            [DE]XXXL[LI]         α/σ2 subunits                    Tyrosinase  
                                                                                                         GPCRs? 
 
Arrestins             phosphorylation         N-domain/polar core         GPCRs, VE-cadherin 
                                                                                                         NHE5, IGF-1, TGF-β 
 
Dab2/ARH          FXNPXY                   PTB domain                      LDL receptors 
                 
Numb                  FXNPXY                   PTB domain                      EGFR, Notch 
 
Epsin/Eps15        ubiquitination             UBDs                                 EGFR, cENaC 
Ent1,2/Ede1        ubiquitination             UBDs                                  Ste2 (yeast GPCR) 
 
HIP1/HIP1R              ?                                ?                                   dAMPA receptors 
                                                                                                         
CALM/AP180           ?                                ?                                                ? 
aLAMP-1, lysosomal associated membrane protein-1 
bCI-MPR, cation-independent mannose 6-phosphate receptor 
cENaC, epithelial sodium channel 
dAMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate 
receptors 
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 CHAPTER 2 
UBIQUITINATION DIFFERENTIALLY REGULATES CLATHRIN-DEPENDENT 
INTERNALIZATION OF PROTEASE-ACTIVATED RECEPTOR-1
 
2.1.   Abstract
PAR1, a GPCR for thrombin, is irreversibly activated by proteolysis.  Consequently, 
PAR1 trafficking is critical for the fidelity of thrombin signaling.  PAR1 displays constitutive 
and agonist-induced internalization, which are clathrin- and dynamin-dependent but 
independent of arrestins.  The clathrin adaptor AP2 is critical for constitutive but not for 
activated PAR1 internalization.  Here we show that ubiquitination negatively regulates PAR1 
constitutive internalization and specifies a distinct clathrin adaptor requirement for activated 
receptor internalization.  PAR1 is basally ubiquitinated and deubiquitinated following 
activation.  A PAR1 lysine-less mutant signaled normally but was not ubiquitinated.  
Constitutive internalization of ubiquitin-deficient PAR1 was markedly enhanced and 
inhibited by fusion of ubiquitin to the C-tail.  Ubiquitin-deficient PAR1 constitutive 
internalization was AP2 dependent, like wild type receptor.  However, unlike wild type 
PAR1, AP2 was required for internalization of activated ubiquitin-deficient receptor, 
suggesting that internalization of ubiquitinated PAR1 requires different endocytic machinery.  
These studies reveal a novel function for ubiquitination in regulation of GPCR 
internalization.    
 
 2.2.   Introduction 
PAR1, a GPCR for thrombin, is important for hemostasis and thrombosis, embryonic 
development and cancer progression [64, 252].  Unlike most GPCRs, PAR1 is irreversibly 
activated by proteolysis.  The PAR1 N-terminus is cleaved by thrombin, which unmasks a 
new N-terminus that acts as a tethered ligand and binds intramolecularly to the receptor to 
trigger transmembrane signaling [4].  Synthetic peptides that mimic the newly formed N-
terminus can activate PAR1 independent of proteolysis.  Due to the irreversible proteolytic 
nature of PAR1 activation, rapid desensitization and receptor trafficking tightly regulate 
PAR1 signaling [91, 115, 116]. 
PAR1 displays two modes of trafficking important for regulation of receptor 
signaling.  Unactivated PAR1 constitutively cycles between the cell surface and an 
intracellular compartment, generating an intracellular pool of uncleaved receptor that 
replenishes the cell surface after thrombin exposure and leads to rapid resensitization to 
thrombin signaling independent of de novo receptor synthesis [166, 227].  Unlike most 
GPCRs, which internalize and recycle, activated PAR1 is internalized, sorted directly to 
lysosomes and degraded [62, 231].  Sorting of activated PAR1 to lysosomes is critical for 
signal termination [91].  Constitutive and agonist-induced PAR1 internalization are clathrin- 
and dynamin-dependent [229].  However, in contrast to most GPCRs, neither constitutive nor 
activated PAR1 internalization require arrestins [115].  Arrestins interact with clathrin and 
AP2 to facilitate internalization of activated GPCRs through clathrin-coated pits [253, 254].  
We recently showed that AP2, and not arrestins, is critical for PAR1 constitutive 
internalization and is essential for cellular recovery of thrombin signaling [166].  
Interestingly, activated PAR1 internalization through clathrin-coated pits is independent of 
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 AP2, suggesting that constitutive and activated receptor internalization require different 
endocytic machinery.  The mechanism(s) that regulate activated PAR1 internalization 
through clathrin-coated pits is not known. 
 Ubiquitin modification of integral membrane proteins can function as an 
internalization and endosomal sorting signal [255].  Ubiquitin, a 76 amino acid protein, is 
recognized by UBDs, which are found in proteins of the endocytic sorting machinery.  
Ubiquitination regulates internalization of the yeast Ste2 and Ste3 GPCRs.  Studies using 
yeast strains that lack specific ubiquitin-conjugating enzymes and ubiquitin defective Ste2 
mutants or chimeras indicate that monoubiquitination is both necessary and sufficient for 
constitutive and agonist-induced receptor internalization [187, 191].  In contrast, several 
recent studies suggest that mammalian GPCR ubiquitination is essential for lysosomal 
sorting but not for receptor internalization.  Direct β2AR ubiquitination is not required for 
internalization but regulates activated receptor lysosomal sorting and degradation [155].  
Similar to the β2AR, ubiquitination of CXCR4 is essential for agonist-promoted receptor 
lysosomal degradation but not for internalization [240].  Although ubiquitination does not 
have a direct role in mammalian GPCR internalization, it has been shown to function 
indirectly.  Indeed, activation-dependent ubiquitination of arrestins is required for β2AR 
internalization [155].  However, the function of ubiquitination in regulation of mammalian 
GPCRs that do not require arrestins for endocytosis is not known.  
We have shown that constitutive and agonist-induced PAR1 internalization is 
clathrin- and dynamin-dependent and independent of arrestins [115].  We recently found that 
the clathrin adaptor AP2 is critical for constitutive but not for agonist-induced PAR1 
internalization [166].  Given these observations and the previous findings that ubiquitin 
56
 regulates yeast GPCR internalization, we examined the function of ubiquitination in PAR1 
trafficking.  Our findings here reveal a novel role for ubiquitination in negative regulation of 
PAR1 constitutive internalization and in specifying a distinct clathrin adaptor requirement for 
activated receptor internalization.  
 
2.3.   Materials and methods 
2.3.1.   Antibodies and materials 
Human α-thrombin was from Enzyme Research Laboratories.  Thrombin receptor 
activating peptides (TRAPs), SFLLRN and TFLLRNPNDK, were synthesized as the 
carboxyl amide and purified by reverse-phase high-pressure liquid chromatography (UNC 
Peptide Facility, Chapel Hill, NC).  
 Monoclonal M1 and M2 anti-FLAG and polyclonal anti-FLAG antibodies and the 
anti-β-actin antibody were from Sigma.  Monoclonal anti-HA antibody conjugated to HRP 
was from Roche and polyclonal anti-HA was from Covance.  Anti-PAR1 rabbit polyclonal 
antibody was previously described [166].  The anti-AP50 (µ2), anti-β2 adaptin, anti-early 
endosomal antigen-1 (EEA1) and anti-clathrin heavy chain monoclonal antibodies were from 
BD Biosciences.  Anti-dynamin monoclonal antibody was from Santa Cruz Biotechnology.  
HRP conjugated goat anti-mouse and goat anti-rabbit antibodies were from Bio-Rad.  Alexa-
488™ and Alexa-594™ -conjugated anti-mouse and anti-rabbit antibodies were from 
Molecular Probes.   
 
2.3.2.   cDNAs and cell lines  
57
 A human PAR1 cDNA containing an amino-terminal FLAG epitope was used to 
generate mutants.  Mutations were introduced by site directed-mutagenesis using 
QuikChange™ Mutagenesis Kit (Stratagene) and confirmed by dideoxy sequencing.  PAR1 
0K and K/R mutants were generated by replacing intracytosolic lysine (K) residues with 
arginine (R).  A PAR1 0K mutant with ubiquitin fused in frame to the C-tail was generated as 
follows.  A Pm1I site was introduced at the 3’ end of the PAR1 0K C-tail and positioned 
such that the PmlI sequence, CACGTG, coincided with the native stop codon.  A SacII site 
was introduced in the 3’ untranslated region 21 bp from the PmlI site.  PCR amplification 
was then used to generate ubiquitin cDNA fragment with 5’ Pm1I site and 3’ SacII sites.  A 
222 bp PmlI/SacII fragment encoding ubiquitin containing a K48 to R48 mutation and glycine 
deletions was then ligated in frame using PAR1 0K 3’ end compatible sites.  PAR1 and 
ubiquitin coding regions were separated by a spacer sequence, HVV.  Insertion of ubiquitin 
in frame after the PAR1 0K C-tail was confirmed by dideoxy sequencing.  
HeLa cells and Rat1 fibroblasts stably expressing PAR1 wildtype and mutants were 
generated and maintained as previously described [91, 229].  HeLa cells were transiently 
transfected with a total plasmid amount of 0.4 µg per 24-well, 0.8 µg per 12-well and 2 µg 
per 6-well using LipofectAMINE Reagent (Invitrogen) according to the manufacturer’s 
instructions and assayed 48 h post-transfection.  HEK293 cells were maintained and 
transfected as described [240].  Briefly, HEK293 cells were plated at ~1 X 106 cells per 10 
cm2 dish were transiently transfected with a total of 7.4 µg of plasmids (consisting of 5 µg of 
FLAG-tagged PAR1, 0.4 µg of HA-tagged ubiquitin and 2 µg of dynamin K44A) using 
FuGene-6 Reagent according to the manufacturer’s instructions.  Cells were then split into 6 
cm plates and assayed 48 h post-transfection.  
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2.3.3.   Small interfering RNAs (siRNAs)  
HeLa cells were transiently transfected with 50 nM of non-specific (ns) or µ2-specific 
siRNAs using LipofectAMINE 2000 according to the manufacturer’s instructions.  The µ2-
siRNA targeting the mRNA sequence 5’- GTG GAT GCC TTT CGG GTC A-3’ and the ns-
siRNA 5’–CTA CGT CCA GGA GCG CAC C–3’ were previously described [166].  The 
clathrin heavy chain siRNA targeting the mRNA sequence 5’-GCA ATG AGC TGT TTG 
AAG A–3’ was used at 50 nM and was previously described [174].  All siRNAs were 
synthesized by Dharmacon, Inc.   
 
2.3.4.  Phosphoinositide hydrolysis 
HeLa cells stably expressing PAR1 wildtype or 0K mutant were labeled with 1.0 
µCi/ml myo-[3H] inositol (American Radiolabeled Chemicals) and accumulated [3H]IPs were 
measured as previously described [115]. 
 
2.3.5.  Immunofluorescence confocal microscopy  
HeLa cells stably expressing PAR1 wildtype or mutants were processed and imaged 
by confocal microscopy as we previously described [115].  Images were acquired using an 
Olympus Fluoview 300 laser scanning confocal imaging system configured with an Olympus 
IX70 fluorescence microscope fitted with a PlanApo 60X oil objective.  Confocal images, X-
Y section at 0.28 µm, were collected sequentially at 800 X 600 resolution with 2X optical 
zoom.  The final composite image was created using Adobe Photoshop 7.0 (Adobe Systems).    
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 2.3.6.  Internalization and recycling assays  
Constitutive and agonist-induced PAR1 internalization were assessed using our 
previously described assays for loss of surface receptor and receptor-bound antibody uptake 
[115, 256].  PAR1 recycling was measured as we previously described [231]. 
 
2.3.7.  PAR1 ubiquitination  
HEK293 cells transiently transfected with FLAG-tagged PAR1 wildtype or mutants, 
HA- or FLAG-tagged ubiquitin and dynamin K44A were incubated with or without agonists 
and then lysed in buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 
pH 8.0, 0.5% (w/v) sodium deoxycholate, 0.1% (v/v) NP-40, 0.1% (w/v) SDS, 100 µM 
sodium orthovanadate, 20 mM N-ethylmaleimide and protease inhibitor tablet (Roche).  
Equivalent amounts of protein lysates were then immunoprecipitated with M2 anti-FLAG or 
anti-HA antibody.  Immunoprecipitates were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes and probed with an anti-HA or M2 anti-FLAG antibody 
conjugated to HRP.  Blots were then stripped and probed with a polyclonal anti-FLAG or -
HA antibody to detect PAR1.  Immunoblots were developed with Enhanced 
Chemiluminescence (Amersham) and imaged by autoradiography.    
 
2.3.8.  Data analysis 
Data were analyzed using Prism 4.0 Software and statistical significance was 
determined using InStat 3.0 (GraphPAD).  Group comparisons were made using an unpaired 
Student’s t-test. 
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 2.4.   Results 
2.4.1.  Basal ubiquitination and agonist-induced deubiquitination of PAR1 
To define the importance of ubiquitination in the regulation of PAR1 trafficking, we 
constructed a PAR1 mutant by replacing the ten intracytosolic lysines (K) residues with 
arginines, which is designated “PAR1 0K” (Figure 2.1A).  To ensure that PAR1 0K mutant 
was not globally disrupted in receptor function, the capacity of the activated receptor to 
promote Gαq-stimulated phosphoinositide hydrolysis was examined.  HeLa cells expressing 
comparable amounts of cell surface PAR1 wildtype and 0K mutant were incubated with 
various concentrations of thrombin and the amounts of [3H]IPs formed were then measured 
(Figure 2.1B).  Both PAR1 wildtype and 0K mutant were equally effective at stimulating 
[3H]IP accumulation as well as at inducing a maximal effect at saturating concentrations of 
thrombin.  The ability of PAR1 0K mutant to couple to G-protein activation like wildtype 
receptor indicates that receptor function is intact. 
We next determined whether the receptor was modified with ubiquitin by directly 
comparing the ubiquitination status of PAR1 wildtype to the lysine-less 0K mutant.  HEK293 
cells transiently co-expressing similar amounts of PAR1 wildtype or 0K mutant together with 
HA-tagged ubiquitin and dynamin K44A were incubated in the absence or presence of 
agonist peptide for 10 min at 37°C.  Cells were lysed, PAR1 was immunoprecipitated and the 
extent of receptor ubiquitination was determined.  Strikingly, in untreated cells, wildtype 
PAR1 displayed a substantial amount of basal ubiquitination detected as a major transfection-
dependent band migrating above ~107 kDa (Figure 2.1C, lane 1), consistent with the addition 
of multiple HA-tagged ubiquitins.  Remarkably, incubation with agonist decreased wildtype 
PAR1 ubiquitination (Figure 2.1C, lane 2).  In contrast, ubiquitination of PAR1 0K was 
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 undetectable in both untreated or agonist treated cells (Figure 2.1C, lanes 3 and 4).  These 
findings suggest that PAR1 is basally ubiquitinated and activation promotes deubiquitination. 
  
2.4.2.  Ubiquitin-deficient PAR1 displays enhanced constitutive internalization 
To investigate the function of ubiquitination in PAR1 trafficking, we examined 
constitutive and agonist-induced loss of cell surface wildtype and ubiquitin-deficient PAR1 
by ELISA.  HeLa cells and Rat1 fibroblasts stably expressing similar amounts of surface 
PAR1 wildtype or 0K mutant were incubated with M1 anti-FLAG antibody for 1 h at 4°C to 
label cell surface receptors, treated with or without agonist for various times at 37°C and the 
amount of receptor remaining on the cell surface was then quantified by ELISA.  In wildtype 
PAR1 expressing cells, agonist induced rapid receptor internalization that continued to 
slowly internalize leading to an ~70% loss of surface PAR1 after 30 min (Figure 2.2A and 
C).  PAR1 0K mutant internalization was comparable to wildtype receptor following agonist 
exposure in both cell types (Figure 2.2A and C).  We next examined constitutive 
internalization of wildtype PAR1 and observed a slow rate of internalization resulting in 10-
20% loss of cell surface receptor after 30 min (Figure 2.2B and D), consistent with that 
previously reported for these cell types [230, 256].  In contrast, ubiquitin-deficient PAR1 0K 
mutant displayed an increased rate of constitutive internalization in which 50-60% of 
receptor is lost from the cell surface after 30 min of incubation in both cell types (Figure 
2.2B and D).  Immunofluorescence microscopy studies also revealed a substantial amount of 
internalized ubiquitin-deficient PAR1 0K mutant in early endosomes compared to wildtype 
receptor in the absence of agonist exposure or antibody prebinding (Figure 2.2E), suggesting 
that the absence of ubiquitination promotes PAR1 constitutive internalization.  
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 To confirm enhanced constitutive internalization of ubiquitin-deficient PAR1 we used 
a receptor-bound antibody capture assay as a measure of receptor internalization.  HeLa cells 
expressing similar amounts of surface PAR1 wildtype or 0K mutant were labeled with 
antibody at 4°C and then incubated in the absence or presence of agonist for the indicated 
times at 37°C.  After incubation, antibody bound to cell surface receptor was stripped, cells 
were lysed and the amount of internalized receptor-bound antibody was quantified by 
ELISA.  In wildtype PAR1 expressing cells,  ~10% of antibody initially bound to cell surface 
receptor was internalized at steady state (Figure 2.3A), whereas virtually no internalized 
antibody was detected in untransfected cells (data not shown).  Remarkably, PAR1 0K 
mutant displayed an increased rate of constitutive internalization with ~50% of receptor-
bound antibody internalized after 15 min (Figure 2.3A).  Agonist caused a robust increase in 
PAR1 wildtype internalization, whereas activated PAR1 0K mutant internalization was 
comparable to constitutive internalization (Figure 2.3B).  A minimal amount of constitutively 
internalized wildtype PAR1 was detected in endosomes by immunofluorescence microscopy, 
whereas PAR1 0K mutant showed substantial redistribution to endosomes in the absence of 
agonist (Figure 2.3C).  The addition of agonist triggered comparable wildtype and ubiquitin-
deficient PAR1 internalization (Figure 2.3C).  Together, these findings provide further 
evidence that the absence of ubiquitination enhances PAR1 constitutive internalization.  
To define the lysine residues important for PAR1 internalization, we examined 
mutants in which lysines in the first or third intracytosolic loops or C-tail were mutated to 
arginines. A mutant PAR1 in which the four C-tail lysine residues were replaced with 
arginines (4K/R) displayed an enhanced rate of constitutive internalization similar to 
ubiquitin-deficient PAR1 (Figure 2.3), whereas PAR1 intracytosolic loop lysine mutants 
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 internalized like wildtype receptor (data not shown).  However, the extent of constitutive 
internalization displayed by PAR1 4K/R was less than that observed with PAR1 0K mutant, 
indicating that in addition to PAR1 C-tail lysines other lysine residues or regulatory domains 
may contribute to constitutive internalization.  To test the role of individual C-tail lysines in 
PAR1 internalization we constructed receptor mutants in which K407, K421 and K422 (3K/R) or 
K421 and K422 (2K/R) were converted to arginines (Figure 2.4A).  The rate of PAR1 3K/R and 
2K/R constitutive internalization was enhanced significantly compared to wildtype receptor 
(Figure 2.4B), suggesting that the distal K421 and K422 are important for constitutive 
internalization.  PAR1 3K/R and 2K/R also showed marked redistribution to endosomes 
compared to wildtype receptor in immunofluorescence microscopy studies (Figure 2.4D), 
whereas agonist caused a similar increase in wildtype and mutant receptor internalization 
(Figure 2.4C and D).  These data suggest that K421 and K422 residues are critical for 
regulation of PAR1 constitutive internalization.  
We next examined whether PAR1 C-tail lysines were important for receptor 
ubiquitination.  HEK293 cells transiently co-expressing PAR1 wildtype, 4K/R and 2K/R 
together with FLAG-ubiquitin and dynamin K44A were treated with or without agonist for 
10 min at 37°C and the extent of receptor ubiquitination was examined.  In untreated cells, a 
major ubiquitinated PAR1 wildtype species that migrated above ~107 kDa was detected and 
the addition of agonist caused a marked decrease in receptor ubiquitination (Figure 2.5, lanes 
1 and 2).  In contrast to wildtype receptor, basal ubiquitination of both PAR1 4K/R and 2 
K/R was substantially reduced irrespective of agonist addition (Figure 2.5, lanes 3-6).  
Together these data suggest that the PAR1 C-tail K421 and K422 residues are the major sites 
for receptor ubiquitination.   
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2.4.3. Ubiquitin fused to the C-tail of PAR1 0K mutant inhibits constitutive 
internalization 
 
Our results suggest an important regulatory role for ubiquitination of C-tail lysines in 
PAR1 internalization.  We therefore tested whether constitutive internalization was affected 
when ubiquitin was fused in frame to the C-tail of ubiquitin-deficient PAR1 0K mutant.  We 
used a modified ubiquitin in which K48 was mutated to arginine (K48R) and the two terminal 
glycine residues (ΔGG) were deleted to avoid extensive modification of ubiquitin and to 
increase the efficiency of PAR1 0K-Ub chimera expression at the cell surface.  We first 
examined PAR1 wildtype and mutant expression in transfected HeLa cells by 
immunoblotting using anti-PAR1 antibodies.  As expected, PAR1 wildtype and 0K mutant 
appeared as one broad major transfection dependent band migrating between ~64 and 98 kDa 
(Figure 2.6A), indicative of post-translation glycosylation of the receptor protein as 
previously reported [24].  The PAR1 0K-Ub chimera migrated as two high molecular weight 
species, consistent with the appearance of multi-ubiquitinated receptor.  PAR1 0K mutant 
displayed an enhanced rate of constitutive internalization.  In contrast, the attachment of 
ubiquitin to the C-tail of PAR1 0K mutant reduced the rate of constitutive internalization 
comparable to that observed with wildtype PAR1 (Figure 2.6B).  The addition of agonist 
induced similar increases in PAR1 wildtype, 0K mutant and 0K-Ub chimera internalization, 
indicating that activated PAR1 0K-Ub internalization remained intact (Figure 2.6C).  
Immunofluorescence microscopy studies were consistent with a marked inhibition of PAR1 
0K-Ub chimera constitutive internalization compared to ubiquitin deficient PAR1, whereas 
agonist induced a comparable increase in wildtype and mutant receptor internalization 
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 (Figure 2.6D).  Together, these data suggest that modification of PAR1 0K with ubiquitin 
negatively regulates constitutive internalization.  
 
2.4.4.   Ubiquitination of PAR1 negatively regulates constitutive internalization but not 
receptor recycling 
 
The endosomal accumulation of ubiquitin-deficient PAR1 may be due to an increased 
rate of constitutive internalization as well as to an inability of PAR1 0K mutant to recycle 
back to the cell surface.  To address this possibility, we examined internalization and 
recycling of wildtype and ubiquitin-deficient PAR1.  HeLa cells expressing PAR1 wildtype 
or 0K mutant were labeled with antibody and then incubated for 30 min at 37°C to facilitate 
constitutive internalization.  After incubation, surface-bound antibody was stripped and 
recovery of previously internalized receptor-bound antibody was followed for various times.  
An initial 30 min incubation at 37°C caused an ~25% decrease in the amount of PAR1 
wildtype, whereas a substantially greater ~50% of PAR1 0K mutant was initially lost from 
the cell surface (Figure 2.7, t1), consistent with an increased rate of constitutive 
internalization.  In both PAR1 wildtype and 0K mutant-expressing cells, a comparable 
amount of previously internalized receptor recycled back to the cell surface (Figure 2.7).  
These results are consistent with the extent of constitutive internalization and recycling of 
PAR1 previously described [231], and indicate that PAR1 recycling is not attenuated with 
ubiquitin-deficient PAR1.  
 
2.4.5.  Internalization of ubiquitin-deficient PAR1 is clathrin and dynamin dependent  
We next examined whether ubiquitin-deficient PAR1 internalized through a clathrin- 
and dynamin-dependent pathway like wildtype receptor [229].  HeLa cells expressing PAR1 
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 wildtype or 0K mutant were transiently transfected with GFP-tagged dynamin wildtype, 
K44A or vector and the amounts of cell surface receptor at steady state were measured.  In 
PAR1 wildtype expressing cells, neither dynamin wildtype nor K44A mutant expression 
affected the amounts of cell surface receptor expression when compared to vector (Figure 
2.8A).  The amount of surface PAR1 0K mutant was also comparable in dynamin wildtype 
and vector transfected cells.  In contrast, co-expression of dynamin K44A increased PAR1 
0K expression detected on the cell surface compared to wildtype receptor or vector (Figure 
2.8A).  In immunofluorescence microscopy studies, constitutive internalization of PAR1 
wildtype and 0K mutant were virtually abolished in K44A expressing cells, whereas in 
adjacent untransfected cells PAR1-containing endosomes were clearly evident (Figure 2.8C, 
arrowhead).  Internalization of activated PAR1 wildtype and 0K mutant were similarly 
inhibited by dynamin K44A (Figure 2.8C, arrowhead), suggesting that wildtype and 
ubiquitin-deficient PAR1 internalization are dynamin-dependent.   
 To determine the role of clathrin in ubiquitin-deficient PAR1 internalization, we used 
siRNA targeting the CHC to deplete HeLa cells of endogenous clathrin.  Expression of CHC 
was significantly decreased in cells transiently transfected with siRNA specifically targeting 
CHC compared to non-specific control (Figure 2.8B, inset).  In control siRNA-transfected 
cells, PAR1 wildtype and ubiquitin-deficient 0K mutant surface levels were comparable.  In 
contrast, the amount of PAR1 0K mutant surface expression was significantly increased in 
CHC siRNA-transfected cells compared to wildtype receptor, consistent with the inhibition 
of ubiquitin-deficient PAR1 constitutive internalization (Figure 2.8B).  Constitutive and 
agonist-induced internalization of wildtype and ubiquitin-deficient PAR1 was virtually 
ablated in CHC-siRNA transfected cells compared to control cells as assessed by 
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 immunofluorescence microscopy (Figure 2.8D).  Together these findings are consistent with 
a clathrin- and dynamin-dependent regulation of wildtype and ubiquitin-deficient PAR1 
internalization.  
 
2.4.6.  Ubiquitination specifies a distinct clathrin adaptor requirement for activated 
PAR1 internalization 
 
We recently reported that the clathrin adaptor AP2 is critical for constitutive but not 
agonist-induced internalization of wildtype PAR1 [166].  To assess AP2 function in 
ubiquitin-deficient PAR1 internalization, we used siRNA targeting the µ2-subunit to deplete 
cells of endogenous AP2 complex (Figure 2.9A, inset and C).  In control siRNA transfected 
cells, ~25% of wildtype PAR1 internalized after 10 min incubation in the absence of agonist, 
whereas constitutive internalization was inhibited significantly in µ2-siRNA transfected cells 
(Figure 2.9A).  A 10 min exposure to agonist caused significant wildtype PAR1 
internalization compared to untreated control irrespective of siRNA treatments (Figure 2.9A).  
These findings are consistent with a different clathrin adaptor requirement for constitutive 
and agonist-induced internalization of wildtype PAR1 as we recently reported [166].  In 
PAR1 0K mutant expressing cells, ~50% of receptor was constitutively internalized in ns-
siRNA control cells, whereas ubiquitin-deficient PAR1 failed to internalize in µ2-siRNA 
transfected cells (Figure 2.9B).  Remarkably, activated PAR1 0K mutant internalization was 
virtually abolished in µ2-siRNA transfected cells, indicating that AP2 is required for agonist-
induced ubiquitin-deficient PAR1 internalization (Figure 2.9B).  Immunofluorescence 
microscopy studies of PAR1 0K mutant expressing cells were consistent with an AP2-
dependent regulation of activated ubiquitin-deficient receptor internalization.  As expected, 
PAR1 wildtype and 0K mutant failed to redistribute to endosomes in AP2-depleted cells in 
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 the absence of agonist (Figure 2.9C).  Exposure to agonist peptide caused a marked increase 
in wildtype PAR1 internalization in µ2-siRNA transfected cells comparable to siRNA control 
cells (Figure 2.9C), consistent with an AP2 independent pathway for activated wildtype 
PAR1 internalization.  In contrast, activated PAR1 0K mutant internalization was markedly 
inhibited in µ2-siRNA transfected cells (Figure 2.9C), suggesting a critical role for AP2 in 
agonist-promoted ubiquitin-deficient PAR1 internalization.  Together, these data suggest a 
novel function for ubiquitination in specifying a distinct clathrin adaptor requirement for 
activated PAR1 internalization. 
 
2.5.  Discussion 
 In the present study, we have defined a novel function for ubiquitination in negative 
regulation of PAR1 constitutive internalization and in specifying a distinct clathrin adaptor 
requirement for activated receptor internalization.  We demonstrate that PAR1 is 
ubiquitinated under basal conditions and deubiquitinated following activation.  
Ubiquitination of PAR1 appears to inhibit constitutive internalization.  This is supported by 
our findings that constitutive internalization of PAR1 is markedly increased in the absence of 
ubiquitination and is inhibited by fusion of ubiquitin to the C-tail of ubiquitin-deficient 
PAR1.  Several GPCRs, including the yeast Ste2 and Ste3 receptors, have been reported to be 
basally ubiquitinated at the plasma membrane, similar to PAR1.  However, in contrast to 
PAR1, ubiquitination of Ste2 and Ste3 receptors promotes constitutive and agonist-induced 
internalization [187, 191].  The mammalian platelet-activating receptor GPCR has also been 
shown to be basally ubiquitinated, however, the role of ubiquitination in receptor trafficking 
was not examined [43].  Our studies also suggest that ubiquitination of PAR1 specifies a 
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 distinct clathrin adaptor requirement for activated receptor internalization that is not critically 
dependent on AP2.  We found that constitutive internalization of ubiquitin-deficient PAR1 
was AP2 dependent, like wildtype receptor.  However, unlike wildtype PAR1, AP2 function 
was also critical for internalization of activated ubiquitin-deficient receptor.  
The ubiquitination of PAR1 is likely a highly dynamic and reversible process, and we 
hypothesize that under basal conditions a pool of receptor is deubiquitinated and regulated by 
AP2.  We previously reported that the µ2-subunit of AP2 binds directly to a tyrosine-based 
motif Y420KKL423 localized at the extreme C-terminus of PAR1 (Figure 2.1A) using surface 
plasmon resonance [166].  In addition, both the µ2-subunit and the tyrosine-based motif are 
essential for promoting PAR1 constitutive internalization in multiple cell types.  In the 
present study, we show that the highly conserved K421 and K422 residues located within the 
PAR1 C-tail tyrosine-based motif are the major sites of ubiquitination and negatively 
regulate constitutive internalization.  Moreover, the fusion of ubiquitin to the C-tail of 
ubiquitin-deficient PAR1 0K mutant places the ubiquitin moiety within five residues of the 
tyrosine-based motif and may allow it to hinder AP2 binding and thereby reduce constitutive 
internalization.  Together these findings raise the intriguing possibility that ubiquitination of 
PAR1 might preclude binding of AP2 to the distal tyrosine-based motif and thereby 
negatively regulate constitutive internalization.  However, the low micromolar affinity 
binding of the PAR1 C-tail with the µ2-subunit is typical of µ2-subunit weak interactions 
with proteins bearing tyrosine-based motifs and has hampered our ability to directly test the 
role of ubiquitination in PAR1 and AP2 interaction in cells using co-immunoprecipitations or 
pull-downs.  Thus, PAR1 ubiquitination may provide a mechanism to retain the majority of 
the receptor at the cell surface and readily available for activation. 
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 PAR1 ubiquitination also appears to have a critical role in specifying a distinct 
clathrin adaptor requirement for activated receptor internalization.  Several clathrin adaptors 
including epsins and eps15 contain UBDs that recognize ubiquitinated cargo and facilitate 
clathrin-dependent internalization.  Interestingly, the yeast homologues of the mammalian 
epsins, Ent1 and Ent2, contain UBDs and facilitate endocytosis of ubiquitinated Ste2 receptor 
[192, 194].  In mammalian cells, epsin is ubiquitinated under basal conditions, which may 
prevent its interaction with AP2, clathrin and membrane lipids, and deubiquitination of epsin 
appears to enhance its endocytic activity [214].  Ubiquitin may also negatively regulate epsin 
function by binding UBDs intramolecularly similar to other endocytic adaptor proteins [203].  
In Drosophila the deubiquitinating enzyme Fat facets/USP9X regulates Delta/Notch receptor 
internalization by deubiquitinating Liquid facets, a homologue of epsin, consistent with a 
function for epsin deubiquitination in regulation of receptor endocytosis [257, 258].  In 
contrast, ubiquitination of arrestins is critical for internalization of certain GPCRs [155].  
However, arrestins are not essential for PAR1 internalization [115], suggesting that activated 
PAR1 internalization may require epsins similar to Ste2 receptor.  However, whether epsin 
and/or ubiquitin regulation of epsin is important for PAR1 internalization will be discussed in 
Chapter 4 of this dissertation.  
 Our studies reveal a novel function for ubiquitination in negative regulation of PAR1 
constitutive internalization and in specifying a distinct clathrin adaptor requirement for 
activated receptor internalization in which AP2 function is not critical.  PAR1 is uniquely 
activated by proteolytic cleavage that results in irreversible activation, unlike normal ligand 
activated GPCRs.  Thus, rapid desensitization and receptor trafficking tightly regulate PAR1 
signaling.  We have shown that PAR1 trafficking is essential for disposal of irreversibly 
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 activated receptor and for replenishing the cell surface with uncleaved receptor after protease 
exposure.  The novel regulation of PAR1 internalization by ubiquitination has a critical role 
in these distinct endocytic pathways.  Interestingly, the regulation of PAR1 internalization by 
ubiquitination is not observed with all protease-activated receptors since ubiquitination of 
PAR2, a second protease-activated GPCR, functions in lysosomal degradation but not in 
receptor internalization [243].  However, whether other GPCRs that do not require arrestins 
for endocytic sorting are similarly regulated by ubiquitination remains to be determined.  Our 
studies bring new insight into novel mechanisms by which ubiquitination functions in 
endocytic sorting of GPCRs in mammalian cells.  The challenge is to now identify the 
physiologically relevant ubiquitin ligases and DUBs that function in PAR1 trafficking. 
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Figure 2.1. PAR1 wildtype and lysine-less 0K mutant signaling and ubiquitination.  (A) 
The PAR1 intracytosolic lysine (K) residues that serve as potential sites for ubiquitination are 
highlighted and were mutated to arginine to generate a “PAR1 0K” mutant. (B) HeLa cells 
stably expressing FLAG-tagged PAR1 wildtype (Wt) and 0K mutant labeled with myo-
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 [3H]inositol were incubated with various concentrations of α-thrombin for 10 min at 37°C in 
media with lithium chloride.  The amounts of accumulated [3H]IPs were then measured.  The 
data shown (mean ± S.D.; n=3) are expressed as the -fold increase in [3H]IPs accumulation 
over basal cpm from one experiment and are representative of three separate experiments.  
The values (mean ± S.D.; n=3) for PAR1 Wt and 0K mutant cell surface expression were 
0.385 ± 0.023 and 0.376 ± 0.044, respectively. (C) HEK293 cells transiently transfected with 
either FLAG-tagged PAR1 Wt or 0K mutant together with HA-tagged ubiquitin and dynamin 
K44A mutant were incubated with or without 100 µM TRAP for 10 min at 37°C.  Cells were 
lysed, immunoprecipitated with M2 anti-FLAG antibody and ubiquitinated PAR1 was 
detected by immunoblotting with an anti-HA antibody conjugated to HRP.  Membranes were 
stripped and then probed with an anti-FLAG polyclonal antibody to detect PAR1.  Cell 
lysates were immunoblotted for dynamin (Dyn) expression to control for differences in 
transfection efficiency and for actin to control for sample loading.  Asterisks indicate the 
detection of the immunoprecipitating antibody heavy and light chain. Similar findings were 
observed in three independent experiments. 
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Figure 2.2.  Internalization of wildtype and ubiquitin-deficient PAR1.  HeLa cells and 
Rat1 fibroblasts stably expressing similar amounts of cell surface PAR1 Wt or 0K mutant 
were incubated with M1 anti-FLAG antibody for 1 h at 4°C such that only cell surface 
receptors bound antibody.  Cells were then incubated in media with (A, C) or without (B, D) 
100 µM TRAP for various times at 37°C.  Cells were fixed and the amount of receptor 
remaining at the cell surface was quantified by ELISA.  The data (mean ± S.D.; n=3) are 
expressed as the fraction of initial cell surface antibody bound at 0 min and are representative 
of three separate experiments.  The difference between PAR1 Wt and 0K constitutive 
internalization at various times was significant (**, P<0.01 and ***, P<0.005). (E) HeLa 
cells expressing PAR1 Wt, 0K mutant or pBJ vector control were incubated in the absence or 
presence of 100 µM TRAP for 15 min at 37°C, fixed, permeabilized and then immunostained 
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 for PAR1 (green) using anti-FLAG polyclonal antibody and for the early endosome marker 
EEA1 (red) using monoclonal anti-EEA1 antibody and imaged by confocal microscopy.  Co-
localization of PAR1 with EEA1 is shown as yellow in the merged image. The insets are 
magnifications of the boxed areas. Scale bar, 10 µm. 
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Figure 2.3. PAR1 C-tail lysine residue mutations enhance constitutive internalization.  
HeLa cells stably expressing similar amounts of PAR1 Wt, 0K or 4K/R mutant were labeled 
with M1 anti-FLAG antibody for 1 h at 4°C, washed and then incubated in media for various 
times at 37°C (A) or with or without 100 µM TRAP for 15 min at 37°C (B).  After 
incubations, cells were stripped of antibody remaining bound to cell surface and internalized 
antibody bound to receptor was quantified by ELISA.  Data (mean ± S.D.; n=3) are 
expressed as the fraction of initial cell surface receptor-bound antibody determined at 0 min 
and are representative of three separate experiments. The difference between PAR1 Wt and 
4K/R mutant constitutive internalization at various times was significant (***, P<0.005). (C) 
HeLa cells expressing PAR1 Wt and 0K mutant labeled with polyclonal anti-FLAG antibody 
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 were either left untreated (0 min) or incubated in the absence (Constitutive) or presence of 
100 µM TRAP for 10 min at 37°C, fixed and processed.  Cells were immunostained for 
PAR1 and imaged by confocal microscopy.  These images are representative of many cells 
examined in three independent experiments. Scale bar, 10 µm. 
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Figure 2.4. PAR1 3K/R and 2K/R display enhanced constitutive internalization.  HeLa 
cells expressing PAR1 Wt or C-tail lysine mutants as depicted in (A) were labeled with M1 
anti-FLAG antibody and then incubated in the media only (B) for various times at 37oC or 
with or without 100 µM TRAP (C) for 15 min at 37°C.  Cells were processed and PAR1 
internalization was quantified as described in Figure 3.  The data (mean ± S.D.; n=3) shown 
are representative of three independent experiments.  The difference between PAR1 Wt and 
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 K/R mutants constitutive internalization at various times was significant (**, P<0.01 or ***, 
P<0.005). (D) PAR1 Wt, 3K/R and 2K/R expressing HeLa cells labeled with anti-FLAG 
polyclonal antibody were either left untreated (0 min) or incubated without (Constitutive) or 
with 100 µM TRAP for 10 min at 37°C, processed and imaged by confocal microscopy. 
Scale bar, 10 µm. 
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Figure 2.5.  PAR1 C-tail lysine residues are major sites of ubiquitination.  HEK293 cells 
transiently transfected with either HA-tagged PAR1 Wt, 4K/R, 2K/R or pcDNA together 
with FLAG-tagged ubiquitin and dynamin K44A and then incubated in the absence or 
presence of 100 µM TRAP for 10 min at 37°C. Cells were lysed, immunoprecipitated with 
anti-HA polyclonal antibody and ubiquitinated PAR1 was detected with M2 anti-FLAG 
conjugated to HRP. Membranes were stripped and then probed with an anti-HA monoclonal 
antibody conjugated to HRP to detect PAR1. Cell lysates were immunoblotted for dynamin 
and actin as controls. These data are representative of at least three independent experiments. 
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Figure 2.6.  Ubiquitin fused to the C-tail of PAR1 0K mutant markedly inhibits 
constitutive internalization.  (A) HeLa cells expressing similar amounts of PAR1 Wt, 0K 
mutant or 0K-Ub K48R ΔGG chimera were lysed, immunoprecipitated with M2 anti-FLAG 
82
 antibody, and immunoblotted for PAR1 using a polyclonal anti-PAR1 antibody. Asterisks 
indicate unprocessed PAR1. These data are representative of three different experiments.   
HeLa cells expressing PAR1 Wt, 0K mutant or 0K-Ub chimera labeled with M1 anti-FLAG 
antibody were incubated in media only (B) for various times at 37°C or with or without 100 
µM TRAP (C) for 15 min at 37°C.  Cells were processed and receptor internalization was 
quantified as described in Figure 3. The data (mean ± S.D.; n=3) shown are representative of 
three independent experiments.  (D) HeLa cells expressing PAR1 Wt, 0K mutant or 0K-Ub 
chimera labeled with anti-FLAG polyclonal antibody were either left untreated (0 min) or 
treated in the absence (Constitutive) or presence of 100 µM TRAP for 10 min at 37°C, fixed, 
processed and imaged by confocal microscopy. Scale bar, 10 µm.  
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Figure 2.7.  Ubiquitin-deficient PAR1 mutant displays normal recycling.  HeLa cells 
expressing PAR1 Wt or 0K mutant labeled with M1 anti-FLAG antibody were incubated in 
media without agonist for 30 min at 37°C to facilitate constitutive internalization. Cells were 
stripped of surface bound antibody and the amount of receptor-bound antibody reappearing at 
the cell surface was measured after various recovery times.  Surface receptor-bound antibody 
was quantitated after the initial 4°C labeling (t0), after 30 min incubation at 37°C in the 
absence of agonist (t1), and after indicated times of recovery.  The data (mean ± S.D.; n=3) 
are expressed as (the amount of receptor-bound antibody at the indicated time points)/(the 
amount of receptor-bound antibody at t0) and are representative of three separate 
experiments. 
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Figure 2.8.  Internalization of ubiquitin deficient PAR1 is clathrin- and dynamin-
dependent.  Wt and 0K mutant expressing HeLa cells were transiently transfected with (A) 
GFP-tagged dynamin wildtype (Wt), K44A mutant, or pcDNA or with (B) 50 nM siRNA 
targeted to either clathrin heavy chain (CHC) or non-specific (ns) mRNA sequences. Inset, 
confirms the loss of clathrin protein in CHC-siRNA transfected cells as detected by 
immunoblot. After transfection, the amount of PAR1 residing on the cell surface at steady 
state was measured by ELISA.  The data (mean ± S.D., n=3) are expressed as the -fold 
increase over surface PAR1 expression detected in vector or ns-siRNA transfected cells and 
are representative of three independent experiments. A significant difference in surface 
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 expression between PAR1 Wt and 0K mutant was detected in K44A mutant transfected cells 
(**, P<0.003) and CHC-siRNA transfected cells (**, P<0.001). PAR1 Wt and 0K mutant 
expressing HeLa cells transiently transfected with GFP-tagged K44A mutant (C) or 50 nM 
ns- or CHC-siRNA (D) were incubated in the absence (Constitutive) or presence of 100 µM 
TRAP for 10 min at 37°C.  Cells were fixed, immunostained for PAR1 or clathrin and then 
imaged by confocal microscopy. These images are representative of many cells examined in 
three separate experiments. Scale bar, 10 µm.  
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Figure 2.9.  AP2 function is critical for constitutive and agonist-induced internalization 
of ubiquitin-deficient PAR1.  HeLa cells expressing PAR1 Wt (A) or 0K mutant (B) were 
transiently transfected with 50 nM siRNA targeted to either µ2 or non-specific (ns) siRNA 
sequences. Cells prelabeled with M1 anti-FLAG antibody were then incubated in the absence 
(Constitutive) or presence of 100 µM TRAP for 10 min at 37°C and the amount of receptor 
remaining on the cell surface was quantified by ELISA. The data (mean ± S.D., n=3) shown 
are representative of three independent experiments.  Inset, confirms the loss of AP2 in µ2-
siRNA transfected cells, whereas actin expression was unaffected. The difference between 
constitutive and agonist-induced PAR1 internalization in ns-siRNA and µ2-siRNA 
transfected cells was significant (**, P<0.01). (C) HeLa cells expressing PAR1 Wt or 0K 
mutant transiently transfected with 50 nM of ns- or µ2-siRNA were incubated in the absence 
(Constitutive) or presence of 100 µM TRAP for 10 min at 37°C. Cells were fixed, processed 
and immunostained for PAR1 or β2-adaptin and imaged by confocal microscopy. The 
images shown are representative of many cells observed in at least three different 
experiments. Scale bar, 10 µm.  
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 CHAPTER 3 
 
DOWN-REGULATION OF PROTEASE-ACTIVATED RECEPTOR-1 IS MEDIATED BY A 
UBIQUITIN-INDEPENDENT PATHWAY
 
3.1 Abstract
SNX1 and SNX2 are the mammalian homologues of the yeast Vps5p retromer 
component that functions in endosome-to-Golgi trafficking.  SNX1 is also implicated in 
endosome-to-lysosome sorting of cell surface receptors, although its requirement in this 
process remains to be determined.  We previously showed that SNX1 functions in endocytic 
sorting of PAR1 by use of a C-terminal fragment of SNX1 that functions as a dominant-
negative.  PAR1, a GPCR, is proteolytically activated by thrombin, internalized, sorted 
predominantly to lysosomes and efficiently degraded.  In these studies, we found that 
depletion of endogenous SNX1 by siRNA markedly inhibited agonist-induced PAR1 
degradation.  SNX1 is known to interact with Hrs, an early endosome associated protein that 
binds ubiquitinated cargo.  However, activated PAR1 degradation was not affected in cells 
depleted of Hrs or Tsg101, an Hrs interacting protein.  Moreover, we show that 
ubiquitination is not required for PAR1 degradation as a ubiquitin-defective PAR1 was able 
to undergo agonist-induced degradation similar to wildtype receptor.  Together, our findings 
establish an essential role for endogenous SNX1 in sorting activated PAR1 to a distinct 
lysosomal degradative pathway that is independent of Hrs, Tsg101 and PAR1 ubiquitination. 
 
3.2 Introduction 
 Lysosomal sorting of most transmembrane proteins occurs by delivery of the cargo 
into MVBs, which are formed by invagination of vesicles from the outer membrane, thus 
forming ILVs.  ILVs are then delivered to the lysosome for degradation.  The process by 
which cargo are sorted from endosomes to MVBs is mediated by the action of the ESCRT 
complexes and additional accessory proteins.  Traditionally, the ESCRT complexes sort 
cargo to lysosomes in a ubiquitin-dependent manner that is mediated by UBDs in several of 
the proteins found in the complexes [232, 233].  Hrs, an accessory protein that appears to 
play a role that accessory to the ESCRT complexes, contains a single UBD domain that is 
able to bind monoubiquitin [235].  Hrs mediates sorting of EGFR and the yeast GPCR, Ste2 
to the vacuole, the yeast equivalent of the lysosome [192].  Hrs binds to Tsg101, an essential 
component of the ESCRT complex.  Tsg101 contains a UBD domain that binds to ubiquitin 
and Hrs and mediates sorting of ubiquitinated cargo to lysosomes for degradation [259, 260].  
Although ubiquitination is an important sorting determinant for most cargo into MVBs, non-
ubiquitinated cargo are sorted into ILVs, suggesting the existence of multiple pathways for 
delivery of cargo to lysosomes [261].  
SNX1 was originally identified in a yeast two-hybrid screen using the cytoplasmic 
tail of the EGFR [247].  A function for SNX1 in endosome-to-lysosome trafficking was then 
suggested based on studies in which SNX1 overexpression enhanced EGFR degradation and 
SNX1 deletion mutants inhibited EGFR degradation [247, 249].  Moreover, endogenous 
SNX1 localizes predominantly to early endosomes by binding to PtdIns(3)P, a phospholipid 
highly enriched in early endosomal membranes [249, 262]. Other cell surface integral 
membrane receptors, including nutrient receptors and receptor tyrosine kinases, also 
associate with SNX1 when heterologously expressed [263].  However, we and others, have 
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 recently shown that neither endogenous SNX1 nor SNX2 is essential for lysosomal 
degradation of EGFR [250, 264].  Thus, whether endogenous SNX1 function is essential for 
endosome-to-lysosome sorting of cell surface receptors in mammalian cells remains to be 
determined. 
 Intracellular trafficking of GPCRs, which comprises the largest family of cell surface 
receptors in the mammalian genome [265], controls the temporal and spatial aspects of 
receptor signaling.  However, the mechanisms that mediate trafficking of GPCRs through the 
endocytic system remain poorly defined.  A protein-protein interaction screen using SNX1 
and a library of 59 GPCR carboxyl terminal tails revealed that SNX1 is capable of interacting 
with at least 10 distinct GPCRs [266].  We also previously demonstrated that SNX1 
associates with PAR1 and that a deletion mutant of SNX1 blocked lysosomal degradation of 
activated PAR1 [248].  Because activated PAR1 is rapidly internalized, sorted predominantly 
to lysosomes and degraded with remarkable efficiency [91, 231], it is a useful model for 
dissecting the molecular mechanism(s) responsible for GPCR lysosomal sorting.  Towards 
elucidating the molecular basis of GPCR trafficking and towards determining whether SNX1 
functions in endosome-to-lysosome sorting in mammalian cells, we examined whether 
SNX1, Hrs, Tsg101 or PAR1 ubiquitination functions in lysosomal degradation of activated 
PAR1.  Our studies reveal for the first time that endogenous SNX1 is essential for sorting 
activated PAR1 to a distinct lysosomal degradative pathway that does not require Hrs, 
Tsg101, or PAR1 ubiquitination.  
 
3.3 Methods and materials 
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 3.3.1.  Antibodies and reagents 
Agonist peptide SFLLRN was synthesized as the carboxyl amide and purified by 
reverse phase high-pressure liquid chromatography (UNC Peptide Facility, Chapel Hill, NC). 
The EGF ligand and leupeptin were purchased from Sigma.  Rabbit anti-PAR1 antibody was 
generated against the amino-terminal peptide sequence-YEPFWEDEEKNESGLTEYC, as 
previously described [52].  Anti-EGFR mouse monoclonal LA22 antibody was from Upstate 
Biotechnology.  Mouse anti-SNX1 antibody was purchased from BD Transduction 
Laboratories.  The rabbit polyclonal anti-SNX1 antibody was generated against full-length 
SNX1 expressed as a glutathione S–transferase fusion protein [263].  Anti-actin antibody was 
obtained from Sigma.  Monoclonal anti-Hrs antibody was purchased from Alexis 
Biochemicals and mouse anti-Tsg101-4A10 antibody was from GeneTex®, Inc.  Anti-
lysosomal-associated membrane protein-1 (LAMP1) H4A3 mouse antibody was obtained 
from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA).  The 
secondary antibodies, goat anti-mouse- and anti-rabbit-conjugated to horseradish peroxidase, 
were from Bio-Rad. Alexa488- and Alexa594-conjugated goat anti-mouse and anti-rabbit 
antibodies were obtained from Molecular Probes.  
 
3.3.2.  Cell lines 
HeLa cells and Rat1 fibroblasts stably expressing an amino-terminal FLAG-tagged 
PAR1 were grown and maintained as described previously [91, 229]. 
 
3.3.3.  siRNA transient transfection 
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 HeLa cells plated at 5 X 105 cells per well of 6-well dishes or at 1.25 X 105 cells per 
well of 12-well dishes were grown overnight. Cells were then transiently transfected with 
100 nM of non-specific, SNX1, Hrs or Tsg101 siRNAs using LipofectAMINE 2000 
according to the manufacturer’s instructions (Invitrogen), and experiments were performed 
48 h later. Small interfering RNAs were from Dharmacon (Lafayette, CO) and designed to 
target the following specific mRNA sequences: SNX1 siRNA3 (5’-CCA CGU GAU CAA 
GUA CCU U-3’), Hrs siRNA (5’-CGA CAA GAA CCC ACA CGU C-3’), Tsg101 siRNA 
(5’- CCU CCA GUC UUC UCU CGU C-3’) and a non-specific (ns) siRNA (5’ –GGC UAC 
GUC CAG GAG CGC ACC-3’) was used as a negative control.  
 
3.3.4.  Immunoprecipitation and immunoblotting 
HeLa cells stably expressing FLAG-tagged PAR1 plated at 5.0 X 105 cells per well in 
a 6-well dish were transiently transfected and grown for 48 h.  Cells were lysed and 
immunoprecipitated with M2 anti-FLAG antibody, as described previously [229, 231, 248].  
Immunoprecipitates were resolved by 9% or 12% SDS-PAGE, transferred and membranes 
were then incubated overnight at 4°C with anti-PAR1 rabbit polyclonal antibody.  Cell 
lysates were run in parallel and immunoblotted for SNX1, SNX2, Hrs, Tsg101, myc or actin 
proteins.  HeLa cells plated at 1.25 X 105 cells per well of 12-well dishes were transiently 
transfected, lysed and immunoblotted for endogenous EGFR.  Membranes were washed, 
incubated with species-specific secondary antibodies-conjugated to horseradish peroxidase 
and washed again.  Immunoblots were then developed using enhanced chemiluminescence 
(Amersham Biosciences), imaged by autoradiography, and quantitated using a Fluor- S 
MultiImager (Bio-Rad). 
92
  
3.3.5.  Immunofluorescence confocal microscopy 
HeLa cells plated at 1.5 X 105 cells per well on fibronectin-coated glass coverslips in 
12-well dishes were transiently transfected and grown for 48 h.  Cells were fixed and 
processed for microscopy as described previously [229].  Colocalization of PAR1 with 
LAMP1 was assessed in cells that were pretreated with 2 mM leupeptin for 1 h. Confocal 
images were acquired using a Fluoview 300 laser scanning confocal imaging system 
(Olympus) configured with an IX70 fluorescence microscope fitted with a PlanApo 60X oil 
objective (Olympus).  Fluorescent images, X-Y section at 0.28 µm, were collected 
sequentially at 800 X 600 resolution with 2X optical zoom.  The final composite images were 
created using Adobe Photoshop CS (Adobe systems).  
 
3.4   Results 
3.4.1.  SNX1 is necessary for sorting activated PAR1 to a degradative pathway 
Genetic and biochemical evidence indicate that SNX1 is part of a “retromer” complex 
that functions in endosome-to-TGN retrograde trafficking [264, 267-269].  SNX1 has also 
been implicated in endosome-to-lysosome sorting of cell surface receptors in mammalian 
cells; however, whether SNX1 is required in this process remains to be determined.  Towards 
defining the functional importance of SNX1 in PAR1 trafficking, we used siRNA to deplete 
HeLa cells of endogenous SNX1 protein.  Endogenous SNX1 expression was virtually 
abolished in cells transfected with SNX1-specific siRNA compared to non-specific (ns) 
control siRNA treated cells (Figure 3.1, middle panels).  To determine whether SNX1 was 
necessary for agonist-induced PAR1 degradation, HeLa cells stably expressing FLAG-tagged 
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 PAR1 were transiently transfected with control or SNX1 siRNA and PAR1 degradation was 
assessed.  In control siRNA treated cells, a significant ~60% loss of receptor protein was 
observed after 90 min exposure to PAR1-specific agonist peptide SFLLRN (Figure 3.1). 
These findings are consistent with the extent of agonist-induced PAR1 degradation typically 
observed in these cells [229]. In contrast, activated PAR1 degradation was markedly 
inhibited in cells lacking endogenous SNX1 (Figure 3.1), only ~8% of receptors were 
degraded following agonist treatment.  These findings suggest that SNX1 is necessary for 
agonist-induced PAR1 degradation.   
 
3.4.2.  Lysosomal degradation of PAR1 is independent of Hrs and Tsg101 activity 
Hrs associates with Tsg101 and regulates endosome-to-lysosome sorting of EGFR 
[238, 239].  Hrs has also been shown to directly interact with SNX1 [236], raising the 
possibility that Hrs and Tsg101 might function in lysosomal sorting of PAR1.  To assess the 
function of these proteins in PAR1 trafficking, we depleted HeLa cells of endogenous Hrs 
and Tsg101 proteins using siRNA and assessed PAR1 degradation.  The expression of 
endogenous Hrs and Tsg101 proteins was virtually abolished following incubation with their 
specific siRNAs compared to control siRNA treated cells (Figure 3.2A, middle panels).   
However, Tsg101 siRNA also caused partial degradation of Hrs protein, although the 
mechanism by which this occurs is unknown.  In cells lacking either Hrs or Tsg101 proteins, 
agonist induced a significant ~60-70% degradation of PAR1 protein that was similar to that 
observed in control siRNA treated cells (Figure 3.2A), indicating that neither Hrs nor Tsg101 
is essential for degradation of PAR1.  To exclude the possibility of aberrant PAR1 
degradation by proteases in a non-lysosomal compartment formed in Hrs and Tsg101 
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 knockdown cells, we examined PAR1 colocalization with LAMP1 in the presence of 
leupeptin.  In all cases, activated PAR1 accumulated in vesicles and showed marked 
colocalization with LAMP1 in the presence of leupeptin, whereas in the absence of protease 
inhibitor, receptor-containing vesicles were not apparent (Figure 3.2B).  These results 
suggest that activated PAR1 is targeted to lysosomes and degraded in cells lacking 
endogenous Hrs and Tsg101.  In contrast to PAR1, however, activated EGFR degradation 
was significantly inhibited in the same cells depleted of Hrs and Tsg101 proteins (Figure 
3.2C), consistent with previous studies showing a requirement for Hrs and Tsg101 in EGFR 
lysosomal sorting and degradation [238].  These data strongly suggest that SNX1 mediates 
sorting of PAR1 to a lysosomal degradative pathway that is independent of Hrs and Tsg101. 
 
3.4.3.   Ubiquitination of PAR1 is not required for agonist-induced lysosomal 
degradation 
 
We next determined whether ubiquitination functions in agonist induced PAR1 
lysosomal degradation by comparing the extent of wildtype versus ubiquitin-deficient PAR1 
degradation following prolonged agonist exposure.  HeLa cells stably expressing similar 
amounts of surface PAR1 wildtype or 0K mutant were incubated with or without agonist for 
90 min at 37°C and the amount of receptor remaining was then measured.  Remarkably, the 
extent of activated ubiquitin-deficient PAR1 degradation was comparable to that observed 
with wildtype receptor (Figure 3.3A), suggesting that PAR1 ubiquitination is not required for 
lysosomal degradation.  To confirm ubiquitin independent degradation of PAR1, we 
examined receptor degradation in Rat1 fibroblasts.  PAR1 wildtype and 0K mutant exhibited 
a comparable ~60% loss of receptor protein following prolonged agonist exposure (Figure 
3.3B), consistent with the extent of PAR1 degradation previously reported in these cell types 
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 [229, 231].  These findings suggest an ubiquitin-independent pathway for agonist-induced 
PAR1 lysosomal sorting and degradation. 
 
 3.5.   Discussion 
In the present study, we have defined for the first time an essential role for 
endogenous SNX1 in endosome-to-lysosome sorting of a cell surface receptor in mammalian 
cells.  We specifically show that SNX1 is necessary for sorting activated PAR1 to a 
lysosomal degradative pathway in HeLa cells.  Interestingly, PAR1 lysosomal degradation 
does not require Hrs, Tsg101 or PAR1 ubiquitination, indicating that multiple distinct 
pathways exist for lysosomal sorting of cell surface receptors in mammalian cells.  
 A recent study using siRNA and HeLa cells suggests that SNX1 has retained a 
conserved function in endosome-to-TGN retrograde trafficking in yeast and mammals [264].  
We also recently demonstrated that endogenous SNX1 is not essential for lysosomal sorting 
of EGFR in HeLa cells [250].  These studies suggested that SNX1 might not function in 
endosome-to-lysosome sorting of cell surface receptors in mammalian cells.  However, we 
report here that SNX1 is essential for sorting PAR1 to a lysosomal degradative pathway.  
Depletion of endogenous SNX1 by siRNA markedly inhibited activated PAR1 degradation, 
whereas receptor internalization was unaffected (data not shown).  We previously showed 
that EGFR degradation occurs normally in these same siRNA transfected cells depleted of 
endogenous SNX1 [250], excluding the possibility of global defects in lysosomal 
degradation.  Moreover, SNX1-dependent lysosomal sorting of PAR1 is consistent with our 
previous work in which we showed that SNX1 associates with PAR1, and that a SNX1 
deletion mutant blocked degradation of activated PAR1 [248].  These data strongly support a 
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 role for SNX1 in endosome-to-lysosome sorting of a cell surface GPCR in mammalian cells.  
Interestingly, SNX1 has recently been shown to directly interact with the cytoplasmic 
carboxyl tail of at least 10 other distinct GPCRs in vitro [266].  Whether SNX1 regulates 
intracellular trafficking of these receptors remains to be determined.   
Our studies further indicate that SNX1 mediates sorting of activated PAR1 to a 
distinct lysosomal sorting pathway that is independent of Hrs and Tsg101. The best-
characterized route from endosomes to lysosomes involves the formation of early endosomal 
tubular extensions that mature into multivesicular bodies/late endosomes that then fuse with 
lysosomes.  Sorting of EGFR through this pathway involves ubiquitin-dependent interaction 
with Hrs and Tsg101 [237-239].  Our findings indicate that neither Hrs nor Tsg101 are 
essential for activated PAR1 lysosomal degradation, whereas in the same cells depleted of 
Hrs or Tsg101, degradation of EGFR is significantly inhibited.  Moreover, SNX1 is required 
for lysosomal degradation of PAR1, but is not involved in EGFR degradation.  In addition to 
PAR1, DOR does not require Tsg101 for agonist-induced lysosomal degradation [246].  This 
study also reported that lysosomal sorting of DOR is dependent on Hrs.  However, in this 
case, overexpression or RNAi-mediated knockdown of Hrs appears to only partially inhibit 
DOR degradation.  Moreover, Hrs is involved in lysosomal sorting of ubiquitinated 
membrane proteins, and agonist-induced lysosomal degradation of DOR occurs independent 
of ubiquitin modification [245].  Thus, DOR may follow a lysosomal sorting pathway similar 
to PAR1.  SNX1 has been shown to directly bind to the DOR cytoplasmic tail in vitro [266]; 
however, whether SNX1 is required for lysosomal degradation of DOR remains to be 
determined. Together, these findings suggest that SNX1 regulates a distinct lysosomal 
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 sorting pathway that targets at least certain GPCRs for degradation independent of Hrs and 
Tsg101. 
A role for ubiquitination in mammalian GPCR lysosomal sorting and degradation has 
been demonstrated.  Agonist-induced ubiquitination of the β2AR and CXCR4 is critical for 
lysosomal degradation but is not required for internalization [155, 240].  The ubiquitin 
moiety on CXCR4 is thought to interact with UBDs in some endocytic adaptor proteins, such 
as Hrs, in order to be efficiently degraded in the lysosome [241].  Hrs interacts with Tsg101 
and promotes assembly of a multiprotein ESCRT complex that binds and sorts ubiquitinated 
cargo into the involuting membrane of multivesicular endosomes in a highly coordinated 
manner [232].  In contrast to β2AR and CXCR4, ubiquitination of PAR1 is not required for 
agonist-induced lysosomal degradation since ubiquitin-deficient PAR1 is degraded 
comparably to wildtype receptor in HeLa cells and Rat1 fibroblasts (Figure 3.3).  These data 
strongly suggest that the conventional ubiquitin-dependent ESCRT-mediated pathway is not 
required for agonist-induced PAR1 lysosomal sorting and degradation.  However, we cannot 
exclude the possibility that ubiquitination of PAR1 has a role in basal turnover of the 
receptor.  
The mechanism by which SNX1 regulates endosome-to-lysosome sorting of PAR1 
probably involves its localization to and pinching off of PAR1-positive endosomal tubules. 
Recent work indicates that SNX1 localization to early endosomes is mediated by two 
membrane binding domains, a PX domain which interacts with PtdInsP and a BAR 
(Bin/Amphiphysin/Rvs) domain that allows SNX1 to dimerize and to sense membrane 
curvature [264].  SNX1 binds to the tubular portion of early endosomes, and forms oligomers 
that may facilitate pinching off of endosomal tubules via interaction with other proteins, 
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 since tubulation induced by SNX1 in vitro was rather weak compared to Drosophilia 
amphiphysin.  In addition, the localization of SNX1 to endosomal membranes is not directly 
responsible for recruitment of PAR1, since we, and others, have failed to detect a direct 
interaction between PAR1 cytoplasmic domains and SNX1 [266].  Thus, other proteins 
associated with SNX1 tubules probably select cargo such as PAR1 for sorting from 
endosomes to lysosomes.  One potential candidate that can mediate transport of cargo from 
tubular sorting endosomes to lysosomes is adaptor protein complex-3 (AP3) [270, 271].  
AP3-dependent lysosomal sorting from tubular sorting endosomes is distinct from 
Hrs/Tsg101 mediated trafficking via multivesicular bodies that form by inward budding of 
the limiting membrane.  The µ3 subunit of AP3 binds directly to di-leucine or tyrosine-based 
sorting signals within the cytoplasmic regions of transmembrane proteins.  The cytoplasmic 
tail of PAR1 contains two tyrosine-based motifs (Yxxφ) and we recently demonstrated that 
the µ2 subunit of AP2 binds directly to the distal tyrosine-based motif to mediate PAR1 
constitutive internalization, an important process for cellular recovery of thrombin signaling 
[166].  However, whether AP3 can also bind directly to one or both of these tyrosine-based 
motifs to promote lysosomal sorting of PAR1 remains to be determined.  
 In summary, our studies demonstrate for the first time an essential role for 
endogenous SNX1 in endosome-to-lysosome sorting of a cell surface receptor in mammalian 
cells.  Moreover, endogenous SNX1 is necessary for sorting PAR1 to a distinct lysosomal 
degradative pathway that is independent of Hrs, Tsg101, and PAR1 ubiquitination. These 
findings bring important insight into how PAR1, and perhaps other GPCRs, are sorted from 
endosomes to lysosomes and degraded.  The challenge now becomes to elucidate the 
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 mechanism by which PAR1, and perhaps other GPCRS, are recruited to the distinct SNX1-
dependent lysosomal sorting degradative pathway.  
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Figure 3.1. SNX1 is essential for agonist-induced PAR1 degradation. HeLa cells stably 
expressing FLAG-tagged PAR1 were transiently transfected with non-specific (ns) or SNX1 
siRNA and then incubated in the absence or presence of 100 µM SFLLRN for 90 min at 
37°C. Cells were lysed and immunoprecipitated with M2 anti-FLAG antibody, and the 
amount of PAR1 remaining was detected by immunoblot analysis using an anti-PAR1 
antibody (upper panel). Cell lysates were immunoblotted for expression of endogenous 
SNX1 or actin to control for equal loading (lower panels). The data (mean ± S.E.) in the bar 
graph are expressed as a percentage of PAR1 remaining compared to untreated control cells. 
Data were determined for each transfection condition and represent the average of three 
separate experiments.  
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Figure 3.2.   Hrs and Tsg101 are not required for activated PAR1 lysosomal 
degradation.  (A) PAR1-expressing HeLa cells transiently transfected with non-specific 
(ns), Hrs or Tsg101 specific siRNAs were incubated in the absence or presence of 100 µM 
SFLLRN for 90 min at 37°C, and the amount of PAR1 protein degradation was then assessed 
as described above.  Cell lysates were immunoblotted with anti-Hrs or -Tsg101 antibodies to 
confirm loss of these proteins in siRNA-transfected cells or for actin expression to control for 
equal loading.  The results (mean ± S.E.) shown in the graph are represented as a percentage 
of PAR1 remaining compared to untreated control cells for each transfection condition and 
are an average of at least three experiments.  (B) PAR1-expressing HeLa cells were treated 
with or without 2 mM leupeptin, and then incubated with 100 µM SFLLRN as described 
above.  Cells were fixed and coimmunostained for PAR1 (green) and LAMP1 (red) and 
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 imaged by confocal microscopy.  Colocalization of PAR1 and LAMP1 is revealed by the 
yellow color in the merged image (arrowheads).  The insets are magnifications of boxed 
areas.  Scale bar, 10 µm.  (C) Serum-starved HeLa cells transfected with Tsg101, Hrs or non-
specific (ns) siRNAs were incubated in the absence or presence of 100 ng/ml EGF ligand for 
30 min at 37ºC and the amount of receptor protein remaining was then determined by 
immunoblot analysis using anti-EGFR antibodies.  Cell lysates run in parallel were 
immunoblotted for Hrs and Tsg101 to confirm loss of protein in siRNA-transfected cells or 
for actin expression to control for equal loading.  Similar results were observed in three 
separate experiments. 
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Figure 3.3.  Agonist-induced degradation of ubiquitin-deficient PAR1.  PAR1 Wt and 0K 
mutant expressing HeLa cells (A) and Rat1 fibroblasts (B) were incubated in the absence or 
presence of 100 µM TRAP for either 90 or 60 min at 37ºC, respectively.  Cells were lysed, 
immunoprecipitated with M2 anti-FLAG antibody, and the amount of PAR1 remaining was 
detected by immunoblot.  Untransfected (UT) HeLa cells or Rat1 fibroblasts controls are 
shown in adjacent lanes.  Asterisks indicate unprocessed PAR1.  The data shown (mean ± 
S.E.) in the bar graph are expressed as the fraction of PAR1 remaining compared with 
untreated cells and represent the average of three separate experiments. 
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CHAPTER 4 
EPSIN FUNCTIONS AS A CLATHRIN ADAPTOR FOR ACTIVATED PROTEASE-
ACTIVATED RECEPTOR-1 INTERNALIZATION
 
4.1.   Abstract
 PAR1, a GPCR for thrombin, is proteolitically activated, internalized and sorted 
predominantly to lysosomes for degradation.  Constitutive and agonist-induced 
internalization of PAR1 occurs via a clathrin- and dynamin-dependent pathway that is 
independent of arrestins.  Recent work has revealed a role for PAR1 ubiquitination in 
specifying the distinct clathrin adaptor proteins that mediates the two modes of PAR1 
internalization.  Towards determining the clathrin adaptor protein that mediates agonist-
induced internalization of PAR1, we used siRNA to deplete cells of the clathrin adaptor 
protein epsin.  Depletion of epsin attenuates agonist-induced internalization of 
heterologously expressed and endogenous PAR1.  Clathrin-mediated endocytosis of other 
cargo, such as the transferrin receptor and β2AR, was unaffected by epsin depletion.  The 
ability of epsin to mediate PAR1 internalization is dependent of receptor ubiquitination as 
epsin depletion has no effect on agonist-induced internalization of a ubiquitin-defective 
PAR1.  Stimulation of PAR1 also results in deubiquitination of epsin which enhances its 
ability to function in clathrin-mediated endocytosis.  Taken together, these data suggest that 
epsin recognizes the ubiquitin moiety on activated PAR1 to mediate receptor endocytosis 
through clathrin-coated pits.   
 
 4.2.   Introduction 
Protease-activated receptor-1 (PAR1), a GPCR for thrombin, is uniquely activated by 
proteolysis.  PAR1 displays two modes of trafficking that are important for regulation of 
signaling.  Constitutive internalization occurs with uncleaved receptors that tonically cycle 
into an endosomal compartment and are subsequently recycled back to the plasma membrane 
[109, 166, 227, 228].  Upon activation, PAR1 is rapidly desensitized, internalized and sorted 
to lysosomes for degradation, all processes that are critical for the fidelity of thrombin 
elicited cellular responses [62, 91, 231].  The constitutive and agonist-induced internalization 
of PAR1 occurs through an arrestin-independent mechanism as demonstrated by use of 
MEFs lacking β-arrestin1/2 and siRNA knockdown of β-arrestin1/2 in HeLa cells [115, 166].  
The tonic internalization of PAR1 is mediated by AP2 via binding to a tyrosine-based motif 
within the C-tail of PAR1 (Y420KKLL), although AP2 does not mediated agonist-induced 
internalization of the receptor.  The ability of AP2 to mediate constitutive internalization of 
PAR1 appears to be controlled by ubiquitination.  PAR1 is basally ubiquitinated and 
undergoes agonist-induced deubiquitination; furthermore, a receptor mutant of PAR1 that is 
defective in ubiquitination displays enhanced constitutive internalization compared to the 
wildtype receptor (Chapter 2 of this dissertation).   The ubiquitination of PAR1 appears to 
preclude the ability of AP2 to bind to the tyrosine-based motif in the C-tail of the receptor; 
therefore, it suggests that ubiquitination of PAR1 may mediate an interaction of the receptor 
with other clathrin adaptor proteins that are able to bind ubiquitinated cargo in order to 
mediate agonist-induced internalization of PAR1.  
 The clathrin adaptor proteins, epsin, eps15 and eps15R contain UBDs that are able to 
recognize the ubiquitin moiety attached to cargo proteins [195].  Epsin, eps15, and eps15R 
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 all reside in puncta at the plasma membrane are known to make contacts with other adaptor 
proteins, such as the α-adaptin appendage of AP2 and with phosphoinositides in the inner 
leaflet of the plasma membrane [196, 200, 217, 220]; thus, suggesting that these adaptor 
proteins may be able to recruit cargo into clathrin-coated pits.  In addition, the adaptor 
protein CALM also resides at the plasma membrane via binding to phosphoinositides and is 
able to recruit cargo into clathrin-coated pits, although by an unknown mechanism [172].  
The interactions between clathrin, clathrin adaptor proteins and phosphoinositides are 
generally low affinity and therefore the ability of one adaptor protein to function during 
internalization of cargo is mediated by several low affinity interactions.  
 Given that PAR1 agonist-induced internalization is clathrin-dependent, but arrestin- 
and AP2-independent, it is highly likely that another clathrin adaptor protein mediates PAR1 
agonist-induced internalization.  Furthermore, upon activation PAR1 is deubiquitinated and a 
ubiquitin-defective PAR1 utilizes an AP2-dependent pathway to internalize upon agonist 
stimulation.  These data suggest that ubiquitination sorts the receptor between the distinct 
AP2-dependent, constitutive internalization pathway or the AP2-independent, agonist-
induced pathway that may be mediated by ubiquitination of PAR1.  This study aimed to 
identify the clathrin adaptor protein that mediates agonist-induced internalization via 
recognition of the basally ubiquitinated form of PAR1. 
 
4.3.   Methods and materials 
4.3.1.   Reagents and antibodies   
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 PAR1 agonist peptides, SFLLRN and TFLLRNPNDK, were synthesized as the 
carboxyl amide and purified by reverse-phase high-pressure liquid chromatography (UNC 
Peptide Facility, Chapel Hill, NC).  Isoproterenol was purchased from Sigma. 
Monoclonal M1 anti-FLAG antibody, polyclonal anti-FLAG antibody and actin 
antibody were purchased from Sigma.  Anti-PAR1 C5433 antibody was generated as 
previously described [166].   The anti-epsin antibody, the anti-CALM antibody, and the anti-
Eps15 antibody were from Santa Cruz.  The anti-Eps15 antibody was from Abgent.  Anti-
AP50 (µ2) and anti-α-adaptin antibodies were from BD Biosciences.  The anti-clathrin light 
chain antibody (α-cons) was generously provided by Frances Brodsky (University of 
California, San Francisco).  The Alexa-488 conjugated transferrin, Alexa-488 conjugated 
goat anti-mouse antibody, Alexa-488 conjugated chicken anti-goat antibody and Alexa-594 
conjugated donkey anti-rabbit antibody were obtained from Molecular Probes.  Human 
biotinylated-transferrin and avidin was obtained from Sigma.  Biocytin and streptavidin 
conjugated to horseradish peroxidase were purchased from Pierce.  Human anti-transferrin 
antibody was from Roche.  The goat anti-mouse HRP conjugated antibody, goat anti-rabbit 
HRP conjugated antibody and donkey anti-goat HRP antibody antibody were from BioRad.   
 
4.3.2.   cDNAs and cell lines   
A human PAR1 cDNA containing an amino-terminal FLAG epitope and 0K mutant 
were previously described in Chapter 2 of this dissertation. A cDNA encoding a FLAG-
tagged β2AR was generously provided by M. von Zastrow (University of California, San 
Francisco).   
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 HeLa cells stably expressing wildtype FLAG-tagged PAR1 Wt, PAR1 0K or β2AR 
were generated and maintained as previously described [229, 231].  HEK293 cells were 
maintained and transfected as described [240].  EA.hy926 endothelial cells were obtained 
from the Cell Culture Facility at the University of North Carolina, Chapel Hill and 
maintained in DMEM containing 10% FBS.   
 
4.3.3.   siRNA transfections  
HeLa cells were plated in fibronectin-coated 24-well plates at a density of 0.3 x 105 
cells/well, fibronectin-coated 12-well plates containing coverslips at a density of 0.8 x 105, or 
6-well plates at a density of 2 x 105 and transiently transfected with 50-200 nM siRNA for 48 
hours using LipofectAMINE 2000 according to the manufacturer’s instructions.  The non-
specific-siRNA targeting the mRNA sequence 5’-CTA CGT CCA GGA GCG CAC C-3’ and 
the µ2-siRNA 5’- GTG GAT GCC TTT CGG GTC A-3’ were previously described [166].  
The epsin-siRNA (5’- GAA CTG GCG TCA CGT TTA C -3’), CALM-siRNA (5’- GAA 
ATG GAA CCA CTA AGA A -3’), eps15-siRNA (5’- AAA CGG AGC TAC AGA TTA T- 
3’) and eps15R-siRNA (5’ – GCA CTT GGA TCG AGA TGA G – 3’) were used as 
previously described [174].  All siRNAs were synthesized by Dharmacon, Inc.   
 
4.3.4.   Electroporation 
siRNAs were introduced into EA.hy926 by electroporation using Amaxa’s 
nucleofection technology.  Approximately 1 x 106 EA.hy926 cells were electroporated with 
600 nM- 2.4 µM siRNA as indicated and were distributed into 8-wells of a 24-well plate.  
Experiments were performed 48 hours post-electroporation.  
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4.3.5.   Immunofluorescence confocal microscopy 
HeLa cells were plates at a density of 0.8 x 105 cells per well on fibronectin-coated 
coverslips and were processed 48 h post-plating or transfected with siRNA and processed 48 
h post-transfection.  To image PAR1 and β2AR internalization, cells were prelabeled with 
polyclonal anti-FLAG or M1 anti-FLAG antibody, respectively, for 1 hour at 4°C to label the 
cell surface cohort.  Cells were then washed to remove unbound antibody and warmed with 
or without 100 µM SFLLRN for PAR1 internalization for 3 min or with 10 µM isoproterenol 
for 30 min for β2AR.  Cells were then fixed with 4% paraformaldehyde for 5 min at 4°C, 
permeabilized with 100% ice-cold methanol for 30 seconds at 4°C and washed three times 
with PBS containing 1% nonfat dry milk and 150 mM sodium acetate, pH 7.  Cells were then 
washed three times in PBS containing 1% nonfat dry milk and incubated with anti-epsin 
antibody (Santa Cruz) for 1 h at room temperature as indicated.  Cells were then washed 
twice with 1% nonfat dry milk, incubated with the appropriated secondary antibody 
conjugated to fluorophores, and processed for confocal microscopy.   
To assess α-adaptin and clathrin light chain staining, HeLa cells were plated at a 
density of 0.8 x 105 cells per well, transfected with the appropriate siRNAs as indicated and 
processed 48 h post-transfection.  Cells were fixed in 4% paraformaldehyde for 5 min at 4°C 
and permeabilized with 0.2% Triton X-100 in PBS for 5 min at 4°C for α-adaptin and with 
100% ice-cold methanol for 30 s for clathrin light chain.  Cells were then processed as 
indicated above.  
To assess internalization of Alexa-488 conjugated transferrin, HeLa cells were plates 
at a density of 0.8 x 105 cells per well in a 12-well plate containing a fibronectin-coated 
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 coverslip, transfected as indicated above, and processed 48 h post-transfection.  Cells were 
serum starved in DMEM containing 1 mg/ml BSA and 10 mM Hepes, pH 7.4 for 90 min at 
37°C and incubated with 50 µg/ml Alexa-488 transferrin for 5 min.  Cells were then fixed 
with 4% paraformaldehyde for 5 min at 4°C, permeabilized with 100% ice-cold methanol for 
30 s at 4°C and processed as described above.   
Images were acquired using an Olympus Fluoview 300 laser scanning confocal 
imaging system configured with an Olympus IX70 fluorescence microscope fitted with a 
PlanApo 60X oil objective.  Confocal images, X-Y section at 0.28 µm, were collected 
sequentially at 800 X 600 resolution with 2X optical zoom.  The final composite image was 
created using Adobe Photoshop 7.0 (Adobe Systems). 
 
4.3.6.   Immunoblotting   
To detect epsin, CALM, eps15R and µ2 expression, cells were transfected or 
electroporated with siRNA as indicated above and cell lysates were resolved by SDS-PAGE, 
transferred to PVDF membranes and immunoblotted with the appropriate antibodies.  
Membranes were then stripped and probed with anti-actin antibody as a loading control. 
 
4.3.7.   Immunoprecipitation and epsin ubiquitination 
To detect eps15 expression, cells were transfected or electroporated with siRNA as 
indicated.  Cells in 6-well plates were lysed in buffer containing 1% Triton X-100, 50 mM 
Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM EDTA, 50 mM NaF, 10 mM sodium pyrophosphate, 
200 mM sodium orthovanadate and protease inhibitors.  Equal amounts of cell lysates, as 
determined using BCA Protein Assay Reagent (Pierce), were used for immunoprecipitation 
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 with anti-Eps15 antibody.  Immunoprecipitates were resolved by SDS-PAGE, transferred to 
PVDF and immunoblotted with anti-Eps15 antibody.  Immunoblots were developed with 
ECL classic (Amersham) and imaged by autoradiography.   
 To detect epsin ubiquitination, HEK293 cells were transiently transfected with 5 µg 
HA-PAR1, 3 µg of epsin and 2 µg of FLAG-ubiquitin for 48 hours.  Cells were stimulated 
with 100 µM SFLLRN for 3 or 5 min or 2 µM A23187 for 5 min at 37oC and then were lysed 
in buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% (w/v) sodium 
deoxycholate, 0.1% (v/v) NP-40, 0.1% (w/v) SDS, 20 mM N-ethylmaleimide and protease 
inhibitor tablet (Roche).  Equivalent amounts of cell lysates were then immunoprecipitated 
with a goat anti-epsin antibody.  Immunoprecipitates were separated by SDS-PAGE, 
transferred to PVDF and immunblotted with an M2 anti-FLAG antibody conjugated to HRP.  
Blots were then stripped and reprobed with a rabbit anti-epsin antibody to detect epsin 
immunoprecipitation.  Immunoblots were developed with Enhanced Chemiluminescence 
(Promega) and imaged by autoradiography.    
 
4.3.8.   Internalization assays   
To assess agonist-induced loss of cell surface receptor, HeLa cells stably expressing 
FLAG-tagged PAR1 wildtype or PAR1 0K mutant were plated in 24-well dishes (Falcon) at 
a density of 0.3 x 105 cells per well and transfected as indicated above.  Cell surface 
receptors were labeled with M1 anti-FLAG antibody for 1 h at 4°C.  Under these conditions, 
only receptors residing on the cell surface bound antibody.  Cells were then incubated in 
DMEM containing 1 mg/ml BSA, 10 mM HEPES, pH 7.4 and 1 mM CaCl2 and were treated 
with or without agonist peptide for various times at 37°C.  Cells were fixed with 4% PFA for 
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 5 min at 4°C and incubated with an HRP-conjugated goat anti-mouse secondary antibody for 
1 h at 25°C.  Cells were then washed and incubated with HRP substrate, 1-Step ABTS (2,2’-
azino-bis-3-ethylbenzthiazoline-6-sulfonic acid) (Pierce) for 10-20 min.  An aliquot was 
removed and the optical density was determined at 405 nm using a Molecular Devices 
SpectraMax Plus microplate reader. 
To assess internalization in EA.hy926 cells, cells were electroporated as indicated 
above and serum starved for 30 min.  Cells were then stimulated with 100 µM 
TFLLRNPNDK for various times, washed with ice-cold PBS, and fixed with 4% 
paraformaldehyde for 5 min at 4°C.  Cells were incubated with anti-PAR1 C5433 antibody 
for 1 h at room temperature followed by incubation with HRP-conjugated goat anti-rabbit 
secondary antibody for 1 h at 25°C.  The amount of remaining cell surface receptors was 
determined as indicated above.   
 To directly measure receptor internalization, HeLa cells stably expressing the PAR1 
wildtype or β2AR were plated in 24-well dishes (Falcon) at a density of 0.8 x 105 cells per 
well and transfected with siRNA as indicated above.  Cell surface receptors were labeled 
with M1 anti-FLAG antibody at 4°C in DMEM containing 1 mg/ml BSA, 10 mM HEPES, 
pH 7.4 and 1 mM CaCl2.  Cells were then incubated in the presence or absence of agonist 
peptide or with isoproterenol for various times at 37°C to induce receptor internalization.  
Antibody remaining bound to cell surface receptors was stripped by washing thrice with ice-
cold PBS, Ca2+- and Mg2+-free, containing 0.04% EDTA.  M1 anti-FLAG antibody binding 
is Ca2+ dependent.  Cells were then lysed in a Triton lysis buffer (50 mM Tris-HCl, pH 7.4, 
100 mM NaCl, 5 mM EDTA, 3% BSA and 1% Triton X-100) and M1 anti-FLAG antibody 
bound to internalized receptor in cell lysates was measured by ELISA [115, 256].   
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4.3.9.   Transferrin receptor internalization   
HeLa cells were plated at 0.3 x 105 cells per well in a 24-well plate and transfected 
with siRNA as described above.  Cells were serum-starved in DMEM containing 1 mg/ml 
BSA and 10 mM Hepes, pH 7.4, for 90 min at 37°C to deplete cells of endogenous 
transferrin.  Cells were then incubated with 2 µg/ml human biotinylated-transferrin for 1 h at 
4°C to label all surface transferrin receptors.  Cells were then washed to remove unbound 
transferrin and warmed to 37°C in DMEM/BSA/Hepes, pH 7.4, for various times to allow for 
transferrin receptor internalization.  Cells were then washed and incubated with 100 µg/ml 
avidin for 1 h at 4°C to block remaining surface bound biotinylated transferrin followed by 
incubation with 100 µg/ml biocytin for 1 h at 4°C.  Cells were then lysed in blocking buffer 
(10 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM EDTA, 0.1% SDS, 0.2% BSA, and 1% 
Triton X-100).  Internalized biotinylated transferrin was then measured by ELISA.  96-well 
plates were coated with 0.5 µg/well of human anti-transferrin antibody overnight at 4°C, 
washed and incubated with blocking buffer for 1 h at 37oC.   Lysates were then added and 
incubated overnight at 4°C.  The plate was then washed, incubated with blocking buffer for 5 
min, washed and incubated with 500 ng/ml streptavidin conjugated to HRP for 1 h at 25°C.  
The plate was then washed, incubated with blocking buffer for 5 min, washed and incubated 
with 1-step ABTS.  The optical density at 405nm of each well was read using a Molecular 
Devices SpectraMax Plus microplate reader.  
 
4.3.10.  Data analysis   
Data were analyzed using Prism 4.0 software. 
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4.4.   Results 
4.4.1.   Epsin regulates PAR1 internalization  
To determine the role of epsin, CALM, eps15 and eps15R in agonist-induced PAR1 
internalization, we used siRNA to deplete HeLa cells of endogenous proteins.  Expression of 
epsin, CALM, eps15 and eps15R was substantially decreased upon transfection with the 
appropriate siRNAs when compared to a non-specific siRNA control.  Additionally, 
simultaneous transfection of epsin, CALM, eps15 and eps15R siRNA was able to deplete the 
proteins to levels observed upon knockdown of each protein individually (Figure 4.1A).  To 
assess the role of epsin, CALM, eps15 and esp15R in PAR1 internalization, PAR1-
expressing HeLa cells were transfected with epsin, CALM, eps15 and eps15R siRNAs and 
incubated with the agonist peptide SFLLRN for various times at 37°C.  The amount of PAR1 
remaining on the cell surface was measured by ELISA.  In non-specific siRNA control cells, 
agonist induced a rapid loss of PAR1 from the cell surface that reached steady state at 15 min 
with ~50% of receptor internalized (Figure 4.1B).  In contrast, agonist-induced 
internalization of PAR1 was substantially reduced in HeLa cells depleted of epsin alone or 
epsin, CALM, eps15 and eps15R (Figure 4.1B).  Knockdown of CALM, eps15 or eps15R 
alone did not affect agonist-induced internalization of PAR1 (data not shown).   
To ensure that reduction in internalization of PAR1 following agonist addition was 
not due to a global decrease in the number of clathrin coated pits formed at the cell surface, 
we examined the localization of AP2 and clathrin by immunofluorescence confocal 
microscopy.  The number of AP2 and clathrin puncta present in non-specific siRNA 
transfected HeLa cells appeared comparable to those in cells depleted of epsin or epsin, 
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 CALM, eps15 and eps15R (Figure 4.1C).  These findings suggest that the attenuation of 
PAR1 internalization observed in epsin-depleted cells is not due to a general decrease in 
clathrin-coated pit formation.  
We next determined whether epsin was involved in PAR1 constitutive internalization 
using a receptor-bound antibody capture assay which is a more accurate measure of receptor 
endocytosis.  HeLa cells stably expressing PAR1 were transiently transfected with siRNA to 
epsin or epsin, CALM, eps15 and eps15R.  Cells were then labeled with M1 anti-FLAG 
antibody at 4oC to label cells surface receptors and incubated in the presence or absence of 
agonist peptide for various times at 37oC.  The antibody remaining bound to cell surface 
receptors was then removed, cells were lysed and the amount of internalized receptor was 
assessed by ELISA.  In non-specific siRNA transfected cells, ~10% of antibody bound to cell 
surface receptors at time zero was internalized (Figure 4.2A), whereas virtually no 
internalized antibody was detected in untransfected HeLa cells (data not shown).  In contrast, 
cells transfected with siRNA directed against epsin or epsin, CALM, eps15, and eps15R 
showed a reduction in the amount of constitutively internalized receptor (Figure 4.2A).  We 
have previously shown that constitutive internalization of PAR1 is controlled by binding of 
the µ2 subunit of AP2 to a tyrosine-based motif in the C-tail of PAR1 [166].  We interpret 
this data to suggest that epsin helps to coordinate binding of AP2 to the C-tail of PAR1.   
It is possible that the loss of agonist-induced internalization of PAR1 upon depletion 
of epsin is due to inhibition of constitutive internalization, as the assay used to assess PAR1 
internalization in Figure 4.1 does not discriminate between agonist-induced and constitutive 
internalization.  Therefore, we measured agonist-induced and constitutive internalization of 
wildtype PAR1 using the antibody capture assay.  In cells transfected with non-specific 
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 siRNA, the difference in constitutive and agonist-induced internalization of PAR1 is ~70%, 
while the difference in cells depleted of epsin or epsin, CALM, eps15 and eps15R is ~30% 
(Figure 4.2B).  These data suggest that the inhibition of constitutive internalization observed 
in epsin depleted cells does not account for the inhibition of agonist-induced internalization 
observed. 
To determine if epsin regulates trafficking of endogenous receptor in native cells, we 
examined PAR1 internalization in an immortalized human endothelial cell line EA.hy926.  
We first determined whether endogenous PAR1 co-localized with epsin in intact cells using 
confocal microscopy.  EA.hy926 cells were labeled with a polyclonal anti-PAR1 antibody at 
4°C to ensure that only cell surface receptors bound antibody.  Cells were then left untreated 
(0 min) or treated with agonist peptide for 3 min at 37°C, fixed, permeabilized and 
immunostained for endogenous PAR1 and epsin.  In agonist treated cells, a substantial 
amount of PAR1 redistributed to puncta that costained for epsin (Figure 4.3A), suggesting 
that activated PAR1 internalization is recruited to clathrin-coated pits enriched in epsin.  We 
next examined whether epsin functioned in agonist-internalization of endogenous PAR1.  
EA.hy926 cells electroporated with siRNAs targeting epsin or epsin, CALM, eps15 and 
eps15R showed substantial loss of adaptor protein levels compared to control siRNA treated 
cells (Figure 4.3B). In control siRNA treated cells, agonist-induced internalization of 30% 
PAR1 (Figure 4.3C).  In contrast in cells treated with epsin siRNA or siRNAs targeting all 
four adaptor proteins, internalization of PAR1 was markedly diminished (Figure 4.3C).  
These findings suggest that epsin is an important regulator of PAR1 internalization in native 
systems.  
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 4.4.2.   Internalization of the transferrin and β2AR is not affected in cells depleted of 
epsin, CALM, eps15 or eps15R 
 
To confirm that knockdown of epsin alone or simultaneous knockdown of epsin, 
CALM, eps15 and eps15R does not affect general constitutive, clathrin-mediated 
internalization, we assessed the ability of the transferrin receptor to undergo endocytosis in 
HeLa cells.  Constitutive internalization of the transferrin receptor was previously shown to 
be AP2-dependent [272]; therefore, we used siRNA directed against the µ2 subunit of AP2, 
which depletes the entire complex [166], as a positive control for inhibition of transferrin 
receptor internalization.  HeLa cells were transfected with non-specific, µ2, epsin, or epsin, 
CALM, eps15, and eps15R siRNA and then serum starved to deplete cells of endogenous 
transferrin.  Cells were then labeled with biotinylated transferrin at 4oC to label cell surface 
receptors and warmed to 37°C for various times to allow for constitutive internalization of the 
transferrin receptor.  Cells were then incubated with avidin at 4°C to block cell surface 
biotinylated transferrin, followed by incubation with biocytin to block cell surface avidin.  
Cells were then lysed and the amount of biotinylated transferrin was determined by ELISA.  
In HeLa cells transfected with non-specific siRNA, we observed ~40% of cell surface 
transferrin receptors internalizing following 7.5 min incubation at 37°C (Figure 4.4A).  In 
cells that were transfected with epsin siRNA or with epsin, CALM, eps15, and eps15R 
siRNAs, we observed no significant decrease in the amount of internalized transferrin 
receptor when compared to non-specific siRNA treated cells (Figure 4.4A).  In contrast, in 
cells depleted of AP2 using siRNA directed against µ2, we observed a significant decrease in 
the amount of internalized transferrin receptor.  The siRNA-mediated knockdown of µ2 was 
confirmed by immunoblotting (Figure 4.4A, inset).  Immunofluorescence microscopy 
experiments examining uptake of Alexa-488 conjugated transferrin are consistent with the 
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 quantitative data of transferrin internalization in epsin and epsin, CALM, eps15, and eps15R 
depleted cells (Figure 4.4B).  Taken together, these data suggest that constitutive, clathrin-
mediated endocytosis is still intact in HeLa cells depleted of epsin, CALM, eps15 and 
eps15R 
To determine if epsin, CALM, eps15 or eps15R mediates internalization of other 
GPCRs, we chose to examine the internalization of the β2AR because it uses a classical 
arrestin-dependent pathway of internalization [273].  HeLa cells stably expressing the β2AR 
were transiently transfected with non-specific, epsin, or epsin, CALM, eps15 and eps15R 
siRNA and internalization was assessed using the receptor bound antibody capture assay.  
Cells were labeled with M1 anti-FLAG antibody at 4oC to label cell surface receptors and 
incubated with isoproterenol for various times at 37oC.  Cell surface receptor bound antibody 
was removed, cells were lysed and the amount of internalized antibody bound receptors was 
determined by ELISA.  We have previously reported that simultaneously knockdown of β-
arrestin1/2 in our HeLa cells system inhibited agonist-induced internalization of the β2AR 
[166].  In cells transfected with non-specific siRNA, ~25% of the initial cell surface receptors 
internalized upon 30 min of agonist stimulation.  Similarly, in cells transfected with espin1 or 
epsin, CALM, eps15 and eps15R siRNA, we observed similar amounts of receptor 
internalization (Figure 4.5A).  Immunofluorescence microscopy experiments examining 
internalization of the β2AR in epsin and epsin, CALM, eps15 and eps15R depleted cells 
confirmed the results of the antibody uptake assay (Figure 4.5B).  Together these data 
suggest that the ability of epsin to regulate internalization of PAR1 is not a global mechanism 
that regulates all GPCRs. 
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 4.4.3.   Internalization of an ubiquitin-defective PAR1 mutant is not affected in epsin-
depleted cells 
 
We have shown that PAR1 is basally ubiquitinated and undergoes agonist-induced 
deubiquitination as reported in Chapter 2 of this dissertation; therefore, it is possible that 
epsin interacts with the ubiquitinated receptor prior to deubiquitination, to mediate sorting of 
PAR1 into a clathrin-, dynamin- and epsin-dependent internalization pathway.  If this is 
indeed the case, epsin should be unable to mediate internalization of the ubiquitin-defective 
PAR1.  The ubiquitin-defective PAR1 has all ten intracellular lysine residues mutated to 
arginine and is termed PAR1 0K.  To determine if ubiquitination of PAR1 is required for 
sorting the receptor to an epsin-dependent internalization pathway, we examined 
internalization of the PAR1 0K mutant in epsin depleted cells.  HeLa cells stably expressing 
PAR1 0K mutant were transiently transfected with non-specific siRNA, epsin siRNA, or 
epsin, CALM, eps15, and eps15R siRNA.  Cells were then labeled with M1 anti-FLAG 
antibody at 4oC to label cell surface receptors, stimulated with agonist peptide at 37oC, fixed 
and the amount of receptors remaining on the cell surface was determined by ELISA.  In 
cells transfected with non-specific siRNA, we observed ~50% of PAR1 0K mutant 
internalized upon agonist stimulation (Figure 4.6A).  Similarly, in cells transfected with epsin 
siRNA or epsin, CALM, eps15, and eps15R siRNA, we observed a similar amount of the 
PAR1 0K mutant internalized upon agonist stimulation (Figure 4.6A).  These data suggest 
that ubiquitination of PAR1 is required for epsin-dependent internalization of PAR1.  These 
data are consistent with data in Chapter 2 of this dissertation showing that agonist-induced 
internalization of the PAR1 0K mutant occurs via an AP2-dependent pathway.   
To confirm that the PAR1 0K mutant does not utilize an epsin-dependent mechanism 
of internalization, we examined the ability of the wildtype PAR1 and PAR1 0K mutant to co-
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 localize with endogenous epsin in immunofluorescence microscopy experiments.  HeLa cells 
stably expressing similar amounts of PAR1 wildtype or 0K mutant were labeled with M1 
anti-FLAG antibody at 4oC to label cell surface receptors.  Cells were then incubated in the 
presence of agonist peptide, SFLLRN, for 3 min at 37oC, fixed, permeabilized and stained for 
epsin and PAR1.  In cells expressing PAR1 wildtype or PAR1 0K mutant, we observed the 
majority of receptors (red) residing in the plasma membrane in unstimulated cells, while 
epsin was in puncta (green) (Figure 4.6B, 0 min).  Upon stimulation, PAR1 wildtype 
redistributed into puncta that colocalized with epsin (yellow) (Figure 4.6B, 3 min, merge).  In 
contrast, the PAR1 0K mutant redistributed into puncta that did not co-localize with epsin 
(Figure 4.6B, 3 min, merge).  Together these data suggest that ubiquitination of PAR1 is 
essential for promoting internalization of the receptor via an epsin-dependent pathway.   
 
4.4.4.   Activation of PAR1 induces deubiquitination of epsin 
 Epsin is ubiquitinated under basal conditions and undergoes deubiquitination 
following an increase in intracellular calcium levels [204].  Given that PAR1 activation 
increases intracellular calcium levels [166], we hypothesized that PAR1 activation may 
stimulate epsin deubiquitination.  HEK293 cells transiently transfected with PAR1, epsin and 
ubiquitin were stimulated with agonist peptide or a calcium ionophore, A23187, as a positive 
control.  Cells were lysed, epsin was immunoprecipitated and the extent of epsin 
ubiquitination was determined.  Epsin is basally ubiquitinated and PAR1 stimulation results 
in epsin deubiquitination that occurs to an extent similar to that observed with the calcium 
ionophore (Figure 4.7).  These data confirm that epsin is basally ubiquitinated and suggest 
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 that an increase in intracellular calcium stimulated by PAR1 is sufficient to mediate epsin 
deubiquitination. 
 
4.5.   Discussion 
In the present study we have defined a novel role for the clathrin adaptor epsin in 
regulating PAR1 internalization that appears to involve recognition of the ubiquitinated 
receptor.  In HeLa cells stably expressing PAR1, depletion of epsin caused a substantial 
reduction in both constitutive and agonist-induced PAR1 internalization, whereas 
internalization of an ubiquitin-defective PAR1 mutant remained intact.  Moreover, in an 
endothelial cell line expressing endogenous PAR1, epsin depletion also impaired 
internalization of endogenous PAR1 induced by agonist.  In contrast, neither transferrin or 
β2AR internalization were affected in cells lacking epsin, suggesting that activated PAR1 
internalization is specified by distinct endocytic machinery that recognize ubiquitinated 
cargo.  In addition, activation of PAR1 reduced epsin ubiquitination, an event important for 
enhancing epsin’s endocytic activity, further supporting a role for epsin function in PAR1 
internalization.  These findings demonstrate a critical role for epsin in regulation of PAR1 
internalization. 
  The majority of GPCRs, including the prototypical β2AR, internalize through a 
clathrin- and dynamin-dependent pathway that require arrestins.  Arrestins facilitate activated 
GPCR internalization by binding directly to the clathrin heavy chain and the β2-adaptin 
subunit of AP2 [253, 274].  We have shown in multiple cell types that arrestins are not 
essential for PAR1 constitutive or agonist-induced internalization [115, 166].  In addition, the 
µ2 subunit of AP2 directly binds to a tyrosine-based motif in the cytoplasmic tail of PAR1 to 
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 mediate constitutive internalization [166].  In Chapter 2 of this dissertation, we also showed 
that PAR1 is basally ubiquitinated and that ubiquitination specifies a clathrin adaptor 
requirement for activated PAR1 internalization through clathrin-coated pits that is distinct 
from AP2.  Here, we now report that epsin regulates PAR1 internalization through 
mechanisms that appear to involve receptor ubiquitination.  Both constitutive and agonist-
induced PAR1 internalization were significantly impaired in cells depleted of epsin, whereas 
internalization of ubiquitin-defective PAR1 was not effected.  Moreover, ubiquitination of 
PAR1 was important for co-localization with endogenous epsin in intact cells.  In contrast, 
β2AR internalization, which requires arrestins, remained intact in epsin depleted HeLa cells.  
Moreover, although β2AR is ubiquitinated following agonist stimulation this is not required 
for internalization [155]. Together, these findings suggest a critical role for epsin in 
regulation of trafficking of a distinct set of GPCRs through a ubiquitin-dependent mechanism 
in mammalian cells. 
 Our study also indicates that activation of PAR1 induces deubiquitination of epsin, 
which may be critical for regulating activated receptor internalization.  Epsin is basally 
ubiquitinated and an influx of Ca2+ initiates rapid deubiquitination mediated by the actions of 
the deubiquitinating enzyme FAM/USP9X [204].  The basal ubiquitination of epsin is 
thought to negatively regulate its endocytic activity by either binding intramolecularly to 
UBDs within the adaptor protein [203] or by preventing epsin interaction with AP2, clathrin 
and plasma membrane lipids [214].  Epsin contains three UBDs that recognize ubiquitinated 
cargo and facilitate internalization through clathrin-coated pits.  In addition to UBDs, epsin 
contains NPF motifs that bind epsin homology (EH) domains in eps15 and eps15R.  Epsin 
and eps15 interact with each other and are likely to function cooperatively to recruit 
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 ubiquitinated cargo to clathrin-coated pits.  Indeed, in cells depleted of epsin and eps15 
adaptor proteins, the inhibition of agonist-induced PAR1 internalization is more pronounced 
compared to constitutive internalization, suggesting the eps15 adaptor proteins may act 
cooperatively with epsin to promote PAR1 internalization.  Indeed in yeast, the epsin 
homologues, Ent1 and Ent2, as well as the eps15 homolog, Ede1 have been shown to 
regulate internalization of ubiquitinated Ste2 receptor [192].   
 In addition to agonist-induced internalization, epsin is also important for PAR1 
constitutive internalization. These findings suggest that epsin can act as an accessory 
molecule perhaps together with AP2 to recruit unactivated PAR1 to clathrin-coated pits for 
internalization.  Interestingly, a recent study has identified another accessory protein termed 
TTP (Transferrin receptor Trafficking Protein) as a critical mediator of transferrin receptor 
constitutive endocytosis [275].  Similar to constitutive internalization of PAR1, constitutive 
endocytosis of transferrin is critically dependent on AP2 function. However, TTP function 
was also shown to be essential for transferrin receptor endocytosis similar to AP2 and appear 
to function synergistically perhaps through increasing the avidity of cargo and clathrin 
adaptor protein interactions.  Although epsin is known to be basally ubiquitinated, this is a 
dynamic process and it is likely that a certain amount of epsin is deubiquitinated under basal 
conditions and competent to function in clathrin-dependent endocytosis.  In addition, epsin 
can directly bind to clathrin and AP2 and could act to increase the avidity of receptor binding 
to AP2 and epsin to promote receptor endocytosis.  
 Our studies provide mechanistic insight into the molecular mechanisms responsible 
for PAR1 internalization.  The proteolytic nature of PAR1 activation is distinct from most 
reversibly activated GPCRs and consequently receptor internalization and lysosomal sorting 
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 are critical for the fidelity of thrombin signaling.  Thrombin and PAR1 are important 
mediators of endothelial cell migration during embryonic development and vascular injury 
[64].  Cell migration requires repeated sampling of the local environment in order to detect 
small changes in agonist concentrations and gradients.  The use of epsin as an important 
clathrin adaptor may be important to ensure non-competitive endocytosis of the receptor or 
epsin may confer important properties for signal regulation as demonstrated by its ability to 
interact with GAPs for small GTPases [198, 199].  It will be important to determine whether 
disruption of epsin affects thrombin signaling and/or cell migration in vitro and in vivo.  
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Figure 4.1.  Knockdown of epsin by siRNA inhibits agonist-induced PAR1 
internalization, but not clathrin-coated pit formation.  (A) HeLa cells were transiently 
transfected with 200 nM non-specific siRNA or 50 nM epsin, CALM, eps15 or eps15R 
siRNA for 48 hours as indicated. To detect knockdown of epsin, CALM and eps15R, cell 
lysates were prepared, separated by SDS-PAGE, transferred to PVDF and immunoblotted for 
the indicated proteins.  Membranes were then stripped and probed for actin as a loading 
control.  To detect knockdown of eps15, cells were lysed, immunoprecipitated with anti-
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 eps15 antibody and the amount of remaining eps15 was detected by immunoblotting.  (B)  
HeLa cells stably expressing wildtype PAR1 were transiently transfected with 200 nM non-
specific siRNA or 50 nM epsin, CALM, eps15 or eps15R siRNA for 48 hours as indicated.  
Cells were then stimulated with 100 µM SFLLRN for various times at 37oC, fixed and the 
amount of remaining surface PAR1 was determined by ELISA.  The data (mean ± S.D., n=3) 
are expressed as the fraction of cell surface receptor antibody bound at 0 min and are 
representative of at least three experiments.  (C) HeLa cells were transiently transfected with 
200 nM non-specific siRNA or 50 nM epsin, CALM, eps15, or eps15R siRNA for 48 hours 
as indicated.  Cells were then fixed, stained for clathrin or the α-adaptin subunit of AP2 and 
imaged by confocal microscopy.  The images shown are representative of many cells from 
three individual experiments.  Scale bar, 10 µm. 
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Figure 4.2.  Epsin contributes to constitutive internalization of PAR1.  (A) HeLa cells 
stably expressing wildtype PAR1 were transiently transfected with 200 nM non-specific 
siRNA or 50 nM epsin, CALM, eps15, or eps15R siRNA for 48 hours as indicated.  Cells 
were then labeled with M1 anti-FLAG antibody for 1 hour at 4oC to label the cell surface 
cohort, washed, and then incubated in media alone for various times at 37oC.  Cells were then 
washed in PBS containing EDTA to remove cell surface bound M1 anti-FLAG antibody (M1 
anti-FLAG antibody binding is Ca2+-dependent).  Cells were then lysed and the amount of 
internalized receptors was quantified by ELISA.  Data (mean ± S.D., n=3) are expressed as 
the fraction of the initial amount of receptor bound antibody at 0 min.  The data shown are 
representative of three separate experiments.  (B) HeLa cells stably expressing wildtype 
PAR1 transfected as in (A) were labeled with M1 anti-FLAG antibody for 1 hour at 4oC, 
washed, incubated in the presence or absence of 100 µM SFLLRN for 15 min at 37oC, and 
processed as above. 
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Figure 4.3.  Epsin mediates internalization of endogenous PAR1.  (A) EA.hy926 cells 
were prelabeled with anti-PAR1 antibody for 1 h at 4oC, stimulated with 100 µM 
TFLLRNPNDK for 3 min at 37oC, fixed, permeabilized and immunostained for PAR1 (red) 
and epsin (green).  Cells were then imaged by confocal microscopy.  Colocalization of PAR1 
and epsin is shown as yellow in the merged image.  The data shown represent many cells 
examined from at least three separate experiments.  Scale bar, 10 µm.  (B) EA.hy926 cells 
were electroporated with 2.4 µM ns-siRNA or 600 nM epsin, CALM, eps15 or eps15R-
siRNA for 48 hrs.  To detect knockdown of epsin, CALM and eps15R, cell lysates were 
prepared, separated by SDS-PAGE, transferred to PVDF and immunoblotted for the 
indicated proteins.  Membranes were then stripped and probed for actin as a loading control.  
To detect knockdown of eps15, cells were lysed, immunoprecipitated with anti-eps15 
antibody and the amount of remaining eps15 was detected by immunoblotting.  (C) 
EA.hy926 cells electroporated as described in (B) were incubated with 100 µM 
TFLLRNPNDK for various times at 37oC, fixed, and the amount of remaining surface PAR1 
was detected by cell surface ELISA.  The data (mean ± S.D., n=3) are expressed as (surface 
PAR1 at time zero – surface PAR1 following 10 min TFLLRNPNDK / surface PAR1 at time 
zero) and are representative of at least three individual experiments. 
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Figure 4.4.  Epsin is not involved in constitutive internalization of the transferrin 
receptor.  (A)  HeLa cells were transiently transfected with 200 nM non-specific siRNA, 50 
nM epsin, CALM, eps15, or eps15R or 100 nM µ2 siRNA for 48 hours as indicated.  Cells 
were then serum starved for 1.5 hours to remove endogenous transferrin, incubated with 
biotinylated transferrin for 1 hour at 4oC, and incubated in media for various times at 37oC to 
facilitate constitutive internalization.  Cells were incubated with avidin for 1 hour at 4oC to 
bind cell surface biotinylated transferrin and then incubated with biocytin for 1 hour at 4oC to 
bind cell surface avidin.  Cells were then lysed and the amount of internalized biotinylated 
transferrin was quantified by ELISA.  The data (mean ± S.D., n=3) are expressed as the 
fraction of cell surface bound biotinylated transferrin at 0 min and are representative of at 
least 3 separate experiments.  (B) HeLa cells were transfected as indicated in (A).  Cells were 
then serum starved to remove endogenous transferrin, incubated with Alexa-488 conjugated 
transferrin, and processed for microscopy.  Cells were then imaged by confocal microscopy.  
The images shown represent many cells from at least three separate experiments.    
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Figure 4.5.  Epsin does not mediate agonist-induced internalization of the β2AR.  (A) 
HeLa cells stably expressing the β2AR were transiently transfected with 200 nM non-specific 
siRNA or 50 nM epsin, CALM, eps15 or eps15R siRNA for 48 hours as indicated.   Cells 
were then incubated with M1 anti-FLAG antibody for 1 hour at 4oC to label cell surface 
receptors.  Cells were then incubated in the presence of 10 µM isoproterenol for various 
times at 37oC, washed with PBS/EDTA to removed cell surface receptor bound antibody, 
lysed and the amount of internalized receptor was then quantified by ELISA.  The data (mean 
± S.D., n=3) are expressed as the fraction of cell surface receptor bound antibody at 0 min 
and are representative of at least three experiments.  (B)  HeLa cells stably expressing the 
β2AR were transfected with siRNA as indicated in (A).  Cells were then incubated with M1 
anti-FLAG antibody for 1 hour at 4oC to label the cell surface cohort, washed and incubated 
with 10 mM isoproterenol at 37oC for 30 min.  Cells were then fixed, permeabilized, 
immunostained for β2AR and processed for microscopy.  Images were acquired by confocal 
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 microscopy and represent many cells from at least three separate experiments.  Scale bar, 10 
µm. 
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Figure 4.6.  Epsin does not mediate agonist-induced internalization of ubiquitin-
defective PAR1.  (A) HeLa cells stably expressing PAR1 0K mutant were transiently 
transfected with 200 nM non-specific siRNA or 50 nM epsin, CALM, eps15 or eps15R 
siRNA for 48 hours as indicated.  Cells were then incubated with M1 anti-FLAG antibody 
for 1 hour at 4oC to label the cell surface cohort.  Cells were then incubated in the presence of 
100 µM SFLLRN for various times at 37oC, fixed and the remaining cell surface receptor 
bound antibody was quantified by ELISA.  The data (mean ± S.D., n=3) are expressed as the 
fraction of cell surface receptor bound antibody at 0 min and are representative of at least 
three individual experiments.  (B) HeLa cells stably expressing wildtype PAR1 or PAR1 0K 
mutants were incubated with polyclonal anti-FLAG antibody for 1 hour at 4oC to label the 
cells surface cohort.  Cells were then incubated in the presence of 100 µM SFLLRN for 3 
min at 37oC, fixed, permeabilized and immunostained for PAR1 (red) and epsin (green).  
Images were acquired by confocal microscopy and are representative of many cells from at 
least three separate experiments. 
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Figure 4.7.  PAR1 stimulated deubiquitination of epsin.  HEK293 cells were transiently 
transfected with HA-PAR1, myc-epsin and Flag-ubiquitin for 48 hours.  Cells were then 
stimulated with 100 µM SFLLRN for 3 or 5 min at 37oC or with 2 µM A23187 for 5 min at 
37oC.  Cells were then lysed and epsin was immunoprecipitated.  Immunoprecipitates were 
separated by SDS-PAGE, transferred and immunoblotted for Flag-ubiquitin.  The membrane 
was then stripped and probed for total epsin.  The data shown are representative of at least 
three separate experiments.   
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 CHAPTER 5
GENERAL CONCLUSION AND FUTURE DIRECTIONS
The GPCR family of receptors consists of ~900 members and is the largest family of 
signaling receptors encoded in the mammalian genome.  GPCRs elicit cellular responses to 
diverse extracellular stimuli at the plasma membrane and some internalized receptors 
continue to signal from internal compartments.  Desensitization and receptor trafficking are 
the predominant mechanisms that control GPCR signaling.  Most activated GPCRs are 
rapidly desensitized by phosphorylation and arrestin binding which promotes receptor 
uncoupling from G-proteins within seconds.  GPCR internalization ensues within minutes 
and removes activated receptor from G-proteins and signaling effectors at the plasma 
membrane.  Once internalized, some GPCRs may continue to signal from endosomes, until 
agonist eventually dissociates from receptors or signaling is shut-off.  GPCRs are then 
dephosphorylated and recycled back to the cell surface in a resensitized state competent to 
signal again.  Thus, endocytosis serves multiple functions in the regulation of GPCR 
signaling including signal termination and propagation and receptor resensitization. 
Additionally, trafficking of internalized GPCRs from endosomes to lysosomes and 
consequent receptor degradation is an important process that terminates receptor signaling 
[91].  Despite the importance of GPCR trafficking in regulation of cellular signaling, our 
knowledge of the molecular mechanisms that control these processes is limited and based on 
a few well-studied receptors. 
 PAR1 is unique among the family of GPCRs in that it is activated by a unique 
proteolytic, irreversible mechanism.  Therefore, novel endocytic sorting mechanisms have 
evolved to dispose of irreversibly activated receptors and to resensitize cells to thrombin 
signaling.  Constitutive internalization of PAR1 is important for cellular resensitization of 
thrombin signaling and occurs via a clathrin-, dynamin-, and AP2-dependent mechanism that 
is independent of arrestins (Figure 5.1).  In contrast, activated PAR1 internalization is 
required to definitively shut-off PAR1 signaling and is mediated by a clathrin- and dynamin-
dependent mechanism that requires phosphorylation, but is independent of arrestins and AP2 
(Figure 5.1) [115, 229].  Thus, the focus of this dissertation was to determine the molecular 
basis by which activated PAR1 is internalized via clathrin-coated pits and sorted to 
lysosomes and degraded.  
In Chapter 2 of this dissertation, we found that PAR1 is basally ubiquitinated and 
undergoes agonist-induced deubiquitination (Figure 5.1).  Ubiquitination of PAR1 negatively 
regulates constitutive internalization and thus serves as a mechanism to retain unactivated 
receptors on the cell surface.  Additionally, ubiquitination of PAR1 is important for 
specifying the clathrin adaptor proteins that mediate agonist-induced receptor internalization, 
but ubiquitination is not essential for lysosomal degradation (Figure 5.1).   Our studies reveal 
a novel role for ubiquitination in regulation of mammalian GPCR endocytic sorting. 
 In addition to PAR1, several other GPCRs display constitutive internalization.  A 
splice variant of the thromboxane TPβ receptor displays constitutive internalization through a 
mechanisms that requires a non-canonical tyrosine-based motif, Yxxxφ (Y338SGTI) [138].  
The µ2 subunit of AP2 can accommodate and bind to such Yxxxφ motifs but whether AP2 
functions in TPβ constitutive internalization has not been determined.  The C-tail of TPβ also 
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 contains two lysine residues that could serve as potential sites for ubiquitination, but whether 
ubiquitination plays a role in TPβ constitutive internalization has not been determined.  The 
G-protein coupled platelet activating factor receptor (PAFR) is also basally ubiquitinated, but 
whether this has a function in receptor trafficking has not been examined. Although AP2 
mediates constitutive internalization of some GPCRs, the α1b-AR and CXCR2 harbor non-
canonical motifs that bind AP2 and function to control agonist-induced internalization [168, 
171]. Thus, similar to ubiquitination, AP2 displays diverse functions in regulation of 
mammalian endocytosis. 
Ubiquitination of substrate proteins is a highly dynamic and reversible process 
mediated by the actions of E3 ligases and DUBs.  The E3 ligases and DUBs important for 
PAR1 ubiquitination and deubiquitination have yet to be identified.  Rsp5, which is a 
member of the NEDD-4 family of ubiquitin ligases, ubiquitinates the yeast Ste2 receptor 
[189].  AIP4, another member of the NEDD-4 family of ubiquitin ligases, is an important 
mediator of activated CXCR4 ubiquitination [241].  PAR2 is also ubiquitinated in an agonist-
dependent manner by the actions of the Cbl E3 ligase [243], but how Cbl which is recruited 
to PAR2 is not known.  Although agonist induces ubiquitination of the β2AR, the E3 ligase 
has not been identified [155].  It will be interesting to determine if members of the NEDD-4 
family or Cbl are responsible for PAR1 ubiquitination.  To date there have been no DUBs 
identified that regulate endocytic sorting of any mammalian GPCRs.   Interestingly, CXCR4 
fails to be ubiquitinated in breast cancer cells and consequently promotes cell migration and 
invasion [276].  PAR1 trafficking is also dysregulated in breast cancer cells [92] suggesting 
that perhaps aberrant ubiquitination plays a role in this process.    
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   A role for ubiquitination in mammalian GPCR lysosomal sorting and degradation has 
been demonstrated [155, 240].  The work presented in Chapter 3 of this dissertation shows 
that ubiquitination of PAR1 is not required for degradation since a ubiquitin-defective PAR1 
sorts to lysosomes and is degraded comparable to wildtype receptor.  In addition, we also 
show that agonist-induced degradation of PAR1 is independent of Hrs and Tsg101, two 
adaptor proteins that mediate lysosomal sorting of ubiquitinated cargo.  Interestingly, sorting 
of activated PAR1 to lysosomes for degradation is SNX1-dependent although the mechanism 
by which SNX1 mediates PAR1 degradation remains unknown (Chapter 3).  Lysosomal 
sorting and degradation of PAR1 is critically important for termination of receptor signaling 
[231].  Therefore, elucidating the molecular mechanisms that mediate PAR1 lysosomal 
sorting will be important for understanding thrombin signaling.   
 The molecular determinates that specify lysosomal sorting of PAR1 reside within the 
C-tail region.  A PAR1 chimera containing the C-tail of SPR internalized and recycled, 
whereas a SPR chimera containing the C-tail of PAR1 internalized and degraded like 
wildtype PAR1 [231].  PAR1 contains two highly conserved tyrosine based motifs within its 
C-tail domain, a proximal motif (Y383SIL) is located ten residues from the end of the seventh 
transmembrane domain and a distal motif  (Y420KKL) is found at the extreme C-terminus and 
binds to AP2  [256].  A PAR1 truncation mutant (PAR1 C387Z) that exposes the proximal 
YSIL motif and results in constitutive internalization and degradation of unactivated PAR1, 
whereas a tyrosine-based mutant failed to internalize and degrade [256].  Moreover, agonist-
induced degradation of PAR1 is also impaired when the proximal motif is mutated in the 
context of the full length C-tail [256], suggesting a critical role for this tyrosine-based motif 
in internalization and degradation of PAR1.  In addition to SNX1, recent work in our lab 
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 suggests that the adaptor protein complex-3 (AP3) is also important for regulation of 
activated PAR1 lysosomal sorting and degradation (Paing and Trejo, unpublished data).  AP3 
is found in endosomes and mediates sorting of cargo from endosomes to lysosomes for 
degradation [277].  Thus, the proximal Y383SIL motif may mediate degradation of activated 
PAR1 via interaction with AP3, which may facilitate lysosomal sorting.  Interestingly, 
mutation of the single tyrosine residue within the C-tail of the M2 muscarinic acetylcholine 
receptor also significantly decreases the rate of receptor downregulation [278].  The tyrosine 
residue (Y459) is a critical residue in a canonical tyrosine-based motif (Y459KNI) in the C-tail 
of the M2 muscarinic receptor that may be able to interact with AP3 to mediate degradation 
of the receptor, suggesting that AP3 may function in downregulation of several GPCRs.    
As reported in Chapter 4 of this dissertation, the clathrin adaptor protein epsin 
functions in internalization of activated PAR1.  Activation of PAR1 induces the 
deubiquitination of epsin, which facilitates the ability of epsin to recognize ubiquitinated 
PAR1 and mediate receptor endocytosis via clathrin-coated pits (Figure 5.1).  Our studies 
provide the first evidence for a role of epsin and ubiquitination in facilitating endocytosis of a 
mammalian GPCR. 
In addition to ubiquitination and epsin, phosphorylation of PAR1 is important for 
agonist-induced internalization through clathrin-coated pits [230].  Interestingly, PAR1 is 
also deubiquitinated following activation (Chapter 2).  Therefore, it will be important to 
investigate the interplay between ubiquitination and phosphorylation of activated PAR1.  Is 
ubiquitination required for phosphorylation of PAR1 or is phosphorylation required for 
deubiquitination?  The yeast Ste2 receptor requires ubiquitination for internalization and Ste2 
phosphorylation is required for ubiquitination [190].  Since ubiquitination of Ste2 is 
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 necessary and sufficient for receptor internalization, a phosphorylation defective mutant of 
Ste2 is unable to undergo agonist-induced internalization.  In the case of PAR1, agonist 
promotes deubiquitination of the receptor and therefore, the interplay between ubiquitination 
and phosphorylation of PAR1 may be a novel form of regulation, which is distinct from the 
Ste2 receptor. 
 Activation of PAR1 results in the deubiquitination of epsin that presumably relieves 
an autoinhibitory mechanism whereby the ubiquitin moiety on epsin binds intramolecularly 
with the UBD of epsin.  Thus, the regulation of epsin ubiquitination may be crucial for  
agonist-induced internalization of PAR1.  Epsin is basally phosphorylated and undergoes 
calcium-dependent dephosphorylation by the phosphatase calcineurin [279].  
Dephosphorylation of epsin allows the DUB, FAM/USP9X, to deubiquitinate epsin [204].  
PAR1 activation results in the mobilization of intracellular calcium and activation of kinases, 
phosphatases and other important enzymes.  It will be important to determine if calcium is 
the key regulator of PAR1-mediated deubiquitination of epsin and whether the 
phosphorylation status of epsin changes upon thrombin stimulation.  Moreover, 
understanding the contribution of calcineurin and FAM/USP9X in the regulation of epsin 
function and PAR1 endocytosis is also an important pursuit.  
 In contrast to most GPCRs, which require arrestins for internalization, epsins are 
required for activated PAR1 internalization.  Why would PAR1 evolve to utilize epsin for 
internalization as opposed to arrestins?  One simple explanation may be to ensure that 
proteolytically activated PAR1 is rapidly internalized from the cell surface by not competing 
with other activated GPCRs for arrestins.  Indeed, it is generally accepted that internalization 
of cargo through clathrin-coated pits can be saturated but is non-competitive, thus cargo that 
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 use distinct clathrin adaptor proteins are efficiently internalized through the same clathrin 
coated-pit [143, 144].  In addition, epsins may facilitate signaling by PAR1 similar to how 
arrestins function to control various aspects of GPCR signaling.  Indeed, a function for the 
ENTH domain of epsin and its yeast homologues Ent1,2 has been shown recently to regulate 
signaling to small G-proteins by sequestering or inactivating GAPs for Cdc42 and Rac1 [198, 
199].  In yeast, the ENTH domain of Ent1,2 is both necessary and sufficient for cell viability 
and polarity.  Interaction of GAPs for Cdc42 with the ENTH domain of Ent1,2 results in 
increased Cdc42⋅GTP levels.  The activated form of Cdc42 is believed to function in spatial 
and temporal activation of endocytosis and cell polarity [199].  The interaction of the ENTH 
domain of epsin with GAPs for Cdc42 and the role of epsin in PAR1 internalization suggests 
that PAR1 may utilize epsin as a clathrin adaptor protein for internalization to further control 
activation of Cdc42 or other small G-proteins by a non-traditional mechanism.  It will be 
interesting to determine if the ENTH domain of epsin via its interaction with Cdc42 and 
Rac1 plays a role in PAR1 mediated signaling and cell migration.      
 In conclusion, our work has defined a novel role for ubiquitination in regulation of 
mammalian GPCR endocytosis through clathrin-coated pits.  In future studies, it will be 
important to examine the role of ubiquitination and epsin in regulation of PAR1 signaling 
which might provide important insight into how thrombin-elicited cellular responses are 
controlled.  Ubiquitination of PAR1 does not appear to function in coupling at least to Gαq, 
as the ubiquitin-defective PAR1 is able to couple to PI hydrolysis comparable to wildtype 
PAR1 (Chapter 2); however, the role of PAR1 ubiquitination in regulation of other signaling 
pathways has yet to be examined.  In recent work, our laboratory has shown that the 
formation of an intracellular pool of PAR1 resulting from constitutive internalization is not 
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 only important for rapid recovery of thrombin signaling, but also for sustaining signaling to 
ERK1/2 activation, an important mediator of mitogenic responses (Paing and Trejo, 
unpublished data).  Given the increased constitutive internalization of ubiquitin-defective 
PAR1, it is likely that the duration of PAR1 signaling to certain effectors is markedly 
changed.  Thus, it will be important to determine how signaling by ubiquitin-defective PAR1 
impacts thrombin-stimulated cellular proliferation and migration.  In addition, epsin 
depletion impairs agonist-induced PAR1 internalization and thereby increases the amount of 
active receptors at the cell surface at a given time.  These observations suggest that epsin and 
ubiquitination of PAR1 will have important functions in regulation of receptor signaling. 
Moreover, future studies aimed an identifying the important mediators of PAR1 
ubiquitination and deubiquitination may provide new targets for the development of drugs to 
control thrombin signaling in vascular disease and cancer progression.  
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Figure 5.1.  Model of PAR1 Trafficking.  In a basal state 80-90% of unactivated PAR1 
resides at the plasma membrane, while 10-20% is constitutively internalized into an 
intracellular pool.  This pool of receptors is responsible for restoring thrombin 
responsiveness.  AP2 binds to a tyrosine-based motif  (Y420KKL) in the extreme C-terminus 
of PAR1 to mediate constitutive internalization of PAR1.  PAR1 is also basally ubiquitinated 
and it appears that a deubiquitinated form of the receptor binds AP2 to facilitate constitutive 
internalization of the receptor.  The DUB that deubiquitinates unactivated PAR1 remains 
unknown.  PAR1 is then recycled to the plasma membrane where it is ubiquitinated by an E3 
ubiquitin ligase that also remains unknown.  Upon exposure to thrombin, the protease binds 
to and cleaves the amino-terminal exodomain of the receptor to initiate transmembrane 
signaling including an increase in intracellular calcium.  The increase in intracellular calcium 
results in deubiquitination of the clathrin adaptor protein epsin, thus allowing epsin to 
interact with the ubiquitinated form of the receptor.  The receptor is also phosphorylated,  
recruited into clathrin-coated pits where it is deubiquitinated by an unknown DUB, and 
sorted to an early endosomal compartment.  PAR1 is then sorted to lysosomes via a 
ubiquitin-, Hrs-, and Tsg101-independent mechanism.   
143
 REFERENCES 
1. Mann, K. G. (2003). Thrombin: can't live without it; probably die from it. Chest 124, 
1S-3S. 
2. Mann, K. G. (2003). Thrombin formation. Chest 124, 4S-10S. 
3. Macfarlane, S. R., Seatter, M. J., Kanke, T., Hunter, G. D., and Plevin, R. (2001). 
Proteinase-activated receptors. Pharmacol Rev 53, 245-82. 
4. Vu, T. K., Hung, D. T., Wheaton, V. I., and Coughlin, S. R. (1991). Molecular 
cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of 
receptor activation. Cell 64, 1057-68. 
5. Gerszten, R. E., Chen, J., Ishii, M., Ishii, K., Wang, L., Nanevicz, T., Turck, C. W., 
Vu, T. K., and Coughlin, S. R. (1994). Specificity of the thrombin receptor for agonist 
peptide is defined by its extracellular surface. Nature 368, 648-51. 
6. Rasmussen, U. B., Vouret-Craviari, V., Jallat, S., Schlesinger, Y., Pages, G., Pavirani, 
A., Lecocq, J. P., Pouyssegur, J., and Van Obberghen-Schilling, E. (1991). cDNA 
cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ 
mobilization. FEBS Lett 288, 123-8. 
7. Tanaka H, S. L., Duong LT, and Rodan GA (1993). Cloning of the mouse thrombin 
receptor from osteoblastic cells and regulation of its expression by 1,25-
dihydroxyvitamin-D(3) and parathyroid hormone. J Bone Miner Res 8, S143. 
8. Zhong, C., Hayzer, D. J., Corson, M. A., and Runge, M. S. (1992). Molecular cloning 
of the rat vascular smooth muscle thrombin receptor. Evidence for in vitro regulation 
by basic fibroblast growth factor. J Biol Chem 267, 16975-9. 
9. Hayzer, D. J., Shoji, M., and Hanson, S. R. (2000). cDNAs encoding the baboon 
thrombin receptor indicate a primate transcription start site upstream of putative sites 
reported for the human gene. Thromb Res 98, 195-201. 
10. Stenflo, J., and Fernlund, P. (1982). Amino acid sequence of the heavy chain of 
bovine protein C. J Biol Chem 257, 12180-90. 
144
 11. Vu, T. K., Wheaton, V. I., Hung, D. T., Charo, I., and Coughlin, S. R. (1991). 
Domains specifying thrombin-receptor interaction. Nature 353, 674-7. 
12. Ishii, K., Gerszten, R., Zheng, Y. W., Welsh, J. B., Turck, C. W., and Coughlin, S. R. 
(1995). Determinants of thrombin receptor cleavage. Receptor domains involved, 
specificity, and role of the P3 aspartate. J Biol Chem 270, 16435-40. 
13. Bouton, M. C., Jandrot-Perrus, M., Moog, S., Cazenave, J. P., Guillin, M. C., and 
Lanza, F. (1995). Thrombin interaction with a recombinant N-terminal extracellular 
domain of the thrombin receptor in an acellular system. Biochem J 305 ( Pt 2), 635-
41. 
14. Seiler, S. M., Peluso, M., Michel, I. M., Goldenberg, H., Fenton, J. W., 2nd, 
Riexinger, D., and Natarajan, S. (1995). Inhibition of thrombin and SFLLR-peptide 
stimulation of platelet aggregation, phospholipase A2 and Na+/H+ exchange by a 
thrombin receptor antagonist. Biochem Pharmacol 49, 519-28. 
15. Scarborough, R. M., Naughton, M. A., Teng, W., Hung, D. T., Rose, J., Vu, T. K., 
Wheaton, V. I., Turck, C. W., and Coughlin, S. R. (1992). Tethered ligand agonist 
peptides. Structural requirements for thrombin receptor activation reveal mechanism 
of proteolytic unmasking of agonist function. J Biol Chem 267, 13146-9. 
16. Bahou, W. F., Kutok, J. L., Wong, A., Potter, C. L., and Coller, B. S. (1994). 
Identification of a novel thrombin receptor sequence required for activation-
dependent responses. Blood 84, 4195-202. 
17. Lerner, D. J., Chen, M., Tram, T., and Coughlin, S. R. (1996). Agonist recognition by 
proteinase-activated receptor 2 and thrombin receptor. Importance of extracellular 
loop interactions for receptor function. J Biol Chem 271, 13943-7. 
18. Molino, M., Woolkalis, M. J., Reavey-Cantwell, J., Pratico, D., Andrade-Gordon, P., 
Barnathan, E. S., and Brass, L. F. (1997). Endothelial cell thrombin receptors and 
PAR-2. Two protease-activated receptors located in a single cellular environment. J 
Biol Chem 272, 11133-41. 
19. Camerer, E., Huang, W., and Coughlin, S. R. (2000). Tissue factor- and factor X-
dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad 
Sci U S A 97, 5255-60. 
145
 20. Kuliopulos, A., Covic, L., Seeley, S. K., Sheridan, P. J., Helin, J., and Costello, C. E. 
(1999). Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of 
truncation, and implications for thrombolytic therapy. Biochemistry 38, 4572-85. 
21. Riewald, M., Petrovan, R. J., Donner, A., and Ruf, W. (2003). Activated protein C 
signals through the thrombin receptor PAR1 in endothelial cells. J Endotoxin Res 9, 
317-21. 
22. Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M., and Ruf, W. (2002). 
Activation of endothelial cell protease activated receptor 1 by the protein C pathway. 
Science 296, 1880-2. 
23. Parry, M. A., Myles, T., Tschopp, J., and Stone, S. R. (1996). Cleavage of the 
thrombin receptor: identification of potential activators and inactivators. Biochem J 
320 ( Pt 1), 335-41. 
24. Vouret-Craviari, V., Grall, D., Chambard, J. C., Rasmussen, U. B., Pouyssegur, J., 
and Van Obberghen-Schilling, E. (1995). Post-translational and activation-dependent 
modifications of the G protein-coupled thrombin receptor. J Biol Chem 270, 8367-72. 
25. Weksler, B. B., Jaffe, E. A., Brower, M. S., and Cole, O. F. (1989). Human leukocyte 
cathepsin G and elastase specifically suppress thrombin-induced prostacyclin 
production in human endothelial cells. Blood 74, 1627-34. 
26. Renesto, P., Si-Tahar, M., Moniatte, M., Balloy, V., Van Dorsselaer, A., Pidard, D., 
and Chignard, M. (1997). Specific inhibition of thrombin-induced cell activation by 
the neutrophil proteinases elastase, cathepsin G, and proteinase 3: evidence for 
distinct cleavage sites within the aminoterminal domain of the thrombin receptor. 
Blood 89, 1944-53. 
27. Connolly, A. J., Ishihara, H., Kahn, M. L., Farese, R. V., Jr., and Coughlin, S. R. 
(1996). Role of the thrombin receptor in development and evidence for a second 
receptor. Nature 381, 516-9. 
28. Griffin, C. T., Srinivasan, Y., Zheng, Y. W., Huang, W., and Coughlin, S. R. (2001). 
A role for thrombin receptor signaling in endothelial cells during embryonic 
development. Science 293, 1666-70. 
29. Nystedt, S., Emilsson, K., Wahlestedt, C., and Sundelin, J. (1994). Molecular cloning 
of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 91, 9208-12. 
146
 30. Schwartz, L. B. (1994). Tryptase: a mast cell serine protease. Methods Enzymol 244, 
88-100. 
31. Nystedt, S., Emilsson, K., Larsson, A. K., Strombeck, B., and Sundelin, J. (1995). 
Molecular cloning and functional expression of the gene encoding the human 
proteinase-activated receptor 2. Eur J Biochem 232, 84-9. 
32. al-Ani, B., Saifeddine, M., and Hollenberg, M. D. (1995). Detection of functional 
receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-
NH2, in rat vascular and gastric smooth muscle. Can J Physiol Pharmacol 73, 1203-7. 
33. Komuro, T., Miwa, S., Minowa, T., Okamoto, Y., Enoki, T., Ninomiya, H., Zhang, X. 
F., Uemura, Y., Kikuchi, H., and Masaki, T. (1997). The involvement of a novel 
mechanism distinct from the thrombin receptor in the vasocontraction induced by 
trypsin. Br J Pharmacol 120, 851-6. 
34. Roy, S. S., Saifeddine, M., Loutzenhiser, R., Triggle, C. R., and Hollenberg, M. D. 
(1998). Dual endothelium-dependent vascular activities of proteinase-activated 
receptor-2-activating peptides: evidence for receptor heterogeneity. Br J Pharmacol 
123, 1434-40. 
35. Saifeddine, M., Roy, S. S., Al-Ani, B., Triggle, C. R., and Hollenberg, M. D. (1998). 
Endothelium-dependent contractile actions of proteinase-activated receptor-2-
activating peptides in human umbilical vein: release of a contracting factor via a 
novel receptor. Br J Pharmacol 125, 1445-54. 
36. Vergnolle, N. (1999). Proteinase-activated receptor-2-activating peptides induce 
leukocyte rolling, adhesion, and extravasation in vivo. J Immunol 163, 5064-9. 
37. Vergnolle, N., Macnaughton, W. K., Al-Ani, B., Saifeddine, M., Wallace, J. L., and 
Hollenberg, M. D. (1998). Proteinase-activated receptor 2 (PAR2)-activating 
peptides: identification of a receptor distinct from PAR2 that regulates intestinal 
transport. Proc Natl Acad Sci U S A 95, 7766-71. 
38. Kawabata, A., Kuroda, R., Kuroki, N., Nishikawa, H., Kawai, K., and Araki, H. 
(2000). Characterization of the protease-activated receptor-1-mediated contraction 
and relaxation in the rat duodenal smooth muscle. Life Sci 67, 2521-30. 
147
 39. Kawabata, A., Nishikawa, H., Kuroda, R., Kawai, K., and Hollenberg, M. D. (2000). 
Proteinase-activated receptor-2 (PAR-2): regulation of salivary and pancreatic 
exocrine secretion in vivo in rats and mice. Br J Pharmacol 129, 1808-14. 
40. D'Andrea, M. R., Derian, C. K., Leturcq, D., Baker, S. M., Brunmark, A., Ling, P., 
Darrow, A. L., Santulli, R. J., Brass, L. F., and Andrade-Gordon, P. (1998). 
Characterization of protease-activated receptor-2 immunoreactivity in normal human 
tissues. J Histochem Cytochem 46, 157-64. 
41. Steinhoff, M., Corvera, C. U., Thoma, M. S., Kong, W., McAlpine, B. E., Caughey, 
G. H., Ansel, J. C., and Bunnett, N. W. (1999). Proteinase-activated receptor-2 in 
human skin: tissue distribution and activation of keratinocytes by mast cell tryptase. 
Exp Dermatol 8, 282-94. 
42. Ishihara, H., Connolly, A. J., Zeng, D., Kahn, M. L., Zheng, Y. W., Timmons, C., 
Tram, T., and Coughlin, S. R. (1997). Protease-activated receptor 3 is a second 
thrombin receptor in humans. Nature 386, 502-6. 
43. Dupre, D. J., Chen, Z., Le Gouill, C., Theriault, C., Parent, J. L., Rola-Pleszczynski, 
M., and Stankova, J. (2003). Trafficking, ubiquitination, and down-regulation of the 
human platelet-activating factor receptor. J Biol Chem 278, 48228-35. 
44. Nakanishi-Matsui, M., Zheng, Y. W., Sulciner, D. J., Weiss, E. J., Ludeman, M. J., 
and Coughlin, S. R. (2000). PAR3 is a cofactor for PAR4 activation by thrombin. 
Nature 404, 609-13. 
45. Kahn, M. L., Zheng, Y. W., Huang, W., Bigornia, V., Zeng, D., Moff, S., Farese, R. 
V., Jr., Tam, C., and Coughlin, S. R. (1998). A dual thrombin receptor system for 
platelet activation. Nature 394, 690-4. 
46. Hauck, R. W., Schulz, C., Schomig, A., Hoffman, R. K., and Panettieri, R. A., Jr. 
(1999). alpha-Thrombin stimulates contraction of human bronchial rings by activation 
of protease-activated receptors. Am J Physiol 277, L22-9. 
47. Bartha, K., Domotor, E., Lanza, F., Adam-Vizi, V., and Machovich, R. (2000). 
Identification of thrombin receptors in rat brain capillary endothelial cells. J Cereb 
Blood Flow Metab 20, 175-82. 
148
 48. Xu, W. F., Andersen, H., Whitmore, T. E., Presnell, S. R., Yee, D. P., Ching, A., 
Gilbert, T., Davie, E. W., and Foster, D. C. (1998). Cloning and characterization of 
human protease-activated receptor 4. Proc Natl Acad Sci U S A 95, 6642-6. 
49. Sambrano, G. R., Huang, W., Faruqi, T., Mahrus, S., Craik, C., and Coughlin, S. R. 
(2000). Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol 
Chem 275, 6819-23. 
50. Sambrano, G. R., Weiss, E. J., Zheng, Y. W., Huang, W., and Coughlin, S. R. (2001). 
Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413, 
74-8. 
51. Ruppel, K. M., Willison, D., Kataoka, H., Wang, A., Zheng, Y. W., Cornelissen, I., 
Yin, L., Xu, S. M., and Coughlin, S. R. (2005). Essential role for Galpha13 in 
endothelial cells during embryonic development. Proc Natl Acad Sci U S A 102, 
8281-6. 
52. Hung, D. T., Vu, T. K., Wheaton, V. I., Charo, I. F., Nelken, N. A., Esmon, N., 
Esmon, C. T., and Coughlin, S. R. (1992). "Mirror image" antagonists of thrombin-
induced platelet activation based on thrombin receptor structure. J Clin Invest 89, 
444-50. 
53. Brass, L. F., Vassallo, R. R., Jr., Belmonte, E., Ahuja, M., Cichowski, K., and Hoxie, 
J. A. (1992). Structure and function of the human platelet thrombin receptor. Studies 
using monoclonal antibodies directed against a defined domain within the receptor N 
terminus. J Biol Chem 267, 13795-8. 
54. Kahn, M. L., Nakanishi-Matsui, M., Shapiro, M. J., Ishihara, H., and Coughlin, S. R. 
(1999). Protease-activated receptors 1 and 4 mediate activation of human platelets by 
thrombin. J Clin Invest 103, 879-87. 
55. Eidt, J. F., Allison, P., Noble, S., Ashton, J., Golino, P., McNatt, J., Buja, L. M., and 
Willerson, J. T. (1988). Thrombin is an important mediator of cyclic coronary blood 
flow variations due to platelet aggregation in stenosed canine coronary arteries. Trans 
Assoc Am Physicians 101, 125-36. 
56. Detwiler, T. C., and Feinman, R. D. (1973). Kinetics of the thrombin-induced release 
of adenosine triphosphate by platelets. Comparison with release of calcium. 
Biochemistry 12, 2462-8. 
149
 57. McGregor, L., Hanss, M., Sayegh, A., Calvette, J. J., Trzeciak, M. C., Ville, D., 
Catimel, B., Viala, J. J., Dechavanne, M., and McGregor, J. L. (1989). Aggregation to 
thrombin and collagen of platelets from a Glanzmann thrombasthenic patient lacking 
glycoproteins IIb and IIIa. Thromb Haemost 62, 962-7. 
58. Watts, I. S., Keery, R. J., and Lumley, P. (1989). Differential ability of agonists to 
express distinct pools of fibrinogen (GpIIb/IIIa) receptors which can mediate the 
aggregation of human platelets. Thromb Haemost 62, 955-61. 
59. Stenberg, P. E., McEver, R. P., Shuman, M. A., Jacques, Y. V., and Bainton, D. F. 
(1985). A platelet alpha-granule membrane protein (GMP-140) is expressed on the 
plasma membrane after activation. J Cell Biol 101, 880-6. 
60. Henn, V., Slupsky, J. R., Grafe, M., Anagnostopoulos, I., Forster, R., Muller-
Berghaus, G., and Kroczek, R. A. (1998). CD40 ligand on activated platelets triggers 
an inflammatory reaction of endothelial cells. Nature 391, 591-4. 
61. Hung, D. T., Wong, Y. H., Vu, T. K., and Coughlin, S. R. (1992). The cloned platelet 
thrombin receptor couples to at least two distinct effectors to stimulate 
phosphoinositide hydrolysis and inhibit adenylyl cyclase. J Biol Chem 267, 20831-4. 
62. Hoxie, J. A., Ahuja, M., Belmonte, E., Pizarro, S., Parton, R., and Brass, L. F. (1993). 
Internalization and recycling of activated thrombin receptors. J Biol Chem 268, 
13756-63. 
63. Bernatowicz, M. S., Klimas, C. E., Hartl, K. S., Peluso, M., Allegretto, N. J., and 
Seiler, S. M. (1996). Development of potent thrombin receptor antagonist peptides. J 
Med Chem 39, 4879-87. 
64. Coughlin, S. R. (2005). Protease-activated receptors in hemostasis, thrombosis and 
vascular biology. J Thromb Haemost 3, 1800-14. 
65. Suh, T. T., Holmback, K., Jensen, N. J., Daugherty, C. C., Small, K., Simon, D. I., 
Potter, S., and Degen, J. L. (1995). Resolution of spontaneous bleeding events but 
failure of pregnancy in fibrinogen-deficient mice. Genes Dev 9, 2020-33. 
66. Sun, W. Y., Witte, D. P., Degen, J. L., Colbert, M. C., Burkart, M. C., Holmback, K., 
Xiao, Q., Bugge, T. H., and Degen, S. J. (1998). Prothrombin deficiency results in 
embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A 95, 7597-602. 
150
 67. Xue, J., Wu, Q., Westfield, L. A., Tuley, E. A., Lu, D., Zhang, Q., Shim, K., Zheng, 
X., and Sadler, J. E. (1998). Incomplete embryonic lethality and fatal neonatal 
hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci U S A 95, 
7603-7. 
68. Hamilton, J. R., Moffatt, J. D., Frauman, A. G., and Cocks, T. M. (2001). Protease-
activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent 
relaxation to thrombin and trypsin in human pulmonary arteries. J Cardiovasc 
Pharmacol 38, 108-19. 
69. Muramatsu, I., Laniyonu, A., Moore, G. J., and Hollenberg, M. D. (1992). Vascular 
actions of thrombin receptor peptide. Can J Physiol Pharmacol 70, 996-1003. 
70. Tesfamariam, B. (1994). Distinct receptors and signaling pathways in alpha-
thrombin- and thrombin receptor peptide-induced vascular contractions. Circ Res 74, 
930-6. 
71. Tesfamariam, B. (1994). Thrombin receptor-mediated vascular relaxation 
differentiated by a receptor antagonist and desensitization. Am J Physiol 267, H1962-
7. 
72. Ku, D. D., and Zaleski, J. K. (1993). Receptor mechanism of thrombin-induced 
endothelium-dependent and endothelium-independent coronary vascular effects in 
dogs. J Cardiovasc Pharmacol 22, 609-16. 
73. Ku, D. D., and Dai, J. (1997). Expression of thrombin receptors in human 
atherosclerotic coronary arteries leads to an exaggerated vasoconstrictory response in 
vitro. J Cardiovasc Pharmacol 30, 649-57. 
74. Tay-Uyboco, J., Poon, M. C., Ahmad, S., and Hollenberg, M. D. (1995). Contractile 
actions of thrombin receptor-derived polypeptides in human umbilical and placental 
vasculature: evidence for distinct receptor systems. Br J Pharmacol 115, 569-78. 
75. Hattori, R., Hamilton, K. K., Fugate, R. D., McEver, R. P., and Sims, P. J. (1989). 
Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid 
redistribution to the cell surface of the intracellular granule membrane protein GMP-
140. J Biol Chem 264, 7768-71. 
151
 76. Daniel, T. O., Gibbs, V. C., Milfay, D. F., Garovoy, M. R., and Williams, L. T. 
(1986). Thrombin stimulates c-sis gene expression in microvascular endothelial cells. 
J Biol Chem 261, 9579-82. 
77. Colotta, F., Sciacca, F. L., Sironi, M., Luini, W., Rabiet, M. J., and Mantovani, A. 
(1994). Expression of monocyte chemotactic protein-1 by monocytes and endothelial 
cells exposed to thrombin. Am J Pathol 144, 975-85. 
78. Lum, H., and Malik, A. B. (1994). Regulation of vascular endothelial barrier function. 
Am J Physiol 267, L223-41. 
79. Feistritzer, C., and Riewald, M. (2005). Endothelial barrier protection by activated 
protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 
crossactivation. Blood 105, 3178-84. 
80. Ludeman, M. J., Kataoka, H., Srinivasan, Y., Esmon, N. L., Esmon, C. T., and 
Coughlin, S. R. (2005). PAR1 cleavage and signaling in response to activated protein 
C and thrombin. J Biol Chem 280, 13122-8. 
81. Derian, C. K., Damiano, B. P., Addo, M. F., Darrow, A. L., D'Andrea, M. R., 
Nedelman, M., Zhang, H. C., Maryanoff, B. E., and Andrade-Gordon, P. (2003). 
Blockade of the thrombin receptor protease-activated receptor-1 with a small-
molecule antagonist prevents thrombus formation and vascular occlusion in 
nonhuman primates. J Pharmacol Exp Ther 304, 855-61. 
82. Weiss, E. J., Hamilton, J. R., Lease, K. E., and Coughlin, S. R. (2002). Protection 
against thrombosis in mice lacking PAR3. Blood 100, 3240-4. 
83. Vandendries, E. R., Hamilton, J. R., Coughlin, S. R., Furie, B., and Furie, B. C. 
(2007). Par4 is required for platelet thrombus propagation but not fibrin generation in 
a mouse model of thrombosis. Proc Natl Acad Sci U S A 104, 288-92. 
84. Tellez, C., and Bar-Eli, M. (2003). Role and regulation of the thrombin receptor 
(PAR-1) in human melanoma. Oncogene 22, 3130-7. 
85. Darmoul, D., Gratio, V., Devaud, H., Lehy, T., and Laburthe, M. (2003). Aberrant 
expression and activation of the thrombin receptor protease-activated receptor-1 
induces cell proliferation and motility in human colon cancer cells. Am J Pathol 162, 
1503-13. 
152
 86. Chay, C. H., Cooper, C. R., Gendernalik, J. D., Dhanasekaran, S. M., Chinnaiyan, A. 
M., Rubin, M. A., Schmaier, A. H., and Pienta, K. J. (2002). A functional thrombin 
receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60, 
760-5. 
87. Even-Ram, S., Uziely, B., Cohen, P., Grisaru-Granovsky, S., Maoz, M., Ginzburg, 
Y., Reich, R., Vlodavsky, I., and Bar-Shavit, R. (1998). Thrombin receptor 
overexpression in malignant and physiological invasion processes. Nat Med 4, 909-
14. 
88. D'Andrea, M. R., Derian, C. K., Santulli, R. J., and Andrade-Gordon, P. (2001). 
Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts 
of normal, benign, and malignant human tissues. Am J Pathol 158, 2031-41. 
89. Bissell, M. J., and Radisky, D. (2001). Putting tumours in context. Nat Rev Cancer 1, 
46-54. 
90. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., and Kuliopulos, A. (2005). 
PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and 
tumorigenesis of breast cancer cells. Cell 120, 303-13. 
91. Trejo, J., Hammes, S. R., and Coughlin, S. R. (1998). Termination of signaling by 
protease-activated receptor-1 is linked to lysosomal sorting. Proc Natl Acad Sci U S 
A 95, 13698-702. 
92. Booden, M. A., Eckert, L. B., Der, C. J., and Trejo, J. (2004). Persistent signaling by 
dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. 
Mol Cell Biol 24, 1990-9. 
93. Guo, H., Liu, D., Gelbard, H., Cheng, T., Insalaco, R., Fernandez, J. A., Griffin, J. H., 
and Zlokovic, B. V. (2004). Activated protein C prevents neuronal apoptosis via 
protease activated receptors 1 and 3. Neuron 41, 563-72. 
94. Zania, P., Kritikou, S., Flordellis, C. S., Maragoudakis, M. E., and Tsopanoglou, N. 
E. (2006). Blockade of angiogenesis by small molecule antagonists to protease-
activated receptor-1: association with endothelial cell growth suppression and 
induction of apoptosis. J Pharmacol Exp Ther 318, 246-54. 
153
 95. Morris, D. R., Ding, Y., Ricks, T. K., Gullapalli, A., Wolfe, B. L., and Trejo, J. 
(2006). Protease-activated receptor-2 is essential for factor VIIa and Xa-induced 
signaling, migration, and invasion of breast cancer cells. Cancer Res 66, 307-14. 
96. Yin, Y. J., Salah, Z., Maoz, M., Ram, S. C., Ochayon, S., Neufeld, G., Katzav, S., and 
Bar-Shavit, R. (2003). Oncogenic transformation induces tumor angiogenesis: a role 
for PAR1 activation. Faseb J 17, 163-74. 
97. McCudden, C. R., Hains, M. D., Kimple, R. J., Siderovski, D. P., and Willard, F. S. 
(2005). G-protein signaling: back to the future. Cell Mol Life Sci 62, 551-77. 
98. Babich, M., King, K. L., and Nissenson, R. A. (1990). Thrombin stimulates inositol 
phosphate production and intracellular free calcium by a pertussis toxin-insensitive 
mechanism in osteosarcoma cells. Endocrinology 126, 948-54. 
99. Kelley, G. G., Kaproth-Joslin, K. A., Reks, S. E., Smrcka, A. V., and Wojcikiewicz, 
R. J. (2006). G-protein-coupled receptor agonists activate endogenous phospholipase 
Cepsilon and phospholipase Cbeta3 in a temporally distinct manner. J Biol Chem 
281, 2639-48. 
100. Trejo, J., Connolly, A. J., and Coughlin, S. R. (1996). The cloned thrombin receptor 
is necessary and sufficient for activation of mitogen-activated protein kinase and 
mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor 
knockout mice. J Biol Chem 271, 21536-41. 
101. Offermanns, S., Toombs, C. F., Hu, Y. H., and Simon, M. I. (1997). Defective 
platelet activation in G alpha(q)-deficient mice. Nature 389, 183-6. 
102. Wang, H., and Reiser, G. (2003). The role of the Ca2+-sensitive tyrosine kinase Pyk2 
and Src in thrombin signalling in rat astrocytes. J Neurochem 84, 1349-57. 
103. Offermanns, S., Laugwitz, K. L., Spicher, K., and Schultz, G. (1994). G proteins of 
the G12 family are activated via thromboxane A2 and thrombin receptors in human 
platelets. Proc Natl Acad Sci U S A 91, 504-8. 
104. Aragay, A. M., Collins, L. R., Post, G. R., Watson, A. J., Feramisco, J. R., Brown, J. 
H., and Simon, M. I. (1995). G12 requirement for thrombin-stimulated gene 
expression and DNA synthesis in 1321N1 astrocytoma cells. J Biol Chem 270, 
20073-7. 
154
 105. Hains, M. D., Wing, M. R., Maddileti, S., Siderovski, D. P., and Harden, T. K. 
(2006). Galpha12/13- and rho-dependent activation of phospholipase C-epsilon by 
lysophosphatidic acid and thrombin receptors. Mol Pharmacol 69, 2068-75. 
106. Klages, B., Brandt, U., Simon, M. I., Schultz, G., and Offermanns, S. (1999). 
Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin 
light chain phosphorylation in mouse platelets. J Cell Biol 144, 745-54. 
107. Offermanns, S., Mancino, V., Revel, J. P., and Simon, M. I. (1997). Vascular system 
defects and impaired cell chemokinesis as a result of Galpha13 deficiency. Science 
275, 533-6. 
108. Vouret-Craviari, V., Boquet, P., Pouyssegur, J., and Van Obberghen-Schilling, E. 
(1998). Regulation of the actin cytoskeleton by thrombin in human endothelial cells: 
role of Rho proteins in endothelial barrier function. Mol Biol Cell 9, 2639-53. 
109. Ishii, K., Hein, L., Kobilka, B., and Coughlin, S. R. (1993). Kinetics of thrombin 
receptor cleavage on intact cells. Relation to signaling. J Biol Chem 268, 9780-6. 
110. Krupnick, J. G., and Benovic, J. L. (1998). The role of receptor kinases and arrestins 
in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38, 289-319. 
111. Ishii, K., Chen, J., Ishii, M., Koch, W. J., Freedman, N. J., Lefkowitz, R. J., and 
Coughlin, S. R. (1994). Inhibition of thrombin receptor signaling by a G-protein 
coupled receptor kinase. Functional specificity among G-protein coupled receptor 
kinases. J Biol Chem 269, 1125-30. 
112. Tiruppathi, C., Yan, W., Sandoval, R., Naqvi, T., Pronin, A. N., Benovic, J. L., and 
Malik, A. B. (2000). G protein-coupled receptor kinase-5 regulates thrombin-
activated signaling in endothelial cells. Proc Natl Acad Sci U S A 97, 7440-5. 
113. Nanevicz, T., Wang, L., Chen, M., Ishii, M., and Coughlin, S. R. (1996). Thrombin 
receptor activating mutations. Alteration of an extracellular agonist recognition 
domain causes constitutive signaling. J Biol Chem 271, 702-6. 
114. Kohout, T. A., and Lefkowitz, R. J. (2003). Regulation of G protein-coupled receptor 
kinases and arrestins during receptor desensitization. Mol Pharmacol 63, 9-18. 
155
 115. Paing, M. M., Stutts, A. B., Kohout, T. A., Lefkowitz, R. J., and Trejo, J. (2002). beta 
-Arrestins regulate protease-activated receptor-1 desensitization but not 
internalization or Down-regulation. J Biol Chem 277, 1292-300. 
116. Chen, C. H., Paing, M. M., and Trejo, J. (2004). Termination of protease-activated 
receptor-1 signaling by beta-arrestins is independent of receptor phosphorylation. J 
Biol Chem 279, 10020-31. 
117. Hinrichsen, L., Meyerholz, A., Groos, S., and Ungewickell, E. J. (2006). Bending a 
membrane: how clathrin affects budding. Proc Natl Acad Sci U S A 103, 8715-20. 
118. Robinson, M. S. (2004). Adaptable adaptors for coated vesicles. Trends Cell Biol 14, 
167-74. 
119. Edeling, M. A., Mishra, S. K., Keyel, P. A., Steinhauser, A. L., Collins, B. M., Roth, 
R., Heuser, J. E., Owen, D. J., and Traub, L. M. (2006). Molecular switches involving 
the AP-2 beta2 appendage regulate endocytic cargo selection and clathrin coat 
assembly. Dev Cell 10, 329-42. 
120. Palade, G. E. (1953). Fine structure of blood capillaries. J Appl Physiol 24, 1424. 
121. Yamada, E. (1955). The fine structure of the gall bladder epithelium of the mouse. J 
Biophys Biochem Cytol 1, 445-58. 
122. Pelkmans, L., and Helenius, A. (2002). Endocytosis via caveolae. Traffic 3, 311-20. 
123. Parton, R. G., and Richards, A. A. (2003). Lipid rafts and caveolae as portals for 
endocytosis: new insights and common mechanisms. Traffic 4, 724-38. 
124. Murata, M., Peranen, J., Schreiner, R., Wieland, F., Kurzchalia, T. V., and Simons, K. 
(1995). VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A 
92, 10339-43. 
125. Trigatti, B. L., Anderson, R. G., and Gerber, G. E. (1999). Identification of caveolin-1 
as a fatty acid binding protein. Biochem Biophys Res Commun 255, 34-9. 
156
 126. Barnett-Norris, J., Lynch, D., and Reggio, P. H. (2005). Lipids, lipid rafts and 
caveolae: their importance for GPCR signaling and their centrality to the 
endocannabinoid system. Life Sci 77, 1625-39. 
127. Xiang, Y., Rybin, V. O., Steinberg, S. F., and Kobilka, B. (2002). Caveolar 
localization dictates physiologic signaling of beta 2-adrenoceptors in neonatal cardiac 
myocytes. J Biol Chem 277, 34280-6. 
128. Pelkmans, L., and Helenius, A. (2003). Insider information: what viruses tell us about 
endocytosis. Curr Opin Cell Biol 15, 414-22. 
129. Kolb-Maurer, A., Wilhelm, M., Weissinger, F., Brocker, E. B., and Goebel, W. 
(2002). Interaction of human hematopoietic stem cells with bacterial pathogens. 
Blood 100, 3703-9. 
130. Fiorentini, C., Falzano, L., Fabbri, A., Stringaro, A., Logozzi, M., Travaglione, S., 
Contamin, S., Arancia, G., Malorni, W., and Fais, S. (2001). Activation of rho 
GTPases by cytotoxic necrotizing factor 1 induces macropinocytosis and scavenging 
activity in epithelial cells. Mol Biol Cell 12, 2061-73. 
131. Reece, J. C., Vardaxis, N. J., Marshall, J. A., Crowe, S. M., and Cameron, P. U. 
(2001). Uptake of HIV and latex particles by fresh and cultured dendritic cells and 
monocytes. Immunol Cell Biol 79, 255-63. 
132. Nichols, B. (2003). Caveosomes and endocytosis of lipid rafts. J Cell Sci 116, 4707-
14. 
133. Rupper, A., Lee, K., Knecht, D., and Cardelli, J. (2001). Sequential activities of 
phosphoinositide 3-kinase, PKB/Aakt, and Rab7 during macropinosome formation in 
Dictyostelium. Mol Biol Cell 12, 2813-24. 
134. Swanson, J. A., Johnson, M. T., Beningo, K., Post, P., Mooseker, M., and Araki, N. 
(1999). A contractile activity that closes phagosomes in macrophages. J Cell Sci 112 ( 
Pt 3), 307-16. 
135. Radhakrishna, H., and Donaldson, J. G. (1997). ADP-ribosylation factor 6 regulates a 
novel plasma membrane recycling pathway. J Cell Biol 139, 49-61. 
157
 136. Chuang, D. M., and Costa, E. (1979). Evidence for internalization of the recognition 
site of beta-adrenergic receptors during receptor subsensitivity induced by (-)-
isoproterenol. Proc Natl Acad Sci U S A 76, 3024-8. 
137. Harden, T. K., Cotton, C. U., Waldo, G. L., Lutton, J. K., and Perkins, J. P. (1980). 
Catecholamine-induced alteration in sedimentation behavior of membrane bound 
beta-adrenergic receptors. Science 210, 441-3. 
138. Parent, J. L., Labrecque, P., Driss Rochdi, M., and Benovic, J. L. (2001). Role of the 
differentially spliced carboxyl terminus in thromboxane A2 receptor trafficking: 
identification of a distinct motif for tonic internalization. J Biol Chem 276, 7079-85. 
139. Bhatnagar, A., Willins, D. L., Gray, J. A., Woods, J., Benovic, J. L., and Roth, B. L. 
(2001). The dynamin-dependent, arrestin-independent internalization of 5-
hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of 
arrestins and 5-HT2A receptors during endocytosis. J Biol Chem 276, 8269-77. 
140. Orsini, M. J., Parent, J. L., Mundell, S. J., Marchese, A., and Benovic, J. L. (2000). 
Trafficking of the HIV coreceptor CXCR4: role of arrestins and identification of 
residues in the C-terminal tail that mediate receptor internalization. J Biol Chem 275, 
25876. 
141. Signoret, N., Rosenkilde, M. M., Klasse, P. J., Schwartz, T. W., Malim, M. H., Hoxie, 
J. A., and Marsh, M. (1998). Differential regulation of CXCR4 and CCR5 
endocytosis. J Cell Sci 111 ( Pt 18), 2819-30. 
142. Marchese, A., Chen, C., Kim, Y. M., and Benovic, J. L. (2003). The ins and outs of G 
protein-coupled receptor trafficking. Trends Biochem Sci 28, 369-76. 
143. Warren, R. A., Green, F. A., Stenberg, P. E., and Enns, C. A. (1998). Distinct 
saturable pathways for the endocytosis of different tyrosine motifs. J Biol Chem 273, 
17056-63. 
144. Santini, F., Marks, M. S., and Keen, J. H. (1998). Endocytic clathrin-coated pit 
formation is independent of receptor internalization signal levels. Mol Biol Cell 9, 
1177-94. 
145. Keyel, P. A., Mishra, S. K., Roth, R., Heuser, J. E., Watkins, S. C., and Traub, L. M. 
(2006). A single common portal for clathrin-mediated endocytosis of distinct cargo 
governed by cargo-selective adaptors. Mol Biol Cell 17, 4300-17. 
158
 146. Perrais, D., and Merrifield, C. J. (2005). Dynamics of endocytic vesicle creation. Dev 
Cell 9, 581-92. 
147. Puthenveedu, M. A., and von Zastrow, M. (2006). Cargo regulates clathrin-coated pit 
dynamics. Cell 127, 113-24. 
148. Mundell, S. J., Luo, J., Benovic, J. L., Conley, P. B., and Poole, A. W. (2006). 
Distinct clathrin-coated pits sort different G protein-coupled receptor cargo. Traffic 7, 
1420-31. 
149. Gaidarov, I., Santini, F., Warren, R. A., and Keen, J. H. (1999). Spatial control of 
coated-pit dynamics in living cells. Nat Cell Biol 1, 1-7. 
150. Hirsch, J. A., Schubert, C., Gurevich, V. V., and Sigler, P. B. (1999). The 2.8 A 
crystal structure of visual arrestin: a model for arrestin's regulation. Cell 97, 257-69. 
151. Gurevich, V. V., and Gurevich, E. V. (2006). The structural basis of arrestin-mediated 
regulation of G-protein-coupled receptors. Pharmacol Ther 110, 465-502. 
152. Satoh, A. K., and Ready, D. F. (2005). Arrestin1 mediates light-dependent rhodopsin 
endocytosis and cell survival. Curr Biol 15, 1722-33. 
153. Orem, N. R., Xia, L., and Dolph, P. J. (2006). An essential role for endocytosis of 
rhodopsin through interaction of visual arrestin with the AP-2 adaptor. J Cell Sci 119, 
3141-8. 
154. Moore, C. A., Milano, S. K., and Benovic, J. L. (2006). Regulation of Receptor 
Trafficking by GRKs and Arrestins. Annu Rev Physiol. 
155. Shenoy, S. K., McDonald, P. H., Kohout, T. A., and Lefkowitz, R. J. (2001). 
Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor 
and beta-arrestin. Science 294, 1307-13. 
156. Gavard, J., and Gutkind, J. S. (2006). VEGF controls endothelial-cell permeability by 
promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8, 
1223-34. 
159
 157. Pals-Rylaarsdam, R., Gurevich, V. V., Lee, K. B., Ptasienski, J. A., Benovic, J. L., 
and Hosey, M. M. (1997). Internalization of the m2 muscarinic acetylcholine 
receptor. Arrestin-independent and -dependent pathways. J Biol Chem 272, 23682-9. 
158. Lee, K. B., Pals-Rylaarsdam, R., Benovic, J. L., and Hosey, M. M. (1998). Arrestin-
independent internalization of the m1, m3, and m4 subtypes of muscarinic cholinergic 
receptors. J Biol Chem 273, 12967-72. 
159. Smyth, E. M., Austin, S. C., Reilly, M. P., and FitzGerald, G. A. (2000). 
Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 
275, 32037-45. 
160. Kohout, T. A., Lin, F. S., Perry, S. J., Conner, D. A., and Lefkowitz, R. J. (2001). 
beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and 
trafficking. Proc Natl Acad Sci U S A 98, 1601-6. 
161. Vines, C. M., Revankar, C. M., Maestas, D. C., LaRusch, L. L., Cimino, D. F., 
Kohout, T. A., Lefkowitz, R. J., and Prossnitz, E. R. (2003). N-formyl peptide 
receptors internalize but do not recycle in the absence of arrestins. J Biol Chem 278, 
41581-4. 
162. Fraile-Ramos, A., Kohout, T. A., Waldhoer, M., and Marsh, M. (2003). Endocytosis 
of the viral chemokine receptor US28 does not require beta-arrestins but is dependent 
on the clathrin-mediated pathway. Traffic 4, 243-53. 
163. Giebing, G., Tolle, M., Jurgensen, J., Eichhorst, J., Furkert, J., Beyermann, M., 
Neuschafer-Rube, F., Rosenthal, W., Zidek, W., van der Giet, M., and Oksche, A. 
(2005). Arrestin-independent internalization and recycling of the urotensin receptor 
contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res 97, 707-
15. 
164. Bonifacino, J. S., and Traub, L. M. (2003). Signals for sorting of transmembrane 
proteins to endosomes and lysosomes. Annu Rev Biochem 72, 395-447. 
165. Ricotta, D., Conner, S. D., Schmid, S. L., von Figura, K., and Honing, S. (2002). 
Phosphorylation of the AP2 mu subunit by AAK1 mediates high affinity binding to 
membrane protein sorting signals. J Cell Biol 156, 791-5. 
160
 166. Paing, M. M., Johnston, C. A., Siderovski, D. P., and Trejo, J. (2006). Clathrin 
adaptor AP2 regulates thrombin receptor constitutive internalization and endothelial 
cell resensitization. Mol Cell Biol 26, 3231-42. 
167. Royle, S. J., Qureshi, O. S., Bobanovic, L. K., Evans, P. R., Owen, D. J., and Murrell-
Lagnado, R. D. (2005). Non-canonical YXXGPhi endocytic motifs: recognition by 
AP2 and preferential utilization in P2X4 receptors. J Cell Sci 118, 3073-80. 
168. Fan, G. H., Yang, W., Wang, X. J., Qian, Q., and Richmond, A. (2001). Identification 
of a motif in the carboxyl terminus of CXCR2 that is involved in adaptin 2 binding 
and receptor internalization. Biochemistry 40, 791-800. 
169. Gabilondo, A. M., Krasel, C., and Lohse, M. J. (1996). Mutations of Tyr326 in the 
beta 2-adrenoceptor disrupt multiple receptor functions. Eur J Pharmacol 307, 243-
50. 
170. Guinamard, R., Signoret, N., Ishiai, M., Marsh, M., Kurosaki, T., and Ravetch, J. V. 
(1999). B cell antigen receptor engagement inhibits stromal cell-derived factor 
(SDF)-1alpha chemotaxis and promotes protein kinase C (PKC)-induced 
internalization of CXCR4. J Exp Med 189, 1461-6. 
171. Diviani, D., Lattion, A. L., Abuin, L., Staub, O., and Cotecchia, S. (2003). The 
adaptor complex 2 directly interacts with the alpha 1b-adrenergic receptor and plays a 
role in receptor endocytosis. J Biol Chem 278, 19331-40. 
172. Tebar, F., Bohlander, S. K., and Sorkin, A. (1999). Clathrin assembly lymphoid 
myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions 
with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol 
Cell 10, 2687-702. 
173. Ford, M. G., Mills, I. G., Peter, B. J., Vallis, Y., Praefcke, G. J., Evans, P. R., and 
McMahon, H. T. (2002). Curvature of clathrin-coated pits driven by epsin. Nature 
419, 361-6. 
174. Huang, F., Khvorova, A., Marshall, W., and Sorkin, A. (2004). Analysis of clathrin-
mediated endocytosis of epidermal growth factor receptor by RNA interference. J 
Biol Chem 279, 16657-61. 
175. Dho, S. E., Trejo, J., Siderovski, D. P., and McGlade, C. J. (2006). Dynamic 
regulation of mammalian numb by G protein-coupled receptors and protein kinase C 
161
 activation: Structural determinants of numb association with the cortical membrane. 
Mol Biol Cell 17, 4142-55. 
176. Kaksonen, M., Toret, C. P., and Drubin, D. G. (2006). Harnessing actin dynamics for 
clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 7, 404-14. 
177. Chen, Y., Thelin, W. R., Yang, B., Milgram, S. L., and Jacobson, K. (2006). 
Transient anchorage of cross-linked glycosyl-phosphatidylinositol-anchored proteins 
depends on cholesterol, Src family kinases, caveolin, and phosphoinositides. J Cell 
Biol 175, 169-78. 
178. Hicke, L. (2001). Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2, 195-
201. 
179. Haglund, K., Di Fiore, P. P., and Dikic, I. (2003). Distinct monoubiquitin signals in 
receptor endocytosis. Trends Biochem Sci 28, 598-603. 
180. Weissman, A. M. (2001). Themes and variations on ubiquitylation. Nat Rev Mol Cell 
Biol 2, 169-78. 
181. Varadan, R., Assfalg, M., Haririnia, A., Raasi, S., Pickart, C., and Fushman, D. 
(2004). Solution conformation of Lys63-linked di-ubiquitin chain provides clues to 
functional diversity of polyubiquitin signaling. J Biol Chem 279, 7055-63. 
182. Kerscher, O., Felberbaum, R., and Hochstrasser, M. (2006). Modification of proteins 
by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22, 159-80. 
183. Wilkinson, K. D. (2000). Ubiquitination and deubiquitination: targeting of proteins 
for degradation by the proteasome. Semin Cell Dev Biol 11, 141-8. 
184. Puente, X. a. L.-O., C. (2004). A genomic analysis of rat proteases and protease 
inhibitors. Genome Res 14, 609-622. 
185. Nijman, S. M., Luna-Vargas, M. P., Velds, A., Brummelkamp, T. R., Dirac, A. M., 
Sixma, T. K., and Bernards, R. (2005). A genomic and functional inventory of 
deubiquitinating enzymes. Cell 123, 773-86. 
162
 186. Amerik, A. Y., and Hochstrasser, M. (2004). Mechanism and function of 
deubiquitinating enzymes. Biochim Biophys Acta 1695, 189-207. 
187. Hicke, L., and Riezman, H. (1996). Ubiquitination of a yeast plasma membrane 
receptor signals its ligand-stimulated endocytosis. Cell 84, 277-87. 
188. Shih, S. C., Sloper-Mould, K. E., and Hicke, L. (2000). Monoubiquitin carries a novel 
internalization signal that is appended to activated receptors. Embo J 19, 187-98. 
189. Dunn, R., and Hicke, L. (2001). Domains of the Rsp5 ubiquitin-protein ligase 
required for receptor-mediated and fluid-phase endocytosis. Mol Biol Cell 12, 421-
35. 
190. Hicke, L., Zanolari, B., and Riezman, H. (1998). Cytoplasmic tail phosphorylation of 
the alpha-factor receptor is required for its ubiquitination and internalization. J Cell 
Biol 141, 349-58. 
191. Terrell, J., Shih, S., Dunn, R., and Hicke, L. (1998). A function for 
monoubiquitination in the internalization of a G protein-coupled receptor. Mol Cell 1, 
193-202. 
192. Shih, S. C., Katzmann, D. J., Schnell, J. D., Sutanto, M., Emr, S. D., and Hicke, L. 
(2002). Epsins and Vps27p/Hrs contain ubiquitin-binding domains that function in 
receptor endocytosis. Nat Cell Biol 4, 389-93. 
193. Roth, A. F., and Davis, N. G. (1996). Ubiquitination of the yeast a-factor receptor. J 
Cell Biol 134, 661-74. 
194. Chen, H., Fre, S., Slepnev, V. I., Capua, M. R., Takei, K., Butler, M. H., Di Fiore, P. 
P., and De Camilli, P. (1998). Epsin is an EH-domain-binding protein implicated in 
clathrin-mediated endocytosis. Nature 394, 793-7. 
195. Wendland, B. (2002). Epsins: adaptors in endocytosis? Nat Rev Mol Cell Biol 3, 971-
7. 
196. Stahelin, R. V., Long, F., Peter, B. J., Murray, D., De Camilli, P., McMahon, H. T., 
and Cho, W. (2003). Contrasting membrane interaction mechanisms of AP180 N-
terminal homology (ANTH) and epsin N-terminal homology (ENTH) domains. J Biol 
Chem 278, 28993-9. 
163
 197. Itoh, T., Koshiba, S., Kigawa, T., Kikuchi, A., Yokoyama, S., and Takenawa, T. 
(2001). Role of the ENTH domain in phosphatidylinositol-4,5-bisphosphate binding 
and endocytosis. Science 291, 1047-51. 
198. Rosse, C., L'Hoste, S., Offner, N., Picard, A., and Camonis, J. (2003). RLIP, an 
effector of the Ral GTPases, is a platform for Cdk1 to phosphorylate epsin during the 
switch off of endocytosis in mitosis. J Biol Chem 278, 30597-604. 
199. Aguilar, R. C., Longhi, S. A., Shaw, J. D., Yeh, L. Y., Kim, S., Schon, A., Freire, E., 
Hsu, A., McCormick, W. K., Watson, H. A., and Wendland, B. (2006). Epsin N-
terminal homology domains perform an essential function regulating Cdc42 through 
binding Cdc42 GTPase-activating proteins. Proc Natl Acad Sci U S A 103, 4116-21. 
200. Hawryluk, M. J., Keyel, P. A., Mishra, S. K., Watkins, S. C., Heuser, J. E., and 
Traub, L. M. (2006). Epsin 1 is a polyubiquitin-selective clathrin-associated sorting 
protein. Traffic 7, 262-81. 
201. Polo, S., Sigismund, S., Faretta, M., Guidi, M., Capua, M. R., Bossi, G., Chen, H., De 
Camilli, P., and Di Fiore, P. P. (2002). A single motif responsible for ubiquitin 
recognition and monoubiquitination in endocytic proteins. Nature 416, 451-5. 
202. Oldham, C. E., Mohney, R. P., Miller, S. L., Hanes, R. N., and O'Bryan, J. P. (2002). 
The ubiquitin-interacting motifs target the endocytic adaptor protein epsin for 
ubiquitination. Curr Biol 12, 1112-6. 
203. Hoeller, D., Crosetto, N., Blagoev, B., Raiborg, C., Tikkanen, R., Wagner, S., 
Kowanetz, K., Breitling, R., Mann, M., Stenmark, H., and Dikic, I. (2006). 
Regulation of ubiquitin-binding proteins by monoubiquitination. Nat Cell Biol 8, 163-
9. 
204. Chen, H., Polo, S., Di Fiore, P. P., and De Camilli, P. V. (2003). Rapid Ca2+-
dependent decrease of protein ubiquitination at synapses. Proc Natl Acad Sci U S A 
100, 14908-13. 
205. Sigismund, S., Woelk, T., Puri, C., Maspero, E., Tacchetti, C., Transidico, P., Di 
Fiore, P. P., and Polo, S. (2005). Clathrin-independent endocytosis of ubiquitinated 
cargos. Proc Natl Acad Sci U S A 102, 2760-5. 
206. Wang, H., Traub, L. M., Weixel, K. M., Hawryluk, M. J., Shah, N., Edinger, R. S., 
Perry, C. J., Kester, L., Butterworth, M. B., Peters, K. W., Kleyman, T. R., Frizzell, 
164
 R. A., and Johnson, J. P. (2006). Clathrin-mediated endocytosis of the epithelial 
sodium channel. Role of epsin. J Biol Chem 281, 14129-35. 
207. Chitnis, A. (2006). Why is delta endocytosis required for effective activation of 
notch? Dev Dyn 235, 886-94. 
208. Le Borgne, R., Bardin, A., and Schweisguth, F. (2005). The roles of receptor and 
ligand endocytosis in regulating Notch signaling. Development 132, 1751-62. 
209. Overstreet, E., Chen, X., Wendland, B., and Fischer, J. A. (2003). Either part of a 
Drosophila epsin protein, divided after the ENTH domain, functions in endocytosis of 
delta in the developing eye. Curr Biol 13, 854-60. 
210. Chen, X., Overstreet, E., Wood, S. A., and Fischer, J. A. (2000). On the conservation 
of function of the Drosophila fat facets deubiquitinating enzyme and Fam, its mouse 
homolog. Dev Genes Evol 210, 603-10. 
211. Overstreet, E., Fitch, E., and Fischer, J. A. (2004). Fat facets and Liquid facets 
promote Delta endocytosis and Delta signaling in the signaling cells. Development 
131, 5355-66. 
212. Tian, X., Hansen, D., Schedl, T., and Skeath, J. B. (2004). Epsin potentiates Notch 
pathway activity in Drosophila and C. elegans. Development 131, 5807-15. 
213. Kalthoff, C., Alves, J., Urbanke, C., Knorr, R., and Ungewickell, E. J. (2002). 
Unusual structural organization of the endocytic proteins AP180 and epsin 1. J Biol 
Chem 277, 8209-16. 
214. Chen, H., and De Camilli, P. (2005). The association of epsin with ubiquitinated 
cargo along the endocytic pathway is negatively regulated by its interaction with 
clathrin. Proc Natl Acad Sci U S A 102, 2766-71. 
215. Fazioli, F., Minichiello, L., Matoskova, B., Wong, W. T., and Di Fiore, P. P. (1993). 
eps15, a novel tyrosine kinase substrate, exhibits transforming activity. Mol Cell Biol 
13, 5814-28. 
216. Wong, W. T., Schumacher, C., Salcini, A. E., Romano, A., Castagnino, P., Pelicci, P. 
G., and Di Fiore, P. P. (1995). A protein-binding domain, EH, identified in the 
165
 receptor tyrosine kinase substrate Eps15 and conserved in evolution. Proc Natl Acad 
Sci U S A 92, 9530-4. 
217. Confalonieri, S., and Di Fiore, P. P. (2002). The Eps15 homology (EH) domain. 
FEBS Lett 513, 24-9. 
218. de Beer, T., Carter, R. E., Lobel-Rice, K. E., Sorkin, A., and Overduin, M. (1998). 
Structure and Asn-Pro-Phe binding pocket of the Eps15 homology domain. Science 
281, 1357-60. 
219. Di Fiore, P. P., Pelicci, P. G., and Sorkin, A. (1997). EH: a novel protein-protein 
interaction domain potentially involved in intracellular sorting. Trends Biochem Sci 
22, 411-3. 
220. Benmerah, A., Gagnon, J., Begue, B., Megarbane, B., Dautry-Varsat, A., and Cerf-
Bensussan, N. (1995). The tyrosine kinase substrate eps15 is constitutively associated 
with the plasma membrane adaptor AP-2. J Cell Biol 131, 1831-8. 
221. Schumacher, C., Knudsen, B. S., Ohuchi, T., Di Fiore, P. P., Glassman, R. H., and 
Hanafusa, H. (1995). The SH3 domain of Crk binds specifically to a conserved 
proline-rich motif in Eps15 and Eps15R. J Biol Chem 270, 15341-7. 
222. Tebar, F., Sorkina, T., Sorkin, A., Ericsson, M., and Kirchhausen, T. (1996). Eps15 is 
a component of clathrin-coated pits and vesicles and is located at the rim of coated 
pits. J Biol Chem 271, 28727-30. 
223. Torrisi, M. R., Lotti, L. V., Belleudi, F., Gradini, R., Salcini, A. E., Confalonieri, S., 
Pelicci, P. G., and Di Fiore, P. P. (1999). Eps15 is recruited to the plasma membrane 
upon epidermal growth factor receptor activation and localizes to components of the 
endocytic pathway during receptor internalization. Mol Biol Cell 10, 417-34. 
224. Coda, L., Salcini, A. E., Confalonieri, S., Pelicci, G., Sorkina, T., Sorkin, A., Pelicci, 
P. G., and Di Fiore, P. P. (1998). Eps15R is a tyrosine kinase substrate with 
characteristics of a docking protein possibly involved in coated pits-mediated 
internalization. J Biol Chem 273, 3003-12. 
225. Benmerah, A., Bayrou, M., Cerf-Bensussan, N., and Dautry-Varsat, A. (1999). 
Inhibition of clathrin-coated pit assembly by an Eps15 mutant. J Cell Sci 112 ( Pt 9), 
1303-11. 
166
 226. Benmerah, A., Poupon, V., Cerf-Bensussan, N., and Dautry-Varsat, A. (2000). 
Mapping of Eps15 domains involved in its targeting to clathrin-coated pits. J Biol 
Chem 275, 3288-95. 
227. Hein, L., Ishii, K., Coughlin, S. R., and Kobilka, B. K. (1994). Intracellular targeting 
and trafficking of thrombin receptors. A novel mechanism for resensitization of a G 
protein-coupled receptor. J Biol Chem 269, 27719-26. 
228. Horvat, R., and Palade, G. E. (1995). The functional thrombin receptor is associated 
with the plasmalemma and a large endosomal network in cultured human umbilical 
vein endothelial cells. J Cell Sci 108 ( Pt 3), 1155-64. 
229. Trejo, J., Altschuler, Y., Fu, H. W., Mostov, K. E., and Coughlin, S. R. (2000). 
Protease-activated receptor-1 down-regulation: a mutant HeLa cell line suggests 
novel requirements for PAR1 phosphorylation and recruitment to clathrin-coated pits. 
J Biol Chem 275, 31255-65. 
230. Shapiro, M. J., Trejo, J., Zeng, D., and Coughlin, S. R. (1996). Role of the thrombin 
receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for 
agonist-triggered versus tonic internalization and intracellular localization. J Biol 
Chem 271, 32874-80. 
231. Trejo, J., and Coughlin, S. R. (1999). The cytoplasmic tails of protease-activated 
receptor-1 and substance P receptor specify sorting to lysosomes versus recycling. J 
Biol Chem 274, 2216-24. 
232. Raiborg, C., Rusten, T. E., and Stenmark, H. (2003). Protein sorting into 
multivesicular endosomes. Curr Opin Cell Biol 15, 446-55. 
233. Slagsvold, T., Pattni, K., Malerod, L., and Stenmark, H. (2006). Endosomal and non-
endosomal functions of ESCRT proteins. Trends Cell Biol 16, 317-26. 
234. Babst, M. (2005). A protein's final ESCRT. Traffic 6, 2-9. 
235. Raiborg, C., Bache, K. G., Gillooly, D. J., Madshus, I. H., Stang, E., and Stenmark, 
H. (2002). Hrs sorts ubiquitinated proteins into clathrin-coated microdomains of early 
endosomes. Nat Cell Biol 4, 394-8. 
167
 236. Chin, L. S., Raynor, M. C., Wei, X., Chen, H. Q., and Li, L. (2001). Hrs interacts 
with sorting nexin 1 and regulates degradation of epidermal growth factor receptor. J 
Biol Chem 276, 7069-78. 
237. Raiborg, C., Bache, K. G., Mehlum, A., Stang, E., and Stenmark, H. (2001). Hrs 
recruits clathrin to early endosomes. Embo J 20, 5008-21. 
238. Lu, Q., Hope, L. W., Brasch, M., Reinhard, C., and Cohen, S. N. (2003). TSG101 
interaction with HRS mediates endosomal trafficking and receptor down-regulation. 
Proc Natl Acad Sci U S A 100, 7626-31. 
239. Bishop, N., Horman, A., and Woodman, P. (2002). Mammalian class E vps proteins 
recognize ubiquitin and act in the removal of endosomal protein-ubiquitin conjugates. 
J Cell Biol 157, 91-101. 
240. Marchese, A., and Benovic, J. L. (2001). Agonist-promoted ubiquitination of the G 
protein-coupled receptor CXCR4 mediates lysosomal sorting. J Biol Chem 276, 
45509-12. 
241. Marchese, A., Raiborg, C., Santini, F., Keen, J. H., Stenmark, H., and Benovic, J. L. 
(2003). The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G 
protein-coupled receptor CXCR4. Dev Cell 5, 709-22. 
242. Martin, N. P., Lefkowitz, R. J., and Shenoy, S. K. (2003). Regulation of V2 
vasopressin receptor degradation by agonist-promoted ubiquitination. J Biol Chem 
278, 45954-9. 
243. Jacob, C., Cottrell, G. S., Gehringer, D., Schmidlin, F., Grady, E. F., and Bunnett, N. 
W. (2005). c-Cbl mediates ubiquitination, degradation, and down-regulation of 
human protease-activated receptor 2. J Biol Chem 280, 16076-87. 
244. Cottrell, G. S., Padilla, B., Pikios, S., Roosterman, D., Steinhoff, M., Gehringer, D., 
Grady, E. F., and Bunnett, N. W. (2006). Ubiquitin-dependent down-regulation of the 
neurokinin-1 receptor. J Biol Chem 281, 27773-83. 
245. Tanowitz, M., and Von Zastrow, M. (2002). Ubiquitination-independent trafficking 
of G protein-coupled receptors to lysosomes. J Biol Chem 277, 50219-22. 
168
 246. Hislop, J. N., Marley, A., and Von Zastrow, M. (2004). Role of mammalian vacuolar 
protein-sorting proteins in endocytic trafficking of a non-ubiquitinated G protein-
coupled receptor to lysosomes. J Biol Chem 279, 22522-31. 
247. Kurten, R. C., Cadena, D. L., and Gill, G. N. (1996). Enhanced degradation of EGF 
receptors by a sorting nexin, SNX1. Science 272, 1008-10. 
248. Wang, Y., Zhou, Y., Szabo, K., Haft, C. R., and Trejo, J. (2002). Down-regulation of 
protease-activated receptor-1 is regulated by sorting nexin 1. Mol Biol Cell 13, 1965-
76. 
249. Zhong, Q., Lazar, C. S., Tronchere, H., Sato, T., Meerloo, T., Yeo, M., Songyang, Z., 
Emr, S. D., and Gill, G. N. (2002). Endosomal localization and function of sorting 
nexin 1. Proc Natl Acad Sci U S A 99, 6767-72. 
250. Gullapalli, A., Garrett, T. A., Paing, M. M., Griffin, C. T., Yang, Y., and Trejo, J. 
(2004). A role for sorting nexin 2 in epidermal growth factor receptor down-
regulation: evidence for distinct functions of sorting nexin 1 and 2 in protein 
trafficking. Mol Biol Cell 15, 2143-55. 
251. Traub, L. M. (2005). Common principles in clathrin-mediated sorting at the Golgi and 
the plasma membrane. Biochim Biophys Acta 1744, 415-37. 
252. Arora, P., Ricks, T. K., and Trejo, J. (2007). Protease-activated receptor signalling, 
endocytic sorting and dysregulation in cancer. J.Cell Sci. In press. 
253. Goodman, O. B., Jr., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., 
Gagnon, A. W., Keen, J. H., and Benovic, J. L. (1996). Beta-arrestin acts as a clathrin 
adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383, 447-50. 
254. Laporte, S. A., Oakley, R. H., Zhang, J., Holt, J. A., Ferguson, S. S., Caron, M. G., 
and Barak, L. S. (1999). The beta2-adrenergic receptor/betaarrestin complex recruits 
the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A 96, 3712-7. 
255. Hicke, L., and Dunn, R. (2003). Regulation of membrane protein transport by 
ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 19, 141-72. 
256. Paing, M. M., Temple, B. R., and Trejo, J. (2004). A tyrosine-based sorting signal 
regulates intracellular trafficking of protease-activated receptor-1: multiple regulatory 
169
 mechanisms for agonist-induced G protein-coupled receptor internalization. J Biol 
Chem 279, 21938-47. 
257. Cadavid, A. L., Ginzel, A., and Fischer, J. A. (2000). The function of the Drosophila 
fat facets deubiquitinating enzyme in limiting photoreceptor cell number is intimately 
associated with endocytosis. Development 127, 1727-36. 
258. Chen, X., Zhang, B., and Fischer, J. A. (2002). A specific protein substrate for a 
deubiquitinating enzyme: Liquid facets is the substrate of Fat facets. Genes Dev 16, 
289-94. 
259. Pornillos, O., Alam, S. L., Rich, R. L., Myszka, D. G., Davis, D. R., and Sundquist, 
W. I. (2002). Structure and functional interactions of the Tsg101 UEV domain. Embo 
J 21, 2397-406. 
260. Katzmann, D. J., Babst, M., and Emr, S. D. (2001). Ubiquitin-dependent sorting into 
the multivesicular body pathway requires the function of a conserved endosomal 
protein sorting complex, ESCRT-I. Cell 106, 145-55. 
261. Reggiori, F., and Pelham, H. R. (2001). Sorting of proteins into multivesicular bodies: 
ubiquitin-dependent and -independent targeting. Embo J 20, 5176-86. 
262. Cozier, G. E., Carlton, J., McGregor, A. H., Gleeson, P. A., Teasdale, R. D., Mellor, 
H., and Cullen, P. J. (2002). The phox homology (PX) domain-dependent, 3-
phosphoinositide-mediated association of sorting nexin-1 with an early sorting 
endosomal compartment is required for its ability to regulate epidermal growth factor 
receptor degradation. J Biol Chem 277, 48730-6. 
263. Haft, C. R., de la Luz Sierra, M., Barr, V. A., Haft, D. H., and Taylor, S. I. (1998). 
Identification of a family of sorting nexin molecules and characterization of their 
association with receptors. Mol Cell Biol 18, 7278-87. 
264. Carlton, J., Bujny, M., Peter, B. J., Oorschot, V. M., Rutherford, A., Mellor, H., 
Klumperman, J., McMahon, H. T., and Cullen, P. J. (2004). Sorting nexin-1 mediates 
tubular endosome-to-TGN transport through coincidence sensing of high- curvature 
membranes and 3-phosphoinositides. Curr Biol 14, 1791-800. 
265. Pierce, K. L., Premont, R. T., and Lefkowitz, R. J. (2002). Seven-transmembrane 
receptors. Nat Rev Mol Cell Biol 3, 639-50. 
170
 266. Heydorn, A., Sondergaard, B. P., Ersboll, B., Holst, B., Nielsen, F. C., Haft, C. R., 
Whistler, J., and Schwartz, T. W. (2004). A library of 7TM receptor C-terminal tails. 
Interactions with the proposed post-endocytic sorting proteins ERM-binding 
phosphoprotein 50 (EBP50), N-ethylmaleimide-sensitive factor (NSF), sorting nexin 
1 (SNX1), and G protein-coupled receptor-associated sorting protein (GASP). J Biol 
Chem 279, 54291-303. 
267. Seaman, M. N., McCaffery, J. M., and Emr, S. D. (1998). A membrane coat complex 
essential for endosome-to-Golgi retrograde transport in yeast. J Cell Biol 142, 665-81. 
268. Nothwehr, S. F., and Hindes, A. E. (1997). The yeast VPS5/GRD2 gene encodes a 
sorting nexin-1-like protein required for localizing membrane proteins to the late 
Golgi. J Cell Sci 110 ( Pt 9), 1063-72. 
269. Horazdovsky, B. F., Davies, B. A., Seaman, M. N., McLaughlin, S. A., Yoon, S., and 
Emr, S. D. (1997). A sorting nexin-1 homologue, Vps5p, forms a complex with 
Vps17p and is required for recycling the vacuolar protein-sorting receptor. Mol Biol 
Cell 8, 1529-41. 
270. Peden, A. A., Oorschot, V., Hesser, B. A., Austin, C. D., Scheller, R. H., and 
Klumperman, J. (2004). Localization of the AP-3 adaptor complex defines a novel 
endosomal exit site for lysosomal membrane proteins. J Cell Biol 164, 1065-76. 
271. Ihrke, G., Kyttala, A., Russell, M. R., Rous, B. A., and Luzio, J. P. (2004). 
Differential use of two AP-3-mediated pathways by lysosomal membrane proteins. 
Traffic 5, 946-62. 
272. Motley, A., Bright, N. A., Seaman, M. N., and Robinson, M. S. (2003). Clathrin-
mediated endocytosis in AP-2-depleted cells. J Cell Biol 162, 909-18. 
273. Shenoy, S. K., and Lefkowitz, R. J. (2003). Multifaceted roles of beta-arrestins in the 
regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem 
J 375, 503-15. 
274. Ferguson, S. S., Downey, W. E., 3rd, Colapietro, A. M., Barak, L. S., Menard, L., and 
Caron, M. G. (1996). Role of beta-arrestin in mediating agonist-promoted G protein-
coupled receptor internalization. Science 271, 363-6. 
171
 275. Tosoni, D., Puri, C., Confalonieri, S., Salcini, A. E., De Camilli, P., Tacchetti, C., and 
Di Fiore, P. P. (2005). TTP specifically regulates the internalization of the transferrin 
receptor. Cell 123, 875-88. 
276. Li, Y. M., Pan, Y., Wei, Y., Cheng, X., Zhou, B. P., Tan, M., Zhou, X., Xia, W., 
Hortobagyi, G. N., Yu, D., and Hung, M. C. (2004). Upregulation of CXCR4 is 
essential for HER2-mediated tumor metastasis. Cancer Cell 6, 459-69. 
277. Newell-Litwa, K., Seong, E., Burmeister, M., and Faundez, V. (2007). Neuronal and 
non-neuronal functions of the AP-3 sorting machinery. J Cell Sci 120, 531-41. 
278. Goldman, P. S., and Nathanson, N. M. (1994). Differential role of the carboxyl-
terminal tyrosine in down-regulation and sequestration of the m2 muscarinic 
acetylcholine receptor. J Biol Chem 269, 15640-5. 
279. Chen, H., Slepnev, V. I., Di Fiore, P. P., and De Camilli, P. (1999). The interaction of 
epsin and Eps15 with the clathrin adaptor AP-2 is inhibited by mitotic 
phosphorylation and enhanced by stimulation-dependent dephosphorylation in nerve 
terminals. J Biol Chem 274, 3257-60. 
 
 
172
